* DDT Nov-Dec 2006 Round 5 11/10/06 7:20 PM Page 2
November/December 2006 Vol 6 No 10 IN THIS ISSUE Corporate Profiles 16
Drug Delivery Technologies 73
Excipients, Polymers, Liposomes & Lipids 90
Contract Pharmaceutical & Biological Development Services 96
Machinery & Laboratory Equipment and Software 109
Technology Spotlight 114
The science & business of specialty pharma, biotechnology, and drug delivery
www.drugdeliverytech.com * DDT Nov-Dec 2006 Round 5 11/10/06 7:22 PM Page 3 * DDT Nov-Dec 2006 Round 5 11/10/06 7:22 PM Page 4 * DDT Nov-Dec 2006 Round 5 11/10/06 7:22 PM Page 5
November/December 2006 Vol 6 No 10 PUBLISHER/PRESIDENT Ralph Vitaro EXECUTIVE EDITORIAL DIRECTOR Dan Marino, MSc [email protected] CREATIVE DIRECTOR Shalamar Q. Eagel CONTROLLER Debbie Carrillo CONTRIBUTING EDITORS Cindy H. Dubin Debra Bingham Jason McKinnie TECHNICAL OPERATIONS Mark Newland EDITORIAL SUPPORT Nicholas D. Vitaro ADMINISTRATIVE SUPPORT Kathleen Kenny
Corporate/Editorial Office 219 Changebridge Road, Montville, NJ 07045 Tel: (973)299-1200 Fax: (973) 299-7937 www.drugdeliverytech.com
Advertising Sales Offices
East & Midwest Victoria Geis - Account Executive Cheryl S. Stratos - Account Executive 103 Oronoco Street, Suite 200 Alexandria, VA 22314 Tel: (703) 212-7735 Fax: (703) 548-3733 E-mail: [email protected] E-mail: [email protected] West Coast Warren De Graff Western Regional Manager 818 5th Avenue, Suite 301 San Rafael, CA 94901 Tel: (415) 721-0644 Fax: (415) 721-0665 E-mail: [email protected]
International Ralph Vitaro 219 Changebridge Road
Vol 6 No 10 Montville, NJ 07045 Tel: (973) 299-1200 Fax: (973) 299-7937 E-mail: [email protected]
Mailing List Rental Candy Brecht Tel: (703) 706-0383 Fax: (703) 549-6057 E-mail: [email protected]
All editorial submissions are handled with reasonable care, but the publishers assume no responsibility for the safety November/December 2006 of artwork, photographs, or manuscripts. Every precaution is taken to ensure accuracy, but publishers cannot accept responsibility for the accuracy of information supplied herein or for any opinion expressed. Drug Delivery Technology (ISSN 1537-2898) is published 10 times in 2006, January, February, March, April, May, June, July/August, September, October, and November/December by Drug Delivery Technology LLC, 219 Changebridge Road, Montville NJ 07045. Subscription rates: $99.00 for 1 year in the United States, Canada, and Mexico. $153.00 for 1 year outside the United States, Canada, and Mexico. All subscriptions are payable in US funds, drawn on US banks. Send payment to: Drug Delivery Technology LLC subscription Department, 219 Changebridge Road, Montville NJ 07045. Single copies (prepaid) $15.00, US, Canada, and Mexico; $24.00 in all other countries. Add $5.00 per order for shipping and handling. Periodicals Postage Paid at Montville, NJ 07045-9998 and additional mailing offices. Postmaster: please send address changes to Drug Delivery Technology, 219 Changebridge Road, Montville NJ 07045. All rights reserved under the U.S., International and Pan-American Copyright Conventions. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including by photocopy, recording, or information storage and retrieval system, without written permission from the publisher. Authorization to photocopy
Drug Delivery Technology items for internal or personal use, or the internal or personal use of specific clients, is granted by Drug Delivery Technology LLC for libraries and other users registered with the Copywrite Clearance, 222 Rosewood Drive, Danvers, MA 01923; phone: (978) 750-8400, fax: (978) 750-4470. 4 * DDT Nov-Dec 2006 Round 5 11/10/06 7:22 PM Page 6 DDTNov-Dec2006Round511/10/067:22PMPage7 * 6 Drug Delivery Technology November/December 2006 Vol 6 No 10 BioConvergence Service BioScreen Testing BD Bespak BC Technology Solutions Baxter BioPharma BASF ASSA International ALZA Corporation Systems 3M DrugDelivery opn rfls16 companies include: services aswellvisuals and completecontact information. Featured 2-page spread featuring core technologies, capabilities, products, and For eachparticipating company, thissection presents aspecial Company Profiles aa imtrasDevices Ocular Excipients Lipids Liposomes Proteins Colon &Peptides Controlled Release Vaginal Biomaterials Rectal Transmucosal Polymers Topical Intranasal Nasal Implants Capsules Therapy Gene Mucosal Parenteral 73 Transdermal Inhalation Oral include: applications and stage of development, and partnerships. Technologies their applications, pipeline/investigational technologies and their provides achecklist of currently marketed technologies orservices and Contract Services, and Machinery &Laboratory Equipment &Software, This Report,divided into four sections for DrugDelivery, Excipient, Pipeline Report Technologies & Partnerships, Halozyme Glatt Pharmaceutical Services Genzyme Pharmaceuticals Filtertek Inc. ExcipientFest Eurand Drug DeliveryPartnerships DPT Laboratories Degussa Controlled ReleaseSociety Coating Place Cardinal Health Capsugel Weiler Engineering Scolr Pharma, Inc Safety Syringes RDD Europe PharmaMed Device PharmaCircle NOF Corporation Loparex Inc. Lipocine Kurve Technologies Iomed Huber Engineering Hovione * DDT Nov-Dec 2006 Round 5 11/10/06 7:22 PM Page 8 * DDTNov-Dec2006Round511/10/067:23PMPage9
8 Drug Delivery Technology November/December 2006 Vol 6 No 10 4-color visuals and contact information. services, and devices, featuring dynamic innovative and emerging technologies, Special Report,thissection examines To complement the Company Profiles and Spotlight 114 Delivery Drug * DDT Nov-Dec 2006 Round 5 11/10/06 7:23 PM Page 10 * DDTNov-Dec2006Round511/10/067:23PMPage11
10 Drug Delivery Technology November/December 2006 Vol 6 No 10 Degussa Technical Service Manager Nasser Nyamweya,PhD Systems 3M DrugDelivery General Manager James Vaughan Research Institute Bristol-Myers Squibb Drug Delivery Biopharmaceutics & Director of Exploratory Ronald L.Smith,PhD Pharmascience, Inc Research &Development Director, Pharmaceutical Jack Aurora,PhD Research Institute Mills-Peninsula Diabetes Medical Director Medicine -UCSanFrancisco Clinical Professor of David C.Klonoff,MD,FACP BD Advanced DrugDelivery Development Director of Business Philip Green,PhD MediVas, LLC Development Director, Business Clemmons, PhD,MBA,MS Sonya Summerour SPI Pharma Development Marketing &Commercial Vice President, Global Sarath Chandar, MBA Technology Drug Delivery Director Executive Editorial Dan Marino,MSc Pharmaceuticals Actinium President &CEO Howard S.Wachtler Cardinal Health, PTS Process VP, Strategy &Business Cornell Stamoran Akina, Inc President Kinam Park,PhD McAuliff, LLPP Heller Ehrman White& Attorney atLaw James N.Czaban,JD Baxter Healthcare Associate Director PhD, MS Mahesh Chaubal, Ampad, LLC President &CEO John A.Bermingham Medical Center University of Nebraska Pharmaceutics Associate Professor of Uday B.Kompella,PhD Development Pfizer GlobalResearch & Formulations Director, Research Keith Horspool,PhD GlaxoSmithKline S.R. One, Limited, Investment Manager Philip L.Smith,PhD Pharmaceuticals Brookwood and Chief Scientific Officer Executive Vice President Tom Tice, PhD at Austin University of Texas Professor of Pharmaceutics James W. McGinity, PhD Laboratories Merck Research Associate Director Henry Y. Wu, PhD,MS Corium International President &CTO PharmD, MBA Gary W. Cleary, PhD, GlaxoSmithKline Pharmaceutical Development Investigator, Matthew D.Burke,PhD ALZA Corporation Planning Technology Assessment & Executive Director, New Ravi Kiron,PhD,MBA Eurand President, North America John Fraher * DDT Nov-Dec 2006 Round 5 11/10/06 7:23 PM Page 12 DDTNov-Dec2006FINAL11/14/0612:58PMPage13 *
12 Drug Delivery Technology November/December 2006 Vol 6 No 10 Research Facility State-of-the-Art of Expansion Tris Unveils Pharma T immediate andcontrolledrelease. dosages, andoffer orally tablets disintegrating for forsolidandliquid controlled-release formulations enhance solubilityandbioavailability, provide technologies proprietary company’s technologies. The research anddevelopment ofinnovative delivery drug companyspecialty pharmaceutical engagedinthe capability tothetable forourliquidproducts." commercialization, Tris willbringtheirmanufacturing Reid, “As CEOofInterpharm. we move toward development ofourjointproducts,” addedCameron forthe partnership hasbeenanimportant Pharma of SchedulesItoIV. license DEA controlledsubstanceswithmanufacturing including acommercial-sizevault for capabilities by alsoexpands facility thecompany’s current new productionprocess. features thatstreamlinethedrug The completely flexible, withend-to-endin-built utilitiesand scratch. The resultis15cGMPsuitesthatare todesignandbuildtheplantfrom inthefield experts hiredtop onoutsidecontractors,thecompany than rely andsetouttobuildit.Rather facility manufacturing and new technologies inthepipeline.” operations scalable tokeep pacewithseveral moredeals phaseofgrowth andkeeps our puzzle forourfirst Founder of pieceofthe Tris “Thisisthefinal Pharma. development,”our drug saidKetan Mehta,CEOand capabilities andalsoenables ustocontinueinvest in products. finished suspensions, andoralsolutions,packagingforthe scale commercialproductionoftablets, capsules,liquid andmedium- supplies, submissionbatches,eCTDfiling, facility. The company canprovide clinical itspartners inone all thecapabilities,includingmanufacturing, transition of thathas Tris toatechnology Pharma firm FDA-compliantof-the-art, andmarksthe cGMPfacility innovative delivery drug technologies. capabilities arearesultofthecompany’s successwithits South Brunswick,New Jersey, campus. These expanded ata facility researchandmanufacturing state-of-the-art pharmaceutical company,pharmaceutical recently unveiled anew aprivatelyris Pharma, owned specialty Tris isaprivately Pharma owned product-focused and Tris "The relationshipbetween Interpharm Tris envisioned Pharma acutting-edge enhancesourmanufacturing “This facility This 30,000-square-footexpansion addsastate- * DDTNov-Dec2006Round511/10/067:23PMPage14 to adverse events. were biochemical,andonewas ectopic.Nopatientswithdrew fromthestudydue 12 women (20%).Ofthese12pregnancies, eightwere clinical(fetalsac),three RFF Pen. The majority ofwomen ovulated (79%)and pregnancy was achieved in theGonal-f patients whoendpoint(61/61,100%)preferred completedtheprimary theGonal-fRFFPenpatients who preferred tovials/ampulesandsyringes. All injection method. choose apreferred endpointwas of The primary theproportion tocomparetheirtreatmentexperiencesinterview thatasked and participants was measured using anin-treatmentquestionnaireaswell asapost-treatment a pre-treatmentquestionnairewhile with theGonal-fRFFPen patientsatisfaction 6 months.Patient with priorgonadotropintherapy satisfaction was measuredusing gonadotropin therapy administeredwithvials/ampulesandsyringeswithinthepast diameter K14mm.Eligible patientshadundergone atleastonetreatmentcycle of days followed by untilaleadfolliclereachedmean doseadjustmentifnecessary RFF Pen,for5 doseofrecombinantfollitropinalfa patientsadministeredafixed undergoing ovulation inductionforoligoanovulatory infertility. UsingtheGonal-f centers intheUSandincluded62premenopausalwomen ages18to40years The PhaseIIIb,prospective, open-labelstudywas conductedatninefertility majority ofpatientswho completetreatmenteventually succeedinhaving achild. Center forHealthStatisticsoftheCentersDiseaseControlandPrevention. The ababy in2002,accordingtotheNational toterm getting pregnant orcarrying medications orloadcartridges. RFF Pen delivers ofGonal-fRFFwithoutneedingtomix aliquidformulation of folliclesintheovaries. andready-to-use multi-dosedevice, Gonal-f A prefilled FSH,whichsupplement orreplacenaturally stimulatesthedevelopment occurring (r-hFSH) ofhumanfolliclestimulatinghormone prescribedto recombinant form The mostprescribedgonadotropinintheworld, Gonal-fisahighly consistent help peoplemanagetheirexperience withinfertility.” other research,we alsoknowsuchasFertility services, LifeLinesalso thatsupport RFF Pen, which was designed tobequickandeasyforpatientsuse. Through Endocrinology, Serono,Inc.“Thisstudystrongly theuseofGonal-f supports improving thepatientexperience,” saidDavid Executive Stern, Vice President, (19%, n=11/59,p0.007). preparation (3%,n=2/61)comparedtowhen usingvials/ampulesandsyringes contacted theirhealthcareprovider two ormoretimestoaskquestionsaboutdose syringes. ofpatients When usingthePen, smallerproportion asignificantly compared with29%(n=17/59)who foundthesameforvials/ampulesand forusingthePen= 54/61)ofpatientsfoundinstructions easytounderstand very other women consideringgonadotropintreatment(p<0.001).Inaddition,89%(n interval [94.1%,100.0%])andwould recommenditto syringes (95%confidence the Gonal-fRFFPen tobelessstressfulthanmethodsinvolving vials/ampulesand increasing thechanceofapositive outcome.” patients prefer, centersmay fertility minimizetreatmentdropoutrateswhile from Abington Reproductive Medicine, Abington, PA. “Byproviding productsthat said StephenG.Somkuti,MD, PhD, theleadauthorandcoordinatinginvestigator MedicalResearchandOpinion Current vials/ampules andsyringes. The studywas published by thepeer-reviewed journal injection)totheirprevious treatmentwithconventional(follitropin alfa fertility S Gonal-f Study Shows Patient Preference for study in which patients reported that they preferred theGonal-fRFFPenstudy inwhichthatthey preferred patientsreported erono recently announcedtheresultsofaPhaseIIIb,prospective, open-label About 12%ofwomen (7.3million)intheUSaged15to44haddifficulty ofreproductive“Serono iscommittedtoadvancing healthby thefield whoAll participants statedaninjectionpreference(n=61/61)founduseof treatmentsuccess,”“Patient isacriticalcomponenttoinfertility satisfaction ® RFF Pen toTreat Infertility
13 Drug Delivery Technology November/December 2006 Vol 6 No 10 * DDTNov-Dec2006Round511/10/067:23PMPage15
14 Drug Delivery Technology November/December 2006 Vol 6 No 10 Chief Executive ofEndo.“Endohasexpanded its Officer topain,”complementary saidPeter A. Lankau,Presidentand strategic goalofexpanding intotherapeuticareasthatare in early stagedevelopment basedon theProGelztechnology. chemotherapeutic treatment.RxKinetixalsohasotherproducts often occurincancerpatientsundergoing radiationand prevention oforalmucositis(OM),painfulmouthsoresthat deliveryRK-0202 is inclinicalPhaseIIforthe drug platform. ProGelz with theactiveinitsproprietary formulated ingredient of2006. quarter price allocation,tobetaken inthefourth expense purchase ofapproximately $26million,subjecttofinal time charge forthewrite-off ofacquiredin-processR&D expense. This excludes transaction-relatedexpenses andtheone- diluted sharebasedonincrementalresearchanddevelopment by2006 adjustedearnings approximately $0.02peradjusted milestones. The acquisitionisexpected tobedilutive toEndo's paymentsearn-out basedonclinicaldevelopment andregulatory million, withthepotentialforuptoanadditional$95millionin Pharmaceuticals Inc. Pharmaceuticals newly created wholly owned ofEndo subsidiary company andits21employees willnow ofa operateaspart mucositis andothersupportive care oncology conditions. The that develops new ofapproved formulations productsfororal privately heldcompany inBoulder, headquartered Colorado, acquired alloftheoutstandingstockRxKinetix,Inc.,a E $95 Million AcquiresEndo Pharmaceuticals RxKinetix; Worth Deal Potentially wholly owned subsidiary, Inc.,has EndoPharmaceuticals HoldingsInc.recentlyndo Pharmaceuticals announcedits “The acquisitionofRxKinetixis consistentwithour RxKinetix’s leadproduct isRK-0202,atopicaloral-rinse The transactionincludesanup-frontpayment ofupto$20 healthcare professionalsandconsumers alike. meetingtheneedsof both brandedandgenericpharmaceuticals, researches, develops, produces, andmarkets abroadproductoffering of products. Inc.subsidiary,Through itsEndoPharmaceuticals thecompany companypharmaceutical withmarket leadershipinpainmanagement debilitating complicationsoforalmucositisasaresulttheirtreatments. chemotherapy-treated patientsinthe US,400,000may develop the receive Oftheestimated900,000 parenteralnutritionalsupport. increasing antibiotic,fluid, and analgesicuse,andrequiringpatientsto effects addtorelatedmedicalcostsby prolonginghospitalstays, cancer andtransplant-relatedmorbiditymortality. Further, theseside chemotherapy andradiationtherapy, andcontributeconsiderably to dehydration and, insomecases,infectionoftenleadtodose-limitationof oral inflammation,ormucositis,inthemouth. The resultingweight loss, marrow transplantation, patientsoftendevelop painfulanddebilitating chemotherapy. Duringthecourseofhigh-dosecancertherapy andbone patients undergoing combination treatmentofradiationand of theproductinintendedpatientpopulation-headandneckcancer Phase IItrialsofRK-0202tocontinuecharacterizetheclinicalprofile therapeuticareas.”other complementary Endoplanstoconductadditional insupportivesimilar specialist-focusedopportunities careoncology and care treatmentsintheRxKinetixpipeline. We intendtocontinueseek colleagues inthedevelopment ofthisandothercancer-related palliative extension ofthisfranchise,andwe lookforward toworking withournew trials. A productsuchasRK-0202,ifapproved, would beanatural in development inPhaseIII forbreakthroughcancerpain,iscurrently ER andOpanatablets, andRapinyl, ourquick-dissolvingfentanyl tablet commercial presenceamongoncologists withtherecentlaunchofOpana Endo Pharmaceuticals HoldingsInc. isafullyEndo Pharmaceuticals specialty integrated * DDTNov-Dec2006Round511/10/067:23PMPage16 S SPI Pharma’s Patent Pharmaburst? Issued! opttv datg o t utmr’formulations. a competitive advantage foritscustomers’ technologies, thecompany hasbecomeavalued sourceforcompletecustomdelivery systems. This provides Byofferingneutriceutical manufacturers. raw materials,processingcapabilities,andadvanced application willgive platform patented Pharmaburst SPIcustomersa“peaceofmind.” of“Orally Dispersible” usingthe dosageforms, ofpatentsinthefield thatthereisaminefield the fact anew applicationpatent,onaco-ownership drug company. basis,withamajorpharmaceutical filed Given platform. astheirprimary for “OrallyAlso, SPIhas thatusePharmaburst formulations Dispersible” drug the US,Europe, Asia, andSouth America. Several NDA, ANDA, andEuropeanapplicationshave beenfiled (Rx, OTC) technology andNutraceutical productsbasedonPharmaburst have beensuccessfully launchedin when placedintheoralcavity shalldissolve preferably ordisintegrate, withinabout60seconds.” producedbysolid dosageforms directly compressingtheco-processedcarbohydrate system,someofwhich, completely dissolve intheoralcavity ordisintegrate within60seconds. The invention alsocomprisesthe therefrom, which aredirectly formulations compressible someofwhich intosoliddosageforms, rapidly and for solidoraldosageforms): is aglobalcompany withresearch,development, throughouttheworld. facilities and manufacturing conjugation.Eurand anddrug formulations, soluble customizedrelease,taste-masking/fast-dissolving drugs, clinical trialsintheUS.Eurand’s technology include:bioavailability platforms enhancementofpoorly undergoing andotherdiseases,iscurrently PhaseIII associatedwithcystic fibrosis pancreatic insufficiency itself anditspartners. The company’s mostadvanced development product,atreatmentforexocrine products approved by theFDA since2000andhasanextensive pipelineofproductsindevelopment for delivery drug technologies. productsbasedonitsproprietary biopharmaceutical The company hashadthree different products.” inadvancedcurrently contractnegotiations withcompaniesinJapan,Europe,andtheUSforarange of technologies hasreceived leaders,suchasGSK,andwe anenthusiasticreceptionfromindustry are Gearóid Faherty, ChiefExecutive ofEurand.“ThecombinationourMicrocapsand Officer AdvaTab tablets,” oftaste-maskingandoraldisintegrating ourmarket-leading positioninthefields said confirms development, regulatory, andsalesmilestones. have oftheagreement Additional terms notbeendisclosed. GSK willpay payments Eurand aggregate ofupto$42millionbaseduponachievement ofcertain the endof2007. in2006andapplycommence clinicaltrialsundertheagreement formarketing authorizationintheUSby Eurand willretainexclusive, worldwide rights.Itisexpected manufacturing thatthecompanieswill product, andGSKEurandeachhave rightstocommercializetheproductoutsideofUS. certain receive royalties onproductsales.GSKwillhave exclusive rightsintheUStocommercializenew GSKwillfundthedevelopment oftheagreement, product. Undertheterms ofproduct,andEurandwill tabletdisintegration technologies todevelop anew ofanundisclosedGlaxoSmithKline(GSK) formulation E GlaxoSmithKline Eurand Announces Agreement License With Patent No.7118765;Issued:10/10/2006;Co-processedcarbohydrate systemasaquick-dissolve matrix PI Pharma’s novel was excipient aUSpatentonOctober10,2006.(US system,Pharmaburst, granted Eurand is a specialty pharmaceutical companyEurand isaspecialtypharmaceutical thatdevelops and enhancedpharmaceutical GlaxoSmithKline whereby EurandwilluseitsMicrocapstaste-maskingand AdvaTab oral urand recently announcedithasenteredintoadevelopment with andlicenseagreement “We project;we aredelightedthatGSKhaschosenEurandforthisimportant believe itfurther SPI Pharma isaworldand SPI Pharma solutionsforpharmaceutical wideleaderincustomformulation Since theintroductionofthisnovel by delivery platform drug SPIin2002, several Pharmaceutical “The presentinvention comprisesaco-processedcarbohydrate produced system,andformulations
15 Drug Delivery Technology November/December 2006 Vol 6 No 10 DDTNov-Dec2006Round511/10/067:46PMPage17 *
16 Drug Delivery Technology November/December 2006 Vol 6 No 10 to getmarket sooner. 3Mprovidescorporation. inproductdevelopment, expertise toenable andmanufacturing regulatory you We delivery combinetheagilityofaleadingdrug company withtheresourcesofamajor, multinational u xets nrae oropruiyfrsces www.3m.com/dds increasesOur expertise yourfor opportunity success. :(0)6388 :(651)737-5265 (800)643-8086•F: T: t al Minnesota 55144-1000 Paul, St. est:www.3M.com/DDS Website: 3M D MCne,Bd.275-3E-10 Bldg. 3M Center, RUG 3M DrugDeliverySystems countries onsixcontinents. Delivery soldinmorethan60 Systemsarecurrently by system.Productsmanufactured 3MDrug transdermal stand-alone7-dayMDI, andthedevelopment ofthefirst HFAmetered-dose inhaler(MDI),development ofthefirst proven trackrecordincludesdevelopment ofthefirst 3M’s Increasedprobabilityoftechnicalandcommercialsuccess • Speedtomarket • Differentiated products • andbiotechcompanieswith: pharmaceutical and experience expertise canprovide Our technology, Broad rangeofcustomizable systemcomponents • Commercial manufacturing • expertise Global regulatory • Productdevelopment services • Innovative andproven technology • Delivery Systems offers… Between discovery drug andcommercialization,3MDrug innovator delivery. drug forinhalationandtransdermal D ELIVERY S YSTEMS is agloballeaderand * DDT Nov-Dec 2006 Round 5 11/10/06 7:46 PM Page 18 DDTNov-Dec2006Round511/10/067:46PMPage19 *
18 Drug Delivery Technology November/December 2006 Vol 6 No 10 e otcsfrBS hraSltosi ot mrc:Fle uht,Drco;Jve ec,Marketing Manager Javier Beeck, Director; Folker Ruchatz, Key contacts inNorth Solutions forBASF Pharma America: pharmaceutical companiesandtheirresearchdevelopmentpharmaceutical laboratories. process developments. Oneof themainadvantages isitsNew ofthisfacility Jersey location–which isclosetomany physical/chemical analysis. andchemists provide Ourpharmacists toassistcustomerswiththeirproducta specializedexpertise TechnicalBASF’s CenterinLedgewood, Service N.J. and formulations equipmentusedfordosage-form houseslaboratory productionsiteinMinden,Germany.expansion ofourcurrent On theexclusive custom synthesisside,BASF isbuildinganew, active multi-productplantforpharmaceutical –an ingredients with lowerexcipients, soitcanalsobedilutedtoformulations API concentrations. upto85% permits whichAPI informulations, enables theproductionofsmaller, easier-to-swallow tablets. Itblends well with doesnotrequiretheadditionofalubricanttoprevent coating,IbuprofenDC85grade crystal sticking. nanoparticle As a resu associated withwet employed andcompactionprocessescurrently granulation fortypicalibuprofenpowders. Usingaproprietary NwpoutpnigU D approval productpendingUSFDA *New Services: aqueous and solvent granulations, compression, coating, printing, manufacturing ofcreamsandliquidspackaging. compression,coating,printing,manufacturing aqueous andsolvent granulations, ofsoliddosageforms: product.Ourcapabilitiesinclude:manufacturing materials throughpackagingoffinished strength ibuprofentablets. meetscGMPandisableThe facility tohandleupScheduleIIcompounds,fromraw two decadesandisamongtheleadingU.S. ofprescription- manufacturers fornearly producing qualitypharmaceuticals oftablets, ofsolidandsemi-soliddosageforms capsules,liquidscreams. manufacturing The sitehasbeen BASF’s Shreveport,isaflexible, facility La.,contractmanufacturing highcapacitysiteable tohandlethe e:wwpam-ouin.afcm-Eal [email protected] www.pharma-solutions.basf.com -Email: Web: e 80 4-67-Fx:(973) 245-6763 (800)443-0627-Fax : Tel : nslQai,Technical Manager Services Anisul Quadir, lra ak NJ07932 Park, Florham BASF offers excipients suchasKollidon Kollicoat • contract manufacturing services including pharmaceutical finishing and finishing includingpharmaceutical services contractmanufacturing • ofexcipients andactive broadportfolio ingredients; a • BASF companiestobesuccessfulwith: helpspharmaceutical Ibuprofen DC 85* can help pharmaceutical companiestoeliminatesteps Ibuprofen DC85*canhelppharmaceutical direct tableting aids,Lutrol semi-solid tablets, capsules,liquidsandcreams. plantisaflexible, ofsolidand highcapacitysiteforthemanufacture finishing caffeine, theophylline, andretinols.BASF’s Shreveport, La.,pharmaceutical • the services ofanexperienced technicalstaff theservices withindustry-specific • reliability, and expertise in chemistry thatdatesbackto1865. inchemistry andexpertise reliability, BASF offers excipients andactive withproven ingredients qualityand BASF C exclusive customsynthesis; formulation expertise. formulation 100 CampusDrive K EY C ® ORPORATION coatings. Actives includeibuprofen,pseudoephedrine,ephedrine, ONTACTS Products andServices Company Description htsNew What’s ® and Cremophor ® binders and disintegrants, Ludipress binders anddisintegrants, ® solubilizers and emulsifiers, and solubilizers andemulsifiers, lt, it nd ® * DDT Nov-Dec 2006 Round 5 11/10/06 7:46 PM Page 20 DDTNov-Dec2006Round511/10/067:46PMPage21 *
20 Drug Delivery Technology November/December 2006 Vol 6 No 10 and precise particle sizecontrolandenableand preciseparticle dosingflexibility acrossvarious administration routes. molecules andnucleicacids topeptidesandproteins.PROMAXX technology canoffer loading highdrug requirements.Itisapplicable to a broadrangeofmolecules-fromsmall your specific tailored tofit The PROMAXX microspheretechnology isaunique,elegant andcost effective platform, formulation and dissolutionrateeliminatestheneedforundesirable cosolvents. tonanometersize,which sizeofmostdrugs canenhanceadrug’sreduces theparticle saturationsolubility foryourformulations solubilitychallengesandisapplicable for multiple routesofadministration.It Proprietary Formulation Technologies Bottom-line results–lower expenses andincreasedrevenue. • –highly Expertise skilled solutionsforastreamlinedpathtomarket • Reliable supply resources –completecontractmanufacturing • Baxter isaproven CMOprovider offering best-in-classparenteraloutsourcingsolutionsincluding: includestabilitystorage,validation Otherservices anddocumentation,analyticalcrystallization. services. technology. andsterile powder Ourtechnologies dry includelyophilization, vial filling asepticliquidvialfilling, featuresadvanced isolator facility asepticprocessingusingbarrier Ourstate-of-the-art contract services. you fromscale-uptocommercialproduction fordedicatedcytotoxic cantake we facilities, In ourGerman assistance. regulatory Excellence. Baxtercanalsoprovide analytical andmicrobiological aswell services asvalidation and biologics; lyophilization capacityhasincreasedalongwiththeadvancement oftheLyophilization Centerof automated kittingline.Ournewest designedfor linesarespecifically lyophilization andvial-filling syringes. Wein prefilled aswell asafully have addednew filling/finishing, capabilityincartridge makingBaxtertheglobalSCFleader hasexpandedfacility capacitiesforsyringeandvialfilling/finishing, Contract Services - Recipient of the 2006 pharmaceutical Facility Recipient ofthe2006pharmaceutical ofthe Year- Award, Baxter’s Bloomington est:www.baxterbiopharmasolutions.com Website: B AXTER NANOEDGE dispersiontechnology offers innovative - :[email protected] E: iet (847)948-4770 Direct: S (800)422-9837 US: H :(847)948-3642 F: EALTHCARE C ORPORATION packaging. dispersion andPROMAXX microsphere formulation technologiesformulation andenhanced technologies includeNANOEDGE and cytotoxics Proprietary manufacturing. lyophilizationsyringes, vials,andcartridges, into include: development, form/fill/finish delivery.pulmonary) Contractservices focused onparenteral(injectable or technologies andproprietary services customers,offeringbiopharma contract and business isdedicatedtopharma award-winning Solutions BioPharma Baxter Healthcare Corporation’s * DDT Nov-Dec 2006 Round 5 11/10/06 7:46 PM Page 22 DDTNov-Dec2006Round511/10/067:54PMPage23 *
22 Drug Delivery Technology November/December 2006 Vol 6 No 10 3,500 different circuit configurations, four product lines of face masks,andhundredsofotherproducts. fourproductlinesofface 3,500 different circuit configurations, offering fullresearchanddevelopment, qualityassurance,marketing, andsalesoperations. KingSystemsnow offers more than Through awholly owned subsidiary, careproducts, ofanesthesiaandrespiratory KingSystems,Bespakisacustom manufacturer Products Anesthesia &CriticalCare as dosecountersandnasaldevices. ofpatentedvalves,portfolio includingintelligentdevi actuators,andaccessoriesaswell portfolio, anintellectualproperty Bespak’s MDIvalves ensureprecisedosedelivery ofsometheworld’s Bespakoffers drugs. abroa mostprescribedrespiratory Bespak Respiratory Products approach, Bespakoffers anunrivalled abilitytomanageadevice throughoutlife. andwithlessrisk. faster andarobustcontinuous improvementThrough anin-depthunderstandingofdesignformanufacture andmanufacture tested, Bespak provides to minimizetimetomarket, thecapabilityandexpertise allowing productstobecreated, For morethan 40years, Bespakhascontributed tothedesign,development, andindustrializationofleadingmedicaldevices. Device Manufacturing Services businessunits. Bespak plcoperatesthreecomplementary Needle-freeInjection Devices •DiagnosticsComponents&Products • Powder Dry Powder •Dry Drugs InhalersforRespiratory InhalersforProtein&Peptide Delivery • companies. Productsinclude: The company alsodevelops someoftheworld’s andmanufactures mostsuccessfuldevices andheal formajorglobalpharmaceutical office inMumbai,India.Bespak’soffice own productrangeincludes: inIndianapolis,IN, hasfacilities andKent,The group OH,intheUS,King’s Lynn andMiltonKeynes intheUK,andaliaison Actuators • MDI Valves • Disposable Face Masks • DoseCounter&Regime Assurance Devices • itnKye,Buckinghamshire MK125TS -United Kingdom Milton Keynes, lchl rv,Fahrtn od Wolverton Mill South Featherstone Road, Blackhill Drive, :bze@epkcm-Wbie www.bespak.com [email protected] - Website: E: :+4010 560 F +44(0)1908552613 +44(0)1908552600F: T: NasalDelivery Systems • BreathingCircuits • • Bespak has industrialized more Dry Powder BespakhasindustrializedmoreDry Inhalersthanany • Bespak plc Bespakhasdeveloped MeteredDoseInhaler(MDI)valves for • Bespakhasdeveloped arangeofvalue-added that services • Bespakoffers atevery itscustomersexpertise stageofthe • to market. settings. Bespakhasanunrivalled abilitytotake devices safely disposable airway managementproductsforcriticalcare developing and industry delivery systems forthepharmaceutical other company. HA omltosta n other manufacturer. (HFA) thanany formulations marketedmore productscurrently withhydrofluoroalkane life oftheproduct. throughoutthedevelopmentensure conformity andmarketed frequently auditedby bodiesand USandEuropeanregulatory assist ingettingproductstomarket. Ourlaboratoriesare product life-cycle fromconceptcreationtomanufacturing. is agloballeaderinspecialtymedicaldevices, MedicalCheck Valves • Tubes Laryngeal • ces, such thcare d d * DDT Nov-Dec 2006 Round 5 11/10/06 7:54 PM Page 24 DDTNov-Dec2006Round511/10/067:54PMPage25 *
24 Drug Delivery Technology November/December 2006 Vol 6 No 10 solutions forallregional delivery markets andparenteraldrug needs. presence, market awareness packagingknow-how andpharmaceutical allow ustoproposesuitable andresourcestohelpthemachieve theirgoals.Ourworldwide companieswithsupport pharmaceutical With abroadrangeofinnovative Systemsprovides devices BDMedical-Pharmaceutical andservices, patients' needsforcomfort. are designedtomeethealthcareprofessionals'demandsforsafetyandconvenience andtofulfill therapy. productsandcontributetotheoptimizationofdrug pharmaceutical devices All ourprefillable We deliver cost-effective alternatives toconventional delivery drug methods,which differentiate provides andexperienceinapackagingpartner. theexpertise requiredby industry thepharmaceutical reconstitution system,aninjectionorself-injectiondevice, Systems BDMedical-Pharmaceutical BD M -al [email protected] E-Mail: est:www.bdpharma.com Website: EDICAL rnlnLks NJ07417 Franklin Lakes, :(800)225-3310 T: :(201)847-4847 F: Becton Drive 1 -P HARMACEUTICAL S YSTEMS Systems Pharmaceutical BD Medical- spray system, a dry drug system,adry spray syringe,anasal prefillable Whether aglassorplastic industry.pharmaceutical theneeds ofthe fit delivery systemsdesignedto drug developing prefillable is dedicatedto * DDT Nov-Dec 2006 Round 5 11/10/06 7:54 PM Page 26 DDTNov-Dec2006Round511/10/067:55PMPage27 *
26 Drug Delivery Technology November/December 2006 Vol 6 No 10 access toBioConvergence asifthey were locatednext door–reducingbothtravel costsandtimeaway foreach from the office resource planning(ERP)systemto allow anddata. ourclientsreal-timeaccesstotheir information This enables worldwide clie notebook (ELN)systemandenterprise utilizeourelectronic laboratory andanalyticaldemands forformulation development. We Markets: with: cGLP laboratory Facilities: include: Our services developed more than20commercialproducts. processing moleculesthatareunstable insolution.Ourresearchscientists have emulsions, andlyophilized forbothsmallandlarge molecules.Inaddition,we formulations have informulatin uniqueexpertise Technical Services: Formulation, Filling, Freeze • Environmental Chamber • Autoclave • Glove Box forContainment& • Laminar Flow Hood • WaterSystem Purified • Drying &CappingEquipment Drying Requirements Atmospheric Inert BioConvergence companiesworldwide withbiotechandpharmaceutical to createsolutionsmeettheirgrowing partners BioConvergence’s housesa30,000-sq-ftcGMPwarehouse new facility and2,500-sq-ft 50,000-sq-ftstate-of-the-art General BioConvergence offers solutionstomeetyour parenteralproductdevelopment needsforsolutions,suspensions, Analytical MethodDevelopment • ProcessDevelopment • &Formulation Pre-formulation • Validation & Development •UV-Vis Plate-basedProtein Assays • Electrophoresis,IncludingSDS-PAGE, • ELISA • CE, IncludingCZE,CGE&cIEF • HPLC,IncludingUV&PDA • FTIR,IncludingProteinSecondary • X-ray Powder Diffraction • LCMassSpectrometry • IEF, WesternBlot Detection Structure AnalysisStructure :[email protected] Website www.bioc.us E: :829110 :812.961.1733 812.961.1700-F: T: loigo,IN47404 Bloomington, 4320 West ZenithDrive B Business Development IO Analytical C ONVERGENCE te: GMPmaterialsmanagement • Other: • Technology Transfer toClinical& Support • Pre-clinical& Toxicology BatchManufacture • StabilityStorage& Testing • Lyophilization CycleDevelopment &Optimization • Commercial Manufacturing Sites Commercial Manufacturing rdcsmeigrgltr requirements. products meetingregulatory contribute tothedevelopment ofsafe,effective, andstable experience alongwithourquality-by-design strategy substantial development expertise, Our scientific dedicated toproviding best-in-classoutsourcingservices. Indiana, BioConvergence isawomen-owned business material transactions,andSOPs.LocatedinBloomington, notebooks,ERP laboratory in ourresearchscientists’ provides clientsreal-timesecureaccesstotheirdatafound ofitskind,transparency solution,which isthefirst industry. tothepharmaceutical consulting services Oure- management (includingcoldchainstorage),and parenteral productdevelopment, cGMPmaterials providerexperienced contractservice offering cGLP Corporate Description: Consulting • LLC XRPDDataCollectionInSituDuring • Karl Fischer Moisture Analysis • Development-scale Freeze Dryer • Freeze-Dry Microscopy • Differential ScanningCalorimetry • Lyophilization Specialized for Lyophilization BioConvergence isan nts’ client. g and * DDT Nov-Dec 2006 Round 5 11/10/06 7:55 PM Page 28 DDTNov-Dec2006Round511/10/067:55PMPage29 *
28 Drug Delivery Technology November/December 2006 Vol 6 No 10 CAPSUGEL’s host ofimpressive features: CFS 1000,thisdevelopment-scale machinewill helpgetyour producttomarketwitha faster successful Thesuccessor to thehighly andsealingmachineisamustforyour R&Dlab. filling If your company isworking thenthenew withlipid-basedformulations, CFS1200 Products /Services tohelpaddressthechallengeofpoorly services solublecompounds. formulations drug Capsugelalsooffers liquid industry. throughoutthepharmaceutical for theirhigh-qualityperformance • A robust filling pumpwith highly accuratetemperaturecontrol robustfilling A • ensured withgentlehandlingofcapsulesbefore Productintegrity • andseal1,200capsules/hr Liquidfill • CAPSUGEL G sealing and during the drying cycle sealing andduringthedrying est:www.capsugel.com Website: 100 Route 206North epc,NJ07977 Peapack, capsule products, in both gelatin and non-gelatin grades, aregloballycapsule products,inbothgelatinandnon-gelatingrades, recognized LOBAL H EADQUARTERS ..C U.S. 535 North Road Emerald rewo,SC29646 Greenwood, :888-783-6361 T: :888-783-6360 F: ONTACT I NFORMATION TM liquid * DDT Nov-Dec 2006 Round 5 11/10/06 7:55 PM Page 30 DDTNov-Dec2006Round511/10/067:58PMPage31 *
30 Drug Delivery Technology November/December 2006 Vol 6 No 10 provides arangeofcreative options. through creative sitesanddedicatedcapacity, forback-upmanufacturing arrangements CardinalHealth requiredtomeetevencapacity andsupport themost challenginglaunchplanningrequirements. And Through ourglobalnetwork CardinalHealthprovides offacilities, ourcustomersthemanufacturing andpatients. prescribers, pharmacists, We provide therightcapacity-when andwhere you needit. welaunch accelerationservices, canhelpyou shelves gettopharmacy quicker, visibilityto withgreater Cardinal Healthcanreducetime-andoftentotalcost -toshipment. And by CardinalHealth’s integrating andsupply development,formulation, doseform issues.Byintegrating andpackaging, manufacturing, we have experience inhelpingourcustomersresolve quality, offer, technology thatwe In every Chain Streamlining theSupply foryour ordoseform product. patent-protectedformulation engineer amoreefficient, swallowingdifficulty atraditionaltablet. Trust theprecision,speed, andingenuityofCardinalHealthto technology, forexample, improves patientcomplianceforchildrenorolderpatientswho may have reduced sideeffects or have broadenedacceptanceamongdifferent patienttypes.Zydis®fast-dissolve Health hasatrackrecordofimproving thesuccessofmany productsby developing thatoffer dosageforms thatwilloptimizebioavailability from aformulation orenhancepatientcompliance.Cardinal benefit new ishow drug muchitimproves resultsforpatients.Even themostsophisticatednew compoundcan a makes allthedifference.Sometimes therightdosageform inmarketing factor successof A significant Drug Delivery Systems on5continents. andtopicals-in37facilities products, inhaledforms, oraltechnologies -fromtraditionalandproprietary tosterile optionsintheindustry manufacturing launch, andentirelifecycle. CardinalHealthalsooffers development thebroadestrangeofdoseform and throughoutadrug’s expertise development, applications, CardinalHealthbringsitscustomersinnovative commercialization services. With several decadesofexperience andmorethan1,500patentspatent in development, delivery technologies, drug packaging,and product contractmanufacturing, andbiotechnology thepharmaceutical industries,Cardinal Healthisagloballeader market share.Serving development, tohelpourcustomersacceleratedrug and services streamlinethesupply chain,andgrow tolaunchandbeyond,laboratory CardinalHealthoffers anunmatchedrangeofworld-class technologies technologies, thathelpbringqualityproductstomarketanddeliver faster value. andservices greater From Cardinal Health provides andbiotechnology itspharmaceutical customersintegrated, enabling :(6)7034 :(732)537-5949 (866)720-3148•F: T: est:www.cardinal.com/pts Website: oest New Jersey 08873 Somerset, 14 Schoolhouse Road :[email protected] E: C ARDINAL H EALTH * DDT Nov-Dec 2006 Round 5 11/10/06 7:58 PM Page 32 DDTNov-Dec2006FINAL11/13/069:36AMPage33 *
32 Drug Delivery Technology November/December 2006 Vol 6 No 10 Honest and confidential research and manufacturing services have services researchandmanufacturing intheindustry. madeustheleaderandmosttrusted Honest andconfidential bead, manner andscheduledtomeetyourparticle, needs. ortablet project ishandledinaconfidential coatingneeds.Every The possibilitiesarealmostlimitless. The innovative, creative staff oftheCoatingPlaceispreparedtotake onallyour or odormasking,entericdelivery, controlledrelease,sustaineddelayed modification. property release,andsurface aredesigned forawidevarietymaterials. Ourformulations ofdesiredoutcomes,includingimproved stability, shelflife,tast chemists have successfully developed andappliedthem toanequally awiderangeofformulations widerangeofcore continues todevelop, cutting-edge andoperateproprietary manufacture, Wurster coatingequipmentforouroperations.Our Wurster fluid bedcoatingunitsthatwillaccommodatebatchsizesrangingfrom0.010toover 600kg.Coating PlaceInc. andtaste-masking. barrier controlled oraldelivery, suchasenteric,delayed, orsustainedrelease.Othercoating applicationsincludemoistureoroxygen Coatingcapabilitiesincludesoftgels, hardshellcapsules,andtablets.manufacturing. Development applicationsinclude inthiscoatingtechnology andexpertise experience. Ourhistory isunmatchedintheindustry. andnewformulations technology. Ourproductionstaff includesnumerousemployees withmorethan20years ofcoating to-swallow liquidsmake itsimpletotake your medicinewherever you go. easy- ofsustained-releasesoliddosageforms.These create 12-hourtime-releaseliquidsuspensionsthatcanmatchtheprofiles The originalmanagement,with34years of Wurster coatingexperience, remainsactive inthedevelopment of Our 110,000-sq-ftFDA-registered islocatedin facility Verona, Wisconsin. Productionsuitesareequippedwitharangeof andpancoatingforbothR&Dcommercial offeredServices includetablet compression,capsulefilling, Coating Placeprovides Wurster tothefollowing services coatingandothermanufacturing markets: ControlledSubstance(ScheduleII–V) • •OTC Rx,Branded, andGeneric • :(0)8492 :(608)845-9526 (608)854-9521•F: T: est:www.encap.com Website: T HE aio,WI53593 Madison, :[email protected] E: C 200 Paoli Street OATING P LACE than 50 able toapply rangingfromless thisprocesstoparticles chemistshave CoatingPlaceformulation support. been inaGMPenvironmentmanufacturing withanalytical technology transfer, scale-up,andcommercial and beads. We provide development, contractformulation powders, crystals, granules, microencapsulation offine Coating PlaceInc. processing parameters. coatpercentthickness,andother with formulation, canbeoptimized coating processes.Coatingproperties tobedevelopedformulations ineithersolvent oraqueous hasorganicfacility solvent capabilitiesthatallow ,I Our new ion resin drug-release systemallows ionresindrug-release usto Our new NC m . uptoseveral centimetersindiameter. Our m specializes in Wurster fluidbed e, * DDT Nov-Dec 2006 FINAL 11/13/06 9:36 AM Page 34 DDTNov-Dec2006FINAL11/13/069:37AMPage35 *
34 Drug Delivery Technology November/December 2006 Vol 6 No 10 :[email protected] E: T: (732) 981-5383 Option 4 (732)981-5383Option T: D ictaa,NJ08855 Piscattaway, EGUSSA :(732)981-5371 F: Pharma PolymersPharma Turner Place 2 C ORPORATION est:www.pharma-polymers.com Website: :[email protected] E: D EGUSSA 49 amtd,Germany 64293 Darmstadt, :+49-6151-18-4019 T: :+49-6151-18-3520 F: Kirschenallee 45 G-P - AG Röhm GmbH HARMA P OLYMERS EUDRAGIT EUDRAGIT of polymer intheformulation. different amounts can becontrolledby release. Thus, thedesiredreleaseprofile polymer willreducethe incorporated diltiazem. Naturally, ahigheramountof for ahighly water-soluble like drug strongsustainedreleaseeffectvery even togeneratea issufficient formulation Only 10%ofpolymer inthetablet effective asasustainedrelease polymer. conditions. relaxation, even underacceleratedICH stable phaseofpolymer afterashort isreachedand release profile final the caseofdiltiazemmatrixtablets, the goodstoragestability. In tablets show EUDRAGIT Visit: www.eudragit.com/nm30d release behavior. showgranulation astrongersustained bymanufactured using fluid bed polymer thetablets inthegranule, Due tothebetterdistributionof techniques. with bothmanufacturing show goodsustainedreleaseproperties mixer orfluidbedsystem. The tablets wet ineither highshear granulation ® ® ® NM 30Disvery NM 30Dbasedmatrix NM 30Dissuitable for * DDT Nov-Dec 2006 FINAL 11/13/06 9:37 AM Page 36 DDTNov-Dec2006FINAL11/13/069:37AMPage37 *
36 Drug Delivery Technology November/December 2006 Vol 6 No 10 get your next product to market fast and with confidence, callDPT– get your next producttomarketandwithconfidence, fast professionalswithunparalleledknowledge equipmentandprocesses. andexperience, usingstate-of-the-art be handledby will fromconcepttocommercialmanufacturing, thattheirformulations, solutions.DPTcustomershavemanufacturing confidence compliance record. reputation forquality, capabilities,andanexemplary virtually unmatchedtechnicalexpertise, unlimited manufacturing regulat needsthroughinnovation,manufacturing technology, DPThasa Specializinginsemi-solidandliquiddosageforms, andservice. biotechnology,pharmaceutical, development andconsumerhealthcarecompaniesthebestsolutionstotheirdrug and DPT, Inc.company, aDFBPharmaceuticals, isacontractdevelopment organization andmanufacturing (CDMO).DPTprovides Who We Are President ProjectManagement&Marketing Key Personnel: Number ofEmployees: Year Founded: state-of-the-art development,state-of-the-art packaging,anddistributionspace. manufacturing, inSan Headquartered Antonio, thereandtwoTX, DPThasfourfacilities inLakewood, NJ, withmorethan1millionsquarefeeto Facilities Controlled substancesSchedulesII-V • cGMPbatchsizesfrom25kgto22,000 • Four cGMPfacilities • Manufacturing Solutions Formulation andpackagecompatibility assessment • development Packaging specification • andsourcingofrelevant packagingoptions Identification • Packaging Solutions StabilitystudiesunderICHconditions • Analytical andbioanalytical methoddevelopment andvalidation • development Biopharmaceutical • andformulation Pre-formulation • Drug Development Solutions The abilitytodevelop, makes DPTunique. andcommercialize productsinsemi-solidandliquiddosageforms manufacture, To Customers choose DPT as a strategic partner becauseof our abilitytoprovideCustomers chooseDPTasastrategic partner fullydevelopment drug integrated and 1990 Paul Johnson,President;Paul Josephs, Vice PresidentSales&CommercialOperations;MarcIacobucci, Vice 1,500 :(1)4685 :(210)829-8733 (210)476-8159F: T: • Specialized equipment installation, operational qualification, and Specializedequipmentinstallation,operationalqualification, • Extensive packagingcapabilitiesforsemi-solidsandliquids • :[email protected] E: est:www.dptlabs.com Website: DPT L validation services San Antonio, TX 78215 TX San Antonio, 318 McCullough ABORATORIES Turnkey foruniqueandspecializedpackaging sourcingservices • Packaging equipmentsourcing,design,andengineeringservices • The IndustrySource for Semi-solidsandLiquids ClinicaltrialmaterialsPhaseI-IV • Pilotandproof-of-conceptbatchesfrom0.3kg • Processdevelopment andvalidation • ,L TD . SM . ory f * DDT Nov-Dec 2006 FINAL 11/13/06 9:37 AM Page 38 DDTNov-Dec2006FINAL11/13/069:37AMPage39 *
38 Drug Delivery Technology November/December 2006 Vol 6 No 10 * DDT Nov-Dec 2006 FINAL 11/13/06 9:37 AM Page 40 DDTNov-Dec2006FINAL11/13/069:37AMPage41 *
40 Drug Delivery Technology November/December 2006 Vol 6 No 10 u rgdlvr systems. delivery our drug on pleasecallusorvisit ourwebsite, detailed technicalinformation information, where you willfind includingsitesinMilanand Trieste, Italy; Dayton, Ohio(US)andParis, France.world, For more TheCompany hasresearch,development, throughoutthe facilities andmanufacturing Milan, Italy. in over 50countries,have beendeveloped usingourtechnologies. develop novel products. pharmaceutical To date,morethan40 products,marketed by Eurandcustomers enables ustohave morethanonesolutionforany delivery drug problem. biotechnology derived productsfor improved delivery. drug The breadthofourtechnology platforms targeting,technology that,oncecommercialized, drug platform, canbeappliedtosmallmoleculeand that canbeusedaloneorintandemtoprovide delivery uniquedrug solutions. Eurandhasafourth Our commercializedtechnology aremadeupofmultiplenovel platforms delivery drug technologies Taste-Masking &Orally Disintegrating Formulations• Customized Release • Bioavailability EnhancementofPoorly Soluble Drugs • on threecommercializedtechnology platforms: thatisoneofthebroadestinindustry.portfolio The Company’s development drug efforts arebased We delivery inusingourtechnologies challengesandto areexperts drug tosolve themostdifficult Eurand isaglobalcompany withmorethan500employees. arein Itsprincipaloperatingoffices 20060 -Pessano con Bornago :+39-02-95745018/12 F: i .Lte ig 13 Luther King, Via M. :+39-02-95428-309 T: (Milan) Italy est:www.eurand.com Website: :[email protected] E: management. Eurandhasawell-established technology andeffective productsforlife-cycle innovative technologies canbeused toenable thecreationof products. successful pharmaceutical Additionally, our candidatesintoeasy-to-administer, drug difficult turns substances.Usingthesetechnologies,of drug Eurand technology designedtooptimizethedelivery platforms delivery.leader indrug We offer comprehensive andconvenient dosing. efficacy, treatment optionswithsuperiorsafety, enhanced needs. To thisend, theCompanypatients’ develops technologies andproducts thatbettersatisfy development andcommercializationofbreakthrough technologies. Eurandisdedicatedtothecontinued productsusingourinnovativebiopharmaceutical develops and enhancedpharmaceutical Eurand For morethan30years, Eurandhasbeenaworld is a specialty pharmaceutical companyis aspecialtypharmaceutical that adla Ohio45377 Vandalia, :(937)898-9669 T: :(937)898-9529 F: 845 Center Drive * DDT Nov-Dec 2006 FINAL 11/13/06 9:38 AM Page 42 DDTNov-Dec2006FINAL11/13/069:38AMPage43 *
42 Drug Delivery Technology November/December 2006 Vol 6 No 10 requirements for performance, durability,requirements forperformance, delivery andcost. innovation inthemedicalindustry, designs customsolutionsthatmeetorexceed customer three continentsandannualrevenues ofover $95million. The company, recognized forits components, andtechnically moldedassemblies, hasnearly 1000employees locatedacross fluidcontrol Filtertek, aworldwide offilters, leaderinthedesignandmanufacture product asyou do. you’re withasourcethatputsasmuchintothedevelopment assured ofpartnering ofyour precision.Bychoosing Filtertektoproduceyourdeliverymanufacturing drug components, components forcriticalmedicalapplicationstakes designingenuity, technicalknowledge, and With designinganddeveloping somuchridingonproductqualityandperformance, tailoredtoourcustomers uniquebusinessneeds. productsandservices finished desire for“turn-key” projectsaffords toquickly offer theopportunity Filtertek andefficiently growing inthedevelopmentpositioned asaglobalpartner ofadvanced products.Customers’ medicalcleanrooms,andstrategicexpertise, locations,Filtertekisuniquely manufacturing in pacewith“tomorrow’s” medicaltechnology. With ourwiderangeofproductapplications achieve optimalresults. A closecollaborationwith oursuppliersandcustomerskeeps Filtertek iscommittedtoproactive,Filtertek solution-driven productdevelopment tohelpourcustomers theneedsofever-evolvingbetter serve medicalmarket. suchasflow rate,pressuredrop,andapplicationto frombasicspecifications, custom parts sophisticated devices. Iftherightproductisnotyet available, we have todesign theexpertise quality productsforany medicalapplicationfromsimple,traditionalcomponentstohighly to provide resultsforourcustomers.Filtertekhascost-effective, high-performance high- hasdeveloped andproducedhundredsofproductinnovationsOEM’s, designed thecompany processing,andequipmentprotection.Meetingthe needsoflarge andsmall pharmaceutical delivery, includingproductsfordrug industry therapies,surgical preparation, respiratory customers. Filtertekdevelops afullrangeofproductsforuseinthemedical andmanufactures critical componentsinlinewithleadingedgemedicaltechnology andtheneedsofour valves, and Pinpoint precisionandstrictattentiontodetailskeep medicalfilters, Filtertek otc:CrsMa,Marketing Specialist Maar, Chris Contact: est:www.filtertek.com Website: :(800)648-0791(Main) T: :[email protected] E: Hebron, Illinois 60034 Illinois Hebron, FILTERTEK INC. :(815)648-2416 T: 11411 Price Road * DDT Nov-Dec 2006 FINAL 11/13/06 9:38 AM Page 44 DDTNov-Dec2006FINAL11/13/069:38AMPage45 *
44 Drug Delivery Technology November/December 2006 Vol 6 No 10 LipoBridge LipoMask excreted Isnotmetabolizedandisrapidly • Improves solubility • by andexcipients formulated mixingdrug Easily • TheBBBnaturally limitsmostmoleculesfromenteringtheCNS,especially than600Daltons.Duetothislimitati thosegreater • pharmaceutical action.LipoMask pharmaceutical (reticuloendotheial system)uptake normally seenwithconventional lipidsandconsequently have morechancestogetthedesi Collaboration offers throughDesignforPeptide customizedsolutionsforpeptidesformulations Delivery complete solutiontodeliver andassesspoorly compoundsintheCNS. brainpenetrantdrug The Brookwood –GenzymePharmaceutica Advantages ofLipoBridge Alzheimer’s, stroke, trauma,Parkinson’s Applicationsincludethetreatmentofbraincancer, technology. andmultiplesclerosis. molecules, peptides,andantibodiesrangingfrom100to155,000Daltonshave beensuccessfully delivered acrosstheBBBusingt temporarily andreversibly openingtightjunctions.Over 100modelcompoundsinclud and intothecentralnervous system(CNS)by offersGenzyme Pharmaceuticals two novel delivery drug technologies: LipoBridge Technology Description withanimmediatefocusinthelipid,services peptide,aminoacidderivative, delivery anddrug markets. inthedevelopment materialsandvalue-addedbusiness partner ofspecialtypharmaceutical technologies, andmanufacturing produ inLiestal,Switzerland, facility inCambridge,MAandourmanufacturing headquarters strives GenzymePharmaceuticals tobeap developing andapplying advanced technologies inthelifesciencestoaddressabroadrangeofunmetmedicalneeds. With ourco Genzyme Pharmaceuticals By combiningLipoBridge Partnerships Sustainedrelease • Reducedtoxicity • Increased circulationtime • efficacy, toxicity. anddecreasingdrug withLipoMask formed nanoparticles properties, Duetotheiruniquesurface Advantages of LipoMask therapyDrug isusually administered parenterally. potentially important drug compoundsarediscardedduringtheR&Dprocess. potentially drug important TM ® increases the circulation half life of lipid particles inblood, improvingincreases thecirculationhalflifeoflipidparticles dru profiles, thereby pharmacokinetic tailoringdrug is aninnovative (BBB compoundsacrosstheblood ofdrug brainbarrier transport designedtofacilitate technology specifically TM ® ® : is a distinct business unit within Genzyme Corporation, oneofworld’sis adistinctbusinessunitwithinGenzymeCorporation, foremostbiotechnology leadersin : with the CNS assessment services of its partner Pharmidex, Genzyme Pharmaceuticals offers GenzymePharmaceuticals Pharmidex, Cerense ofitspartner with theCNSassessmentservices Tissue targeting • Increasedloadingcapacities • time Extendeddegradation • TM is designedtoextend thecirculationtimeofbothsmallandmacromolecules,while reducingtheirtoxicity. :617-768-9765-E:[email protected] F: T: 800-868-8208(US&Canada)or617-374-7248 Genzyme Pharmaceuticals 675 West Kendall Street Cambridge, MA02142 Americas Website: www.genzymepharmaceuticals.com ® and LipoMask TM . T: +41(0)619065959orF:5958 SM :[email protected] E: . CH-4410 Liestal,Switzerland Genzyme Pharmaceuticals TM Rest ofthe World evade theRES Eichenweg 1 red siteof mmercial on, many SM his cts and remier ,a ing small ls g ) * DDT Nov-Dec 2006 FINAL 11/13/06 9:38 AM Page 46 DDTNov-Dec2006FINAL11/13/069:38AMPage47 *
46 Drug Delivery Technology November/December 2006 Vol 6 No 10 To moreabouthow learn we’re expanding, pleasecontactustoscheduleavisit. andGlatt’s CPS™pelletsystem,fluidbed andhighsheargranulation, our proprietary unsurpassed Wurster HStechnology. expanded capabilityconcentratesoncomplex includingorganic controlled-release R&Dandmanufacturing, solvent coatingcapacit Facility Expansion- direct pelletizationusingourCPS Technology™. focuson capabilitiesare expandingOur pelletmanufacturing tofurther Wurster coatingan layering HSdrug andfunctional film supply ofyour products. arecommittedtoascheduleofup24hours/7days aweek tomeetthemarket demands placedonthe products. We dosage form Contract Manufacturing: CPS Technology™ - Controlled ReleasePellet System both ANDA andNDA products. Drug Delivery Technologies - Technology Transfer forManufacturing Process Scale-Up cGMP Clinical Trial Material Production Process Development (Aqueous and Organic Solvent Processing) Formulation Development deliver acompleteR&Dprogram including: we influidbedandsoliddosagetechnology, Building onourexpertise bysupported acompletelineofanalytical capabilitiesinournewly expanded laboratory. ChemicalEntities,ProductLineExtensions,Over-the-Counter, are Products.OurR&Dservices andGenericDrug including New environment inthedevelopment ofyour products.OurR&Dteamhassucceededindeveloping productsfromabroadlistofcategor Product Development - Services Offered: provided attentiontoqualityandcustomerservice. withthegreatest companiestobringtheirimmediatereleaseandcomplex controlledreleaseproductstomarket.pharmaceutical All ofourservice division ofGlatt Air Techniques, continuestosuccessfully part Inc.,incollaborationwithitsglobalGlattGroupaffiliates, technology, industry. tothepharmaceutical andcontractmanufacturing With over years ofexperience thirty andinnovation, thi Who We Are: Number ofEmployees: Vital Statistics: Glatt Pharmaceutical Services istheleadingprovider Services productdevelopment,Glatt Pharmaceutical ofsoliddosageform delivery drug Year Founded: 1954 - Dense, Spherical, and Uniform Pellets Spherical,andUniform Dense, - Loading(upto~90%) Drug High - Pelletization Direct - Glatt Pharmaceutical Services announcestheinaugurationofitsnew inRamsey, Services soliddosagefacility Glatt Pharmaceutical NJ. Our Glatt Air Techniques, Inc.,USA~150-GlattGroup, Worldwide ~1500 We feature a highly experienced and accomplished group of scientist that participate inateamwork ofscientistthatparticipate experienced andaccomplishedgroup focused featureahighly We Our experienced staff provides first-class cGMP manufacturing of both bulk intermediates and final solid andfinal Our experienced staff ofbothbulkintermediates cGMPmanufacturing provides first-class With afocusoncontrolledrelease,Glattoffers new andnovel enablingtechnologies proprietary for MicroPx Technology™ - DirectPelletization est:www.glattpharmaceuticalservices.com Website: :[email protected] E: G LATT asy New Jersey 07446 Ramsey, P :(201)825-8700 T: :(201)825-0389 F: HARMACEUTICAL ContinuousProcessing - Pellets Dense, Spherical,andUniform - Loading(upto~90%) High Drug - 20 SpearRoad ZRx™ Technology - Zero-OrderRelease Tablet System S ERVICES Once-per-Day Dosing - ZeroorFirst-Order ReleaseCharacteristics - ExtendedRelease Tablet MatrixSystem - ner with s d s are y, ies * DDT Nov-Dec 2006 FINAL 11/13/06 9:39 AM Page 48 DDTNov-Dec2006FINAL11/13/069:39AMPage49 *
48 Drug Delivery Technology November/December 2006 Vol 6 No 10 focused onanumberofdiscrete productopportunities. fromthis technology,injection viathesubcutaneous orintramuscularroutesthatcouldbenefit andisactively from requiring orbenefiting companies thatmarket drugs withpharmaceutical Halozyme isseekingpartnerships injected large proteintherapeutics,suchascytokines andtherapeuticantibodies,inanimalmodels. augmentedthesystemicbioavailability andsignificantly oflocally profiles rHuPH20 changedthepharmacokinetic injected moleculesacrossabroadrangeofmolecularweights Inparticular, andsizeswithouttissuedistortion. Recent pharmacology studieswithHalozyme’s rHuPH20enzymedemonstrateincreaseddispersionoflocally of theskin. within approximately thatdoesnotpermanently delivery alterthearchitecture 24hours,leadingtoadrug platform as 200nanometersmay passfreely throughtheperforatedextracellular matrix,which recovers density itsnormal channelsundertheskin.Moleculesaslarge openingflow temporarily by penetration anddispersionofthesedrugs injectable Enhanze withcertain drugs, co-formulated Technology the canact asa“molecularmachete”tofacilitate "gel"-like substancethatisamajorcomponent oftissuesthroughoutthebody.space-filling When combinedor humanenzymebeinginvestigatedof thenaturally occurring foritsabilitytobreakdown hyaluronic acid(HA),the Enhanze Technology isHalozyme’s delivery drug technology proprietary basedonrHuPH20,arecombinant form Enhanze Technology enables Halozymetodevelop theproductasamedicaldevice, enhancementagent,andtherapeuticdrug. drug enzyme,rHuPH20, anddispersionofotherinjecteddrugs. increase theabsorption Theversatility ofthefirst otc:Mr isn-E [email protected] Mark Wilson -E: Contact: 18 ornoVle od Suite 17 11588 Sorrento Valley Road, est:www.halozyme.com Website: H ALOZYME a ig,CA92121 San Diego, :(858)794-8889 T: :(858)259-2539 F: T HERAPEUTICS process; andHylenex for useasanadjuvant to human hyaluronidase forcumulusremoval intheIVF products: Cumulase The company hasreceived FDA approval fortwo immunogenicity. potential risksofanimalpathogen transmissionand animal slaughterhouse-derived extracts thatcarry replacecurrent recombinant humanenzymesmay enzymes known ashyaluronidases. Halozyme's ofhuman coveringon intellectualproperty thefamily markets. The company’s ofproductsisbased portfolio delivery, palliative care,oncology, andinfertility recombinant humanenzymes(rHuPH20)forthedrug company developing andcommercializing Halozyme Therapeutics ® , the first andonly recombinant thefirst , is abiopharmaceutical * DDT Nov-Dec 2006 FINAL 11/13/06 9:39 AM Page 50 DDTNov-Dec2006FINAL11/13/069:39AMPage51 *
50 Drug Delivery Technology November/December 2006 Vol 6 No 10 For please visitwww.hovione.com. information further elsewhere. ourcustomerswhat they cannotfind do well togive what isdifficult, challenges ofbringingnew APIs tomarket quickly, time”delivery. while ensuring“rightfirst Ouraimisto isbetterequippedtomeetthe partner Nomanufacturing productformulations. synthesis anddrug characteristics.From both API particle labtoindustrialscale, ourinstallationsaredesignedtosupport API micronizationandcryomillingcapabilitiesallowdrying, ustooffer a wide rangeofsolutionstomodifythe also hasextensive designandengineering.Spray-drying, spray-congealing, inparticle expertise freeze- inallmajorareasof onouraccumulatedexpertise Building API development HOVIONE andmanufacture, Particle Design Technologies &cGMPSpray Drying :(0)9820 :(609)918-2615 (609)918-2600F: T: est:www.hovione.com Website: East Windsor, NJ 08520 NJ East Windsor, :[email protected] E: 40 Lake Drive H OVIONE n euaoycompliance. and regulatory products, superiorcustomerservice, dependable andeconomicalhasgiven us aworldwide reputationforquality andreliable solutionsthatare timely our abilitytoprovide customerswith year trackrecordin API development, to topicalapplications. With a50 oral toinjectable andfrominhalation deliveryfor alldrug systems,from ICH cGMPstandards. We offer APIs of manufacture APIs underFDA and design, andkilotomultiton worldwide affairs, regulatory particle chemistry, analytical development, capabilities includeprocess Our support. and regulatory quality,to superiorcustomerservice, New Jersey, HOVIONE iscommitted and a Technology Transfer Centrein approved plantsinEuropeand Asia CMO and API supplier. With FDA of and manufacture APIs bothasa dedicated tothecGMPdevelopment Hovione isaworld-class company Pharmaceutical FineChemicals Exclusively Focused on * DDT Nov-Dec 2006 FINAL 11/13/06 9:39 AM Page 52 DDTNov-Dec2006FINAL11/13/069:39AMPage53 *
52 Drug Delivery Technology November/December 2006 Vol 6 No 10 of J.M. HuberCorporation for pharmaceuticalexcipients. HuberCal Havre deGrace,MD21078 907 Revolution Street Sales &Service Excipients, Havre deGrace LOCATIONS delivery options. proud collaboratorwithcompanieslookingforadvanced excipient anddrug and innovative technologists dedicatedtoyoursuccess,Huberisa formulation industry. forthe pharmaceutical encapsulation services With cGMPfacilities Huber istakinglarge stridesinitsdevelopment ofblending,and granulation, PROCESSING applications. provides productforantacidandfiller afantastic ofSuitabilityforEurope,Huber natural calciumcarbonateandaCertificate alternative applications. forpharmaceutical With yearsinmining ofhistory HuberCalcalciumcarbonates provide acosteffective andnatural Huber’s CALCIUM CARBONATE release theliquidactive todeliver ingredient requiredpotency. doHuber’s productsabsorbtheliquidactives, moreimportantly, weight. Notonly they andeffectively efficiently to 70%by operations, allowing formoreeven distributionandmaterialtransfer. Functionally, Huber’s andmuchlesspronetodustinginplant glidantsarelesspronetoadhesionglassormetalsurfaces alternative glidants,Huber’s glidantsaretwiceasdense, allowing forsmaller, packagingandstorage. moreefficient Huber’s (SiliconDioxideup &CalciumSilicate)have highloadingcarriers carrying beenutilized innumerousformulations glidants(GL100 &200)provide excellent glidancy while beingdenseandeasytohandle. When comparedto Huber’s ® is aregistered trademark ofJ.M. HuberCorporation for calciumcarbonate. RxCIPIENTS – H UBER est:www.rxcipients.com orwww.hubermaterials.com Website: :(1)9972 :[email protected] (410)939-7228 E: T: E NGINEERED Benicia, CA94510 3909 BPark Road Granulations, Manufacturing Benicia Plant ar eGae MD21078 Havre deGrace, M 907 Revolution Street ATERIALS – without royalty ormilestonepayments. packaged instandardbottles. Additionally, FM1000issoldasanexcipient Huber's portfolio includesRxCIPIENTS Huber's portfolio fororaldosagetabletspowders.contract manufacturing andformulated providesCorporation, highly powders, functionalexcipients, granulated and pleasant mouthfeel,areproducedonstandardtablet presses,andcanbe seconds inthemouth. Tablet containingFM1000have formulations a the creationofhighdose,robusttablets inlessthan30 thatdisintegrate Huber’s technology RxCIPIENTSrapiddisintegration (FM1000)enables EXCIPIENTS applications;andcustomprocessingcapability. filler and inert Huber Engineered Materials, glidant, and carrier applications;Hubercal glidant, andcarrier , ATOF PART ..H J.M. UBER Modesto, CA95356 700 DKiernan Avenue Blending, Packaging, Contract Manufacturing Microencapsulations, Granulations, Triturations, Modesto Plant C ORPORATION division oftheJ. M.Huber a ® excipients forrapiddisintegration, ® – calcium carbonateforantacid ® is aregistered trademark * DDT Nov-Dec 2006 FINAL 11/13/06 9:40 AM Page 54 DDTNov-Dec2006Round511/10/068:08PMPage55 *
54 Drug Delivery Technology November/December 2006 Vol 6 No 10 inflammatory, antibiotic,andantiviral compounds. hasdemonstratedthattheOcuPhorSystem iscapable ofdelivering anti-angiogenic, anti- theCompany Additionally, clinicalstudiesinhumanvolunteersPreliminary have shown thattheOcuPhorSystemisbothsafeandwell tolerated. OcuPhor’sFeasibility studies confirmed abilitytodeliver abroadrangeofanti-angiogenic tothebackofeye. drugs researchefforts, weThrough bothcollaborationsandinternal advancements have withtheOcuPhor System. madesignificant technologyOcuPhor hasbeendesignedasaplatform todeliver therapeutic compoundstoposteriorsegments oftheeye. administrationwithoutthecollateraltissuedamageassociatedwithsurgery,site-specific lasers,needleinjections,orimplan IontoDex including enhancingourreusable dosecontrollers,improving ourdisposable electrodepatches,anddeveloping new products. offer themostcomprehensive lineofiontophoreticproductsavailable onthemarket. basketball, hockey, andgolf.Clinicianshave administeredover systems. 28millionpatienttreatmentsusingourcurrent We conditions,includingthosesufferedinflammatory by topOlympic athletesandprofessional athletesinfootball,baseball, therapy corticosteroid inclinicsnationwidetotreatavariety ofloc forsite-specific productsareusedprimarily Our current Transdermal DrugDelivery tissue, includingthesclerainophthalmicapplications. technology hasalsobeenshown toeffectively compoundsthroughotherbody transport patches.Ourproprietary transdermal thanpassive faster significantly Iontophoresisisapplicabledrugs insertion. toabroadrangeofcompoundsandcantransport fluids,and/ortoavoid ofcarrier thedamagecausedby needle injection,tominimizetheinfiltration anddrug insertion Ourtechnology andproductsareusedinsituationswhenelectrical current. itisadvisable toavoid thepainfromneedle ofwater-soluble usinglow-level ionicdrugs methodofenhancingandcontrollingthetransport non-invasive a technology, administration oftherapeuticstothebackeye. Our delivery system,trademarked OcuPhor technology, we have developed delivery anoculardrug systemthatseekstoaddressthesafeandeffectiveUsing ourproprietary Ophthalmic DrugDelivery (NSAIDs),includingCox-II drugs inhibitors. non-steroidal anti-inflammatory ofdexamethasone while avoidingbenefits all ofthegastrointestinal(GI)andothersystemicsideeffects sucha oforaldrugs, unmet medicalneedby offeringpatient in-homeuse.IontoDex patientstheanti-inflammatory couldaddressasignificant We aredeveloping andmarketing conditions, “next-generation” productsforuseintreatingacutelocalinflammatory TM is a proprietary application of a miniaturized, integrated version integrated ofouractivesystem designed for transport drug applicationofaminiaturized, is aproprietary :(0)6134 r(0)9519 :(801)972-9072 (800)621-3347or(801)975-1191 F: T: atLk iy Utah 84120 Salt Lake City, est:www.iomed.com Website: 2441 South3850 West :[email protected] E: OE,I IOMED, IOMED, Inc. agreements areavailable.agreements medical needs.Licensing,co-development, andmarketing toofferpharmaceuticals uniqueproductsdesignedtosatisfyunmet delivery drug systemsincombinationwithspecialty invasive methods. We areactively toutilizeournon- pursuingopportunities onset, andtherapeuticcontrolnotpossible withotherdelivery innovative delivery, systemsallow systemicorsite-specific rapid forlocalandsystemicapplications. custom deliveryThese profiles andtrans-scleraltechnologyOur versatile transdermal allows for selling active delivery systemsthatemploy drug iontophoresis. OE’ active delivery systemsuse iontophoresis drug IOMED’s NC . is aleaderindeveloping, and manufacturing, TM allows fornon-invasive, , al ts. s * DDT Nov-Dec 2006 Round 5 11/10/06 8:08 PM Page 56 DDTNov-Dec2006Round511/10/068:08PMPage57 *
56 Drug Delivery Technology November/December 2006 Vol 6 No 10 pharmaceutical companies. pharmaceutical Kurve Technology offers global,exclusive licensesintopical,systemicandnose-to-brain therapy areasto Corporate RelationshipsSought and abusecontrol. offers superiorefficacy, rapidonsetofaction,counterfeit/competitorlockouts, compliancemonitoring CPDtechnology andelectronicintelligentdelivery,Incorporating ViaNase ID™Electronic Atomizer ViaNase ID™ Electronic Atomizer ihe ake,VPBusiness Development [email protected] Michael Rackley, Robert Kamp, VP Corporate Development VPCorporate [email protected] Robert Kamp, -al nokreehcm-Wbie www.kurvetech.com [email protected] - Website: E-mail: Key contacts forKurve Inc. Technology, :(2)6094 :(425)673-5783 (425)640-9249F: T: 19805 North Creek Parkway K URVE Kurve Technology,Inc. delivers awiderangeofformulations. • improves patientcompliance; • minimizes peripheraldepositiontolungsandstomach; • saturatestheentirenasalcavity; • region andparanasalsinuses.CPD: compared tospray pumps,withCPDreachingtheolfactory forCPD greater area ofintranasaldepositionwas significantly than traditionaldevices. Clinicalresultsshow thattheaverage andefficiency efficacy withgreater wide rangeofformulations Kurve Technology’s flexible technology candeliver platform a Dispersion (CPD) Superior NasalDrugDelivery withControlled Particle systems forlocal,systemicandnose-to-brainmedicaltherapies. ohl,WA 98011 Bothell, T ECHNOLOGY ,I NC ® . develops delivery device nasaldrug * DDT Nov-Dec 2006 Round 5 11/10/06 8:08 PM Page 58 DDTNov-Dec2006Round511/10/068:08PMPage59 *
58 Drug Delivery Technology November/December 2006 Vol 6 No 10 * DDT Nov-Dec 2006 Round 5 11/10/06 8:08 PM Page 60 DDTNov-Dec2006Round511/10/068:12PMPage61 *
60 Drug Delivery Technology November/December 2006 Vol 6 No 10 chemistries thatcanbeusedto designtherightreleaselinerforyour medicaldevice. processes,slitting,printing,and several substrates,globalextrusion silicone-coating Loparex haspaperandfilm sensitive adhesive) of medicaldevices. toassist inthemanufacture Loparex reliable manufactures andeconomicalreleaseliners thatarealsousedinprocess(i.e.,curingthepressure Process Liners convex-shaped appliances. to and consistentreleasedemandedby toadapt thesedevices. Polystyrene releaselinerscanbethermoformed film-based SLIKproducttoprotecttheadhesive. POLYrelease silicone-coatedPOLY SLIKprovides thestiffness, cleanliness, Self-adhering ostomy bags,worn over anabdominal openingorstoma,utilizeaone-sidepolycoated, one-sideeasy Ostomy Devices are available inawidevariety ofbasisweights. andPolyinter ESP, capability (ESP)andone-sidepolycoated andone-sidesiliconecoated(Polyinter). STICK-NOT, kraft papersandeasyreleasesiliconecoatings,aresuitable, aswell asourin-linepaper-making andsiliconizing consistent releaseaftersterilizationarekey. STICK-NOT commonbandageapplicationconsistsofanadhesive tape,anabsorbent pad, andareleaseliner. Cleanlinessand A Wound Coverings &Bandages :[email protected] est:www.loparex.com [email protected] - Website: E: otc:SeeSudr,Market Manager Steve Saunders, Contact: :(3)7420 :(630)734-2690 (630)734-2700F: T: ees ies u OYSLIK release liners.OurPOLY polystyrene, andpolyethylene film offers polyester, these needs,Loparex cutability, andconsistentrelease,particularly withgeladhesives. To meet requirementsincludecleanliness,thermoformability,Important die- EKG/ECG Electrodes &Electro-Medical Devices Our customizedproductsaredesignedwiththeseapplicationsinmind: withavariety ofreleaselinersto meet thoseneeds. the medicalindustry world’s serves ofsilicone-coated papersandfilms, leaderinthemanufacture including consistentrelease,cleanliness,andtraceability. Loparex, the Medical device have manufacturers specializedneedsforreleaseliners, development ofNew Drug Applications (NDAs). MasterFilesmaintains Drug onmany ofourproductstoassistinthe adhesivesprotecting drug-loaded untilappliedtothepatient.Loparex isusedforprocessing and Polyester insmoothandmattefinishes, film, Cleanliness andconsistentreleasearetobeexpected for TDDS patches. Transdermal Drug Delivery Systems(TDDS) electro-surgical pads. grounding withlow-papers extruded orhigh-densitypolyethylene, areusedfor ilwro,IL60527 Willowbrook, 7700 Griffin 7700 Griffin Way L OPAREX ® brand release liners, manufactured fromsupercalendered brand releaseliners,manufactured ® brand releaseliners,bleached kraft * DDT Nov-Dec 2006 Round 5 11/10/06 8:12 PM Page 62 DDTNov-Dec2006Round511/10/068:12PMPage63 *
62 Drug Delivery Technology November/December 2006 Vol 6 No 10 base formulation series MPCpolymer 1. PUREBRIGHTSL-100 PUREBRIGHT SLSeriesisaNovel SolubilizingKitforany (Protein,Peptide, HydrophobicDrugs andsmallmolecularetc.) Novel SolubilizingKitfor PUREBRIGHTSLSeries 4. impurities (EGandDEG)low POV. NOF’s PEG200,300, and400meetwithmulti-compendialofNF, EP, andJP. PEGsandPEG200,300,400areonly availableUltrapurified atNOFCORPORATION, andfeatureextremely low Multi-Compendial-ND, EP, JP • Hemolysis Low • Low Cell Toxicity • Low (Low Degranulation Allergic Reaction) • extremely provides low thefollowing impurityprofile, featuresofPolysorbate great 80: NOFABLE ESO-9920(Polysorbate 80)ofNOFCORPORATION, Oleic whichAcid (99% up)andan consistsofultra-purified 300&400 Ultra-Pure Polysorbate 80&PEG200, 3. which canbeobtained. bettertransfectionefficiency customers caneasily SpecialcationictypeEL-01-Disrecently encapsulatetheirdrugs. commercializedforgenedelivery in anddevelopphospholipids, butalsoformulate lyophilized liposomes,calledEMPTYLIPOSOME(EL-series),withwhich worldwide productssincethe90sandhave drug agoodreputationamongstourcustomers. We notonly develop new typesof bs,Siuak,Tokyo 150-6019-Japan Shibuya-ku, Ebisu, :+81-3-5424-6741 T: :+81-3-5424-6769 F: NOF C 03 4-chome 20-3, ORPORATION base formulation series PEGPhospholipids 2. PUREBRIGHTSL-200 :dsnonfc.p-Wbie www.nof.com.jp/dds [email protected] - Website: E: We have successfully ofphospholipidsfor suppliedourGMP-grade PHOSPHOLIPIDS&EMPTYLIPOSOMES 2. liposomal formulation. phospholipidsareinjectedas a be lengthenedwhen ourPEGmodified inthebloodstream Inaddition,thehalf-lifeofdrugs can can bemodified. drugs ofPEG,various group kindsofcustomers’ theterminal By arranging derivatives, suchasmethoxy-PEG amines,maleimides,andcarboxlic acid. ranging from200to30,000molecularweight, butalsoactivated PEG excellent purityofmethoxypolyethylene glycols producenotonly We PEGYLATION TECHNOLOGY 1. industry. for DDS,NOFprovides excellent qualityproductsforthepharmaceutical cholesterol pullulan,MPCpolymers, andchitosan. As aworldwide leader oleicacidnonionicsurfactants, PEG, phospholipids,highly purified development andsolubilizers,suchas oninnovative carriers modifiers, drug activity fromBiospheretoOuterSpace,NOFCORP. isfocusedonthe featuringallkindsofhuman chemicalmanufacturer As anintegrated Promoting Innovative DrugDelivery Systems base formulation series CholesterolPEG 3. PUREBRIGHTSL-300 NOF A 1Mri vne Suite1170 Avenue, Martin 11 MERICA ht lis NY10606 White Plains, :(914)681-9790 T: :(914)681-9791 F: C mixture baseformulation series Phospholipids 4. PUREBRIGHTSL-400 ORPORATION USC - ONTACT * DDT Nov-Dec 2006 Round 5 11/10/06 8:12 PM Page 64 * DDT Nov-Dec 2006 Round 5 11/10/06 8:12 PM Page 65 * DDT Nov-Dec 2006 Round 5 11/10/06 8:53 PM Page 66 DDTNov-Dec2006Round511/10/068:13PMPage67 *
66 Drug Delivery Technology November/December 2006 Vol 6 No 10 Amino (USPatent No. 6,517,868–IssuedFebruaryAcid Platform 11,2003,USPatent No. • Dual Polymer 8,2002) (USPatent No.6,337,091-IssuedJanuary Platform • Electrolyte (USPatent No.6,090,411-IssuedJuly Platform 18,2001) • Technology Summary successfully createdmultiple private labelproductsforlarge retailersthatgenerateasourceofroyalty revenues. improvements andvalue-added forhumannutritionalproductapplications. formulations The Company has approved thancurrently anduseless drug manufacture, formulations. immediate-release CDT-Raloxifene forosteoporosis,willpotentially formulation beeasierto OTC market. Italsobelieves candidatealsoinclinicalevaluation, thatitsleadprescription drug an to betheonly inclinicalevaluation currently 12-hour extended-release ibuprofenformulation fortheUS andnutritionalingredients. drugs The Company believes itsleadOTC productcandidate pharmaceutical interactions to facilitate solubility andpotentiallyinteractions tofacilitate permeability. “Amino Acids Patents” allows forsimpleproductionoftablets anduseshydrophobic/polar 6,936,275 –Issued August 30,2005) forlimitationsinotherbiphasic/triphasicsystems. and anionicpolymers tocorrect “Dual-Polymer Patent” allows forsimpleproduction oftablets andcapsulesusesionic generationmatrix-based systems. for limitationsinotherfirst “Salt Patent” allows forsimple two stepprocessingandusesionicinteractionstocorrect In the area of dietary supplements,theCompany’sIn theareaofdietary efforts areconcentratedonmeaningful :(2)3307 :(425)373-0181 (425)373-0171•F: T: eieytechnologies capable ofhandlingchallengingclasses delivery ofrelated toincludeafullplatform expanded itsintellectualproperty licensed from Temple University in1998.Sincethen,SCOLRhas uniquerobusttechnology was applicable patents.Itsfirst broadly delivery positionindrug consistingoffour(4)young and property and nutritionalproducts. introduce distinctive andnovel Over-the-Counter, pharmaceutical, delivery andpatenteddrug technologiesand itsproprietary to companypharmaceutical that leverages expertise, itsformulation Based inBellevue, Washington, Background :[email protected] E: 6512dAeu E Suite 300 3625 132nd Avenue SE, elve Washington 98006 Bellevue, The Company differentiated enjoys intellectual asignificant est:www.scolr.comWebsite: SCOLR P HARMA ,I NC . SCOLR Pharma is aspecialty * DDT Nov-Dec 2006 Round 5 11/10/06 8:13 PM Page 68 DDTNov-Dec2006Round511/10/068:13PMPage69 *
68 Drug Delivery Technology November/December 2006 Vol 6 No 10 compact machineframe. The ASEP-TECH sealingofliquidproductsinonesequentialoperationon andhermetic molding,asepticfilling, the three-stepprocessofblow Solutions the USA. Approximately 100peopleareinvolved ofthesemachines,providing inthedesignandconstruction 21stCentury plant. manufacturing are designedandbuiltina120,000-sq-ft,state-of-the-art in All equipmentisdesignedandmanufactured trademark andisnow buildingthelatestgenerationof ASEP-TECH corporate offices areconveniently offices corporate locatednearChicago'sO'HareInternational Airport. ASEP-TECH help completeyour projectpackage. canassist withprototyping,producttrials,andoutsourcingofkey functions,suchasprocessvalidationdepartment support to packaging. lines withitsBlow/Fill/Seal systemsfordeflashing,leak detection,labeling,andfinal years ofhighquality, ofdesignandmanufacture automatedequipment. Weiler completefinishing hastheabilitytointegrate sterility assuranceforaseptictechnology. settingthestandards tothehighestlevel of research tothedesignofournext-generation Blow/Fill/Seal machines,firmly positioned itprominently attheforefrontofthesedevelopments. We arecontinually applying theresultsofourscientific the worldwide communityandwillchangethefutureofasepticmanufacturing. regulatory Weiler’s proactive stancehas optimization ofmachinedesigntoenhanceprocesscapabilities relatingtosterilityassurance. These efforts arerecognized by area. transport shrouding isavailable toensureaClass10,000environment zoneandthecritical underdynamicconditionsintheextrusion HEPA airshower toensureaClass100environment underdynamicconditionsinthenozzleshroudarea.Optionalparison Eachmachineisalsoequippedwitha testsystemareprovidedintegrity asstandardequipmentfor each machineconfiguration. Blow/Fill/Seal technology asacorecompetency. Weiler began BFSmachinesmorethan30years manufacturing agoundertheBottlepack Weiler EngineeringcontinuestoplaceastrongemphasisonthescienceofBlow/Fill/Seal technology asitrelatestothe Weiler’s datacollection,andfilt system,automaticsterilizationsystemwithintegral patentedelectronically controlledfill Our Technical staff Services isavailable toassistwithcontainerdesignanddevelopment, OurR&D andtechnical support. Our customercommitmentextends beyond thatof typicalmachinebuilders,providing derived andsupport expertise from ® for parenterals, ophthalmics, respiratory drugs, biologicals, drugs, nutraceuticals,andothercomplexfor parenterals,ophthalmics,respiratory solutions. est:www.weilerengineering.com Website: ® :[email protected] E: Global Sales & Service Department Global Sales&Service brand identityprovides increasedfocusforfuturedevelopment andadvancement of W EILER li,Illinois60123 Elgin, 1395 Gateway Drive :(847)697-4900 T: E NGINEERING ® Blow/Fill/Seal Systems. The Weiler designincorporates ,I NC . ASEP-TECH available throughtheapplicationofcustomized advanced asepticliquidprocessingtechnology Engineering, Inc. The corporate focus of Weiler technology. advanced, sterile,asepticliquidpackaging themarketplace withthelatestin serving continuing world-wide leadershipposition, helpsensureits cutting-edge technicalexpertise combination ofworld-class engineeringand services. integrated Weiler's unique Weiler's and facilities manufacturing ® ® brand, continuedwiththe ALP Blow/Fill/Seal and machinery ® Blow/Fill/Seal machines is toprovide themost ® er a * DDT Nov-Dec 2006 Round 5 11/10/06 8:13 PM Page 70 DDTNov-Dec2006Round511/10/068:13PMPage71 *
70 Drug Delivery Technology November/December 2006 Vol 6 No 10 ISO 9001 certified. WeISO 9001certified. proudofourworld-class arevery scientists andunparalleledenvironment breedingexcellence. Xcelience’s 24,000-sq-ft Tampa laboratoriesarefully cGMPcompliantandregistered with theFDA andDEA. isalso The facility Facility Overview and fulltraceabilityofthe API’s weight, “Time toman”clinicaltrialsisconsiderably reduced. excip batchesforclinicaltrialsinaneasier, manner:withnoneedforfilling manufacturing moreprecise,andcost-efficient Xcelience’s of API into capsulesXcelodose capabilities includethepatentedprecisionmicrofilling range oftemperatureandrelative-humidity conditions. Analytical: Solids: • able thefollowing toformulate dosageforms: Formulation: development. Ourscientistshave ofnew ofnew experience inpreformulation substances,generics,andreformulation products. Preformulation: Xcelience offers thefollowing services: commitment toquality. development process.Usingthelatesttechnologies gives usunparalleledspeedtomarket withoutcompromisingourabsolute Led by teamswork adedicatedprojectmanager, asanextension ofyour ourscientific organization throughoutthedrug Xcelience’s Core Services you have theendresultXcelience-XcellingScienceofFormulation Development. and market faster. Bycombiningtheindustry’s development formulation equipme top-performing scientists,withstate-of-the-art development. process, gettingthemtoclini We formulation APIsthroughthedrug consistently move andefficiently oursponsors’ Xcelience, Powders - Granules - Hardgelatincapsuleformulation - Tablet formulation - Tampa-based qualityindrug contractresearchorganization, isthepremiersourceforunsurpassed pharmaceutical a State-of-the art facilities and instrumentation provide andinstrumentation facilities anoptimalenvironment forstabilitystudies,includingafull State-of-the art The scientific team creates options for formulation to meet your dosage range and preferred routeofdelivery. tomeetyour teamcreatesoptionsfor formulation dosagerangeandpreferred The scientific We are clec’ ag fpeomlto tde losu ootmz ordsg omat theearlieststageofdrug studiesallows rangeofpreformulation ustooptimizeyour dosageform Xcelience’s Scalingupandproductionofpilotbatches • batchesforstabilitytesting Manufacturing • development. Contactusfor: Manufacturing: Xcelling theScienceofformulation development Send usyourchallenge today-Xcelience hn:(1)2600 a:(813)286-1105 (813)286-0404Fax: Phone: otc:RnalGtre Vice President Randall Guthrie, Contact: Liquids: • Our scientists are the industry’s most respected in the field offormulation mostrespectedinthefield Our scientistsaretheindustry’s Emulsions - Suspensions - Oralandtopicalliquids - est:www.xcelience.com Website: 5415 West Laurel Street :[email protected] E: ap,FL33607 Tampa, X CELIENCE Processvalidation andtechnology transfer • ofclinicaltrialssuppliesfromPhasel Manufacturing • over-encapsulation, orcoatingofcomparators of API, tableting, encapsulation,placebomatching, through toPhaseIII,includingindividual capsulefilling Semi-solids: • Gels - Ointments - Creams - ™ 600 system.Itcreates ients nts, c * DDT Nov-Dec 2006 Round 5 11/10/06 8:13 PM Page 72 * DDT Nov-Dec 2006 Round 5 11/10/06 8:17 PM Page 73
FEATURING: - Drug Technologies - Excipients, Polymers, Liposomes & Lipids - Contract Pharmaceutical & Biological Development Services - Machinery & Laboratory Equipment & Software * DDT Nov-Dec 2006 Round 5 11/10/06 8:17 PM Page 74
DRUG DELIVERY TECHNOLOGIES DRUG DELIVERY TECHNOLOGIES ALKERMES,INC. 88 Sidney Street Bldg 275-3E-10 Cambridge, MA 02139 See Company Profile St. Paul, MN 55110 Phone: (617) 494-0171 Fax: (617) 494-9263 Phone: (800) 643-8086 Fax: 651-737-5265 e-mail: [email protected] www.3m.com/ddsadv www.alkermes.com Current Technologies/Platforms: Application(s): Current Partner(s): Current Technologies/Platforms: Application(s): Current Partner(s): Inhalation Drug Delivery Systems Systemic/Pulmonary Schering-Plough Corporation, Medisorb® Technology Proprietary, injectable extended-release Confidential and Components Forest Pharmaceuticals, Inc., technology to encapsulate small Boehringer Ingelheim molecules, peptides, and proteins in Pharmaceuticals, Inc., Novartis microspheres made of biodegradable Pharmaceuticals Corporation, polymers. With extended-release profiles GlaxoSmithKline, Sepracor, IVAX lasting from days to months, these microspheres eliminate the need for Transdermal Drug Delivery Transdermal Schering AG, Berlex frequent dosing and may be used for SQ or Systems and Components Laboratoriess, Inc. IM delivery.
Microstructured Transdermal Proteins & Peptides, Vaccines AIR® Technology Pulmonary technology offers unique, Confidential Systems proprietary system for optimized delivery. Pipeline Technologies/Platforms: Application(s): Development stage: System can provide efficient dry-powder delivery of small molecule, peptide, protein, Novel Excipients Transdermal, Pulmonary/Nasal and other macromolecule drug particles to the deep lung. Contact: Brian Gabrio, [email protected] DRUG DELIVERY TECHNOLOGIES Contact: Ken Andrews, Chief Commercial Officer AEROVECTRX CORPORATION DRUG DELIVERY TECHNOLOGIES Suite 1500 3003 Summit Blvd. N.E. ALTEA THERAPEUTICS CORPORATION Atlanta, GA 30319 2056 Weems Road Phone: (404) 460-5450 Fax: (404) 460-5001 Tucker, GA 30084 e-mail: [email protected] Phone: (678) 495-3100 Fax: (678) 495-3130 Website: www.aerovectrx.com e-mail: [email protected] Current Technologies/Platforms: Application(s): Current Partner(s): www.alteatherapeutics.com Aerocurrent Self-administered aerosol drug delivery Under development Current Technologies/Platforms: Application(s): Current Partner(s): Aerolife Mass-immunization for aerosolized CONFIDENTIAL PassPort™ System - Altea Altea Therapeutics is currently developing In January 2006, Altea vaccines for infectious diseases in Therapeutics new transdermal a fentanyl citrate patch for management of Therapeutics and Teikoku developing countries technology enables the sustained moderate-to- severe pain, a basal insulin Seiyaku Co. Ltd. of Japan transdermal delivery of water- patch for treatment of diabetes, an signed an exclusive licensing Aerolife Aerosol drug delivery Under development soluble drugs, peptides, proteins, apomorphine hydrochloride patch for agreement for Japan to develop and nucleotides from a convenient treatment of Parkinson’s disease, and an and commercialize a and cost-effective skin patch. influenza vaccine patch. transdermal patch therapy for Aerocell Disposable mesh/drug cartridge for use Under development the treatment of advanced with Aerocurrent and Aerolife Parkinson’s disease.
Contact: Matthew Kim, CEO Contact: Steven P. Damon, VP Business Development
DRUG DELIVERY TECHNOLOGIES DRUG DELIVERY TECHNOLOGIES AKINA,INC. AMERICAN PEPTIDE COMPANY,INC. Business & Technology Center 777 East Evelyn Avenue 1291 Cumberland Avenue, E130 Sunnyvale, CA 94086 West Lafayette, IN 47906-1385 Phone: (408) 733-7604, x204 Phone: (765) 464-0501 Fax: (765) 464-0820 www.americanpeptide.com e-mail: [email protected] - www.akinainc.com Current Technologies/Platforms: Application(s): Current Partner(s): Current Technologies/Platforms: Application(s): Current Partner(s): Frosta Oral Fast Melting Tablets Samyang Corp. Catalog Peptide, Custom Peptides, Research in Cell Biology, Microbiology, Immunology, Biotechnology and HytroCelle Delivery of poorly soluble drugs (oral and CGMP Peptides, Oligo-Nucleotides, and Drug Discovery. Clinical trial and new drug Pharmaceutical parenteral) Dye Ptoducts, Process Development applications companies; as well as Diagnostic and Antibody companies PollyShell Delivery of protein drugs (parenteral) Contact: Gary Hu, (800) 926-8272, x204 Aquagel Gastric retention devices and diet control Kos Pharmaceuticals
Stentrix Drug delivery from stents
Contact: Kinam Park, PhD, (765) 464-0390, [email protected]
Drug Delivery Technology November/December 2006 Vol 6 No 10 73 * DDT Nov-Dec 2006 Round 5 11/10/06 8:17 PM Page 75
DRUG DELIVERY TECHNOLOGIES DRUG DELIVERY TECHNOLOGIES ANTARES PHARMA,INC. AVEVA DRUG DELIVERY SYSTEMS,INC. 707 Eagleview Boulevard, Suite 414 3250 Commerce Parkway Exton, PA 19341 Miramar, Florida 33025 Phone: (610) 458-6200 Phone: (954) 430-3340 Fax: 954-430-3390 Fax: (610) 458-0756 www.avevadds.com www.antarespharma.com Current Technologies/Platforms: Application(s): Current Partner(s): Current Technologies/Platforms: Application(s): Current Partner(s): Gel Matrix Adhesive Transdermal Once-a-day Isosorbide Dinitrate • Teva Medi-Jector VISION® needle-free Insulin, growth hormone Ferring, JCR, SciGen Patch injectors Pipeline Technologies/Platforms: Application(s): Development stage: Crystal Reservoir Chrono-Controlled Release, Sustained Release, Immediate Release • Pfizer Antares Pharma Vibex™ mini-needle Large and small molecule delivery Clinical trials injectors - single-dose, disposable Volatile Drug System Smoking Cessation Needle-free injection technology Diabetes, obesity Lilly • Perrigo ATD™ Advanced Transdermal Gel Transdermal delivery Clinical trials Membrane Controlled Systems Weight Loss, HRT, Antiemetics, Easy Tec™ Oral Dissolving Tablet Oral delivery Pre-clinical Bronchodilators, CNS Stimulants, Antimigraine • Watson Contact: Mike Kasprick: [email protected], Jim Hattersley: [email protected] Unique Matrix Technology Analgesics, Weight Loss HRT, Antiemetics, CNS Stimulants, Antimigraine DRUG DELIVERY TECHNOLOGIES • Toa Eiyo Liquid/ Semisolid Formulations Analgesics, Hypoglycemics ALZA CORPORATION See Company 1900 Charleston Road Profile Dissolvable/ Aqueous Films Analgesics, Antiemetics, CNS Stimulants, • BioDelivery Sciences Mountain View, CA 94043 Hypoglycemics International Phone: (650) 564-5000 www.alza.com Pipeline Technologies/Platforms: Application(s): Development stage: Current Technologies/Platforms: Application(s): Current Partner(s): Mucosal Breakthrough Pain Clinical Trials
OROS® Oral Pharmacia Corporation (Covera- Transdermal Asthma Preclinical HS®), Novartis (DynaCirc CR®), Pfizer (Cardura® XL Glucotrol® XL, Procardia XL®, Sudafed® 24 Transdermal Asthma Clinical Trails Hour), Muro Pharmaceutical, Inc. (Volmax®), Ortho-McNeil Transdermal Pain Management Clinical Trials Pharmaceutical (Ditropan) XL®), McNeil Consumer & Speciality Contact: Bob Bloder/ Brian Guy Pharmaceuticals (Concerta®)
D-TRANS® Transdermal GSK (Nicoderm® CQ® and Clear DRUG DELIVERY TECHNOLOGIES Nicoderm® CQ®), Boehringer BAXTER HEALTHCARE CORPORATION Ingelheim Pharmaceuticals Route 120 & Wilson Roads (Catapres-TTS), Janssen Round Lake, IL 60073 Pharmaceuticals Inc. T: (800) 422-9837 (domestic) or (847) 948-4770 (Duragesic®), Novartis F: (847) 948-3642 (Transderm-Nitro®, Transderm e-mail: [email protected] Scop®, Estraderm®) www.baxterbiopharmasolutions.com Ortho-McNeil Pharmaceutical (Testoderm®) Current Technologies/Platforms: Application(s): Current Partner(s):
DUROS® Implant Bayer (Viadur®) Enhanced Packaging (Ready-to-Use Premixed, Parenteral Formulations Systems; Ready-to-Mix Systems Pipeline Technologies/Platforms: Application(s): Development stage: PROMAXX Microsphere Technology Protein/Peptide/DNA/Organic Drugs; Macroflux® Transdermal/Theratechnologies Collaboration Pre-clinical Injectable Drug Delivery; Inhalable Drug DUROS® Omega BMI Collaboration for hepatitis Pre-clinical Delivery; Ophthalmic; Nasal STEALTH® her2 Liposomal targeted oncology Pre-clinical ® Not disclosed STEALTH CKD 602 Liposomal oncology Pre-clinical NANOEDGE Dispersion Technology Lyophilized; Aseptic & Terminally Sterilized E-TRANS® fentanyl Transdermal, Acute pain in post operative Phase II Parenterals; Direct Homogenization; setting Microprecipitation L-OROS™ Liquid formulation OROS, oral delivery Actively Seeking Partner ALZAMER® Depot Actively Seeking Partner Cytotoxic Contract Services Lyophilization; Aseptic Liquid Vial Filling; Dry Powder Vial Filling; and Sterile Crsytallization - ALZA is actively seeking partners for all of its technology platforms - Parenteral Contract Services Prefilled Syringes; Lyophilization; Aseptic Contact: [email protected] (for business development/partnership inquiries) Liquid Vial Filling; Cartridge Filling; (650) 564-5555 (for business development/partnership inquiries) Labelling/Packaging; R&D Services; Biologic Manufacturing; Kitting See Company DRUG DELIVERY TECHNOLOGIES Profile ARADIGM CORPORATION Contact: Kim Thomas, (847) 270-5072 3929 Point Eden Way Hayward, CA 94545 DRUG DELIVERY TECHNOLOGIES Phone: (510) 265-9000 Fax: (510) 265-0277 BD MEDICAL -PHARMACEUTICAL SYSTEMS www.aradigm.com 1 Becton Drive, Franklin Lakes, NJ 07417 MC: 407 T: (201) 847-4672 F: (201) 847-4847 Current Technologies/Platforms: Application(s): Current Partner(s): e-mail: [email protected] AERxPulmonary Delivery System Insulin Novo Nordisk www.bd.com Asthma APT Pharmaceuticals Anthrax Canadian Gov’t. Current Technologies/Platforms: Application(s): Current Partner(s): Cystic Fibrosis Proprietary BD Hypak SCF™: Glass Prefillable Parenteral Pulmonary Hypertension United Therapeutics BD™ Pens: Customized Self- Parenteral Injection Devices Many See Company Contact: Tom Chesterman, Chief Financial Officer, [email protected] BD Accuspray™: Nasal Spray System Nasal Profile BD Uniject™: Prefill Injection Device Parenteral BD Preventis™: Automatic Needle Parenteral Shielding System Contact: Jennifer Zolot, [email protected] 74 Drug Delivery Technology November/December 2006 Vol 6 No 10 * DDT Nov-Dec 2006 Round 5 11/10/06 8:18 PM Page 76
See Company Profile DRUG DELIVERY TECHNOLOGIES DRUG DELIVERY TECHNOLOGIES BESPAK PLC BROOKWOOD PHARMACEUTICALS,INC. Blackhill Drive, Featherstone Road, Wolverton Mill South 756 Tom Martin Drive Milton Keynes, Buckinghamshire MK12 5TS Birmingham, AL 35211 United Kingdom Phone: (205) 917-2200 - Fax: (205) 917-2205 Phone: +44(0)1908 552600 - Fax: +44(0)1908 552613 www.brookwoodpharma.com e-mail: [email protected] - www.bespak.com Current Technologies/Platforms: Application(s): Current Partner(s): Current Technologies/Platforms: Application(s): Current Partner(s): Long-acting Parenterals - Microparticle formulations for delivery of small Microparticles molecules, peptides, proteins, nucleic acids, and BK357 HFA MDI Valve MDI: Suspension & Solution HFA Formulations GSK, Teva, Sepracor, Cipla, biological macromolecules by various routes of Boehringer Ingelheim, administration (systemic and local delivery) and Sanofi-Aventis, Chiesi, duration of release of days, weeks, and months. Valeas, Merck Generics Nanoparticles Manufacturing of liposomes, polymeric BK361 Easifill MDI: Suspension & Solution HFA Formulations Confidential nanoparticles, and lipid nanoparticles for clinical trials and commercial supply. Mechanical Dose Counter MDI Dose Counting Confidential Long-acting Parenterals - Injectable Injectable rods of resorbable polymer and drug Undisclosed Pipeline Technologies/Platforms: Application(s): Development stage: Solid Implants for systemic or local delivery with duration of release of days, weeks, or months. UniDose DP Nasal Delivery of Powder Formulations Preclinical VAXCAPTM Vaccine Delivery -Therapeutic & prophylactic vaccines -Mucosal & systemic responses Nasal Cast Modelling Drug Deposition in Nasal Cavity Lab Trials -Antibody & cell-mediated responses -Auto-boosting with single administration Contact Person: Joe Keenan, [email protected] Modified Polymer Surfaces -Covalently linking moieties, such as peptides, proteins, and polysaccharides, to biodegradable DRUG DELIVERY TECHNOLOGIES polymer matrices, such as microparticle rods, fibers, BIODELIVERY SCIENCES INTERNATIONAL,INC. meshes, and other three dimensional shapes. -Applicable to drug delivery formulations or 2501 Aerial Center Parkway, Suite 205 medical devices Morrisville, NC 27560 Phone: (919) 653-5160 Fax: (919) 653-5161 Long-acting, Injectable Hydrophobic -Drug delivery through the use of injectable, Drug Particles hydrophobic drug particles email: [email protected] -Synthesis and particle size control www.bdsinternational.com -cGMP clinical lot manufacturing up to the 75-kg scale Current Technologies/Platforms: Application(s): Current Partner(s): Drug-Eluting Devices Design, development and manufacturing of Bioral® cochleate technology for Oral delivery Sigma-Tau biodegradable drug-eluting devices, e.g., for local oral delivery of products not normally Accentia drug delivery. available orally (hydrophobic drugs, Biopharmaceuticals nucleotides, vaccines, etc.) Contact: Kelly Arlint, (205) 917-2239 BEMA™ technology for transmucosal Transmucosal delivery membrane administration of drugs Pipeline Technologies/Platforms: Application(s): Development Stage: BEMA™ Fentanyl Breakthrough Cancer Pain Phase III BEMA Long Acting Analgesic Pain Phase I
Bioral® Amphotericin B Oral Antifungal Preclinical BEMA™ Zolpidem Insomnia Preclinical
Bioral® siRNAs Oral delivery Preclinical
Contact: Evan Gothard, [email protected] DRUG DELIVERY TECHNOLOGIES BIOJECT INC. 20245 SW 95 Avenue Tualatin, OR 97062 Phone: (800) 683-7221 Fax: 503-692-6698 e-mail: [email protected] www.bioject.com Current Technologies/Platforms: Application(s): Current Partner(s): BioJector® 2000 IM & SQ delivery Trimeris/Roche Vitajet SQ delivery Serono, Merial Needle-free Vial adapter reconstitution Ferring, Amgen Pipeline Technologies/Platforms: Application(s): Development stage:
IJECT pre-filled Self injection Clinical trials Multi-dose injector SQ multi-dose In Development Contact: Mike Redmond
Drug Delivery Technology November/December 2006 Vol 6 No 10 75 * DDT Nov-Dec 2006 FINAL 12/13/06 8:06 PM Page 77
DRUG DELIVERY TECHNOLOGIES DRUG DELIVERY TECHNOLOGIES CAPSUGEL CHRYSALIS TECHNOLOGIES (DIVISION OF PMUSA) 535 North Emerald Road 7801 Whitepine Road Greenwood, SC 29646 Richmond, VA 23237 Phone: (888) 783-6361 Fax: (888) 783-6360 Phone: (804) 864-4325 Fax: (804) 864-4443 email: [email protected] [email protected] www.capsugel.com www.chrysalis-technologies.com Current Technologies/Platforms: Application(s): Current Partner(s): Current Technologies/Platforms: Application(s): Current Partner(s): Capsules Hard gelatin, HPMC and pullulan Capillary Aerosol Generation Pulmonary Drug Delivery Discovery Labs PCcaps® Capsules & dosing syringe system ideally suited for oral dosage to rodents in pre-clinical studies Contact: Dr. Patrick D. Lilly
DBcaps® Capsules designed for overencapsulation in Undisclosed double blind clinical studies DRUG DELIVERY TECHNOLOGIES CIMA LABS INC. ® Licaps Empty capsules designed for liquid-in gelatin 10000 Valley View Road and HPMC y mpan ee Co Eden Prairie, MN 55344 S e Profil Phone: (952) 947-8700 www.cimalabs.com Contact: Glenda Oliver-Smith
DRUG DELIVERY TECHNOLOGIES Current Technologies/Platforms: Application(s): Current Partner(s): CARDINAL HEALTH 14 Schoolhouse Road OraSolv® An orally disentegrating tablet that combines taste Bristol-Meyers Squibb Somerset, New Jersey 08873 masked active drug ingredients with a low (Tempra FirsTabs), Novartis effervescence system; blistered (Triaminic Softchews), Phone: (866) 720-3148 Fax: (732) 537-5949 Organon (Remeron SolTab) email: [email protected] Alamo (FazaClo), Schering- www.cardinal.com/pts Plough (CLARINEX Reditabs) Current Technologies/Platforms: Application(s): Current Partner(s): DuraSolv® An orally disentegrating tablet that combines taste AstraZeneca (Zomig-ZMT), masked active drug ingredients with or without a Schwarz-Pharma (NuLev), ® Zydis Oral (fast-dissolve tablets) low effervescence system; blistered or bottled Wyeth (Alavert & Dimetapp Capsules Soft gelatin & hard-shell gelatin ND), Schwarz-Pharma (NuLev, Parcopa, Niravam) Microsponge® Topical (Cross-linked polymethacrylate copolymer particles) PakSolv® Light and moisture proof proprietary packaging All partners utilize PakSolv pany ® Com system; also physically protects ODTs as either product or trade EnSolv Oral Modified Release See e Profil sample packaging EnCirc® Oral Modified Release EnVel® Oral Modified Release OraVescent® Enhanced-absorption drug delivery system Cephalon (fentanyl) intended to improve the transport of active drug Contact: (866) 720-3148 (toll-free) or [email protected] ingredients across mucosal membranes; may improve biovailability and accelerate the onset of DRUG DELIVERY TECHNOLOGIES action of some active drug ingredients CELSION CORPORATION Contact: Business Development, (952) 947-8700 10220-L Old Columbia Road DRUG DELIVERY TECHNOLOGIES Columbia, MD 21046 Phone: (410) 290-5390 Fax: (410) 290-5394 CIRRUS PHARMACEUTICALS, INC. email: [email protected] P.O. Box 14748 www.celsion.com Research Triangle Park, NC 27709-4748 Phone: (919) 884-2064 Fax: (919) 884-2075 Current Technologies/Platforms: Application(s): Current Partner(s): email: [email protected] Adaptive Phased Array Treatment Focused microwave heating (Breast Cancer) MIT www.cirruspharm.com
Thermodynamic Therapy Drug Focused delivery of encapsulated drugs using Duke University (in Phase I Current Technologies/Platforms: Application(s): Current Partner(s): Delivery System thermosensitive liposomes (Prostate, Liver, for Prostate Cancer and entering Phase I for Liver Cancer) Dry Powder Inhaler Formulation & Development Inhalation Confidential Pipeline Technologies/Platforms: Application(s): Development stage: Meter Dose Inhaler Formulation & Targeted Gene Therapy Technology Heat-activated Gene Expression Preclinical (Memorial Sloan Development Inhalation Kettering) Nasal Spray Formulation & Contact: Anthony Deasey, EVP & COO, (410) 290-5390 x4899 Development Inhalation
DRUG DELIVERY TECHNOLOGIES Nebulizer Solution Formulation & Development Inhalation CHR.HANSEN 9015 W. Maple Street Parenteral Formulation & Development Parenteral Milwaukee, WI 53214 Phone: (800) 558-0802 Fax: (414) 607-5959 Oral Drug Formulation & Development Oral email: [email protected] www.chr-hansen.com Topical Formulation & Development Topical, Transdermal Current Technologies/Platforms: Application(s): Current Partner(s): Peptide & Protein Formulation & Various Development Chr. Hansen Sugar Spheres NF Timed release Contact: Michael Branciforti (919) 321-4043
76 Drug Delivery Technology November/December 2006 Vol 6 No 10 * DDT Nov-Dec 2006 Round 5 11/10/06 8:18 PM Page 78
DRUG DELIVERY TECHNOLOGIES DRUG DELIVERY TECHNOLOGIES CORIUM INTERNATIONAL DENDRITIC NANOTECHNOLOGIES,INC. 2686 Middlefield Road, Suite G 2625 Denison Drive Redwood City, CA 94063 Mount Pleasant, MI 48858 Phone: (650) 298-8255 Fax: (650) 298-8012 Phone: (989) 774-6565 Fax: (989) 774-2322 email: [email protected] email: [email protected] www.coriumgroup.com www.dnanotech.com Current Technologies/Platforms: Application(s): Current Partner(s): Current Technologies/Platforms: Application(s): Current Partner(s): Corplex™ Hydrogel Transdermal, mucosal, wound care, device, Pharma, specialty, generic, STARBURST™ Dendrimer Platform Drug Delivery, Imaging Large Pharma Companies and diagnostic products wound care, and device Enhanced Drug Solubility Actively Seeking Partner MicroCor™ Micro Delivery System companies Priostar™ Dendrimer Platform Drug Delivery, Imaging Actively Seeking Partner Delivery Modifiers/Permeation Enhanced Drug Solubility Actively Seeking Partner Enhancers Pipeline Technologies/Platforms: Application(s): Development stage: Contact: Deb Fox, PhD, V.P. of Business Development, (203) 775-7124, email: [email protected] MRI Agent undisclosed Blood pool, targeted organs Pre-clinical DRUG DELIVERY TECHNOLOGIES Cisplatin-Dendrimer formulation Ovarian cancer Pre-clinical Drug Formulation undisclosed Oncology Late Development CP KELCO siRNA Formulation Transfection Pre-clinical 8355 Aero Drive Contact: Ryan Hayes, PhD, Director of Business Development, (989) 774-6565 San Diego, CA 92123 Phone: (858) 292-4900 Fax: (858) 292-4901 DRUG DELIVERY TECHNOLOGIES email: [email protected] DEPOMED,INC. www.cpkelco.com 1360 O’Brien Drive Current Technologies/Platforms: Application(s): Current Partner(s): Menlo Park, CA 94025
KELTROL® xanthan gum Oral drug delivery systems Phone: (650) 462-5900 XANTURAL® xanthan gum Mucosal drug delivery www.depomed.com KELCOGEL® gellan gum Transdermal drug delivery Current Technologies/Platforms: Application(s): Current Partner(s): GELRITE® gellan gum Controlled & sustained drug release GENU® pectin Colonic drug delivery Gastric Retention (GR) System Proprietary, oral, controlled-release drug delivery Biovail, Inc., ActivBiotics and GENU® carrageenan Edible film delivery systems system AVI BioPharma
Contact: Anne Sinha, (858) 467-6615 Pipeline Technologies/Platforms: Application(s): Development stage: Metformin GR Type II diabetes (oral) Conducting second phase III DRUG DELIVERY TECHNOLOGIES Ciprofloxacin GR Urinary Tract Infection (oral) Phase III Gabapentin GR Seizures/Pain (oral) Phase I completed CYDEX,INC. Furosemide GR Diuretic (oral) Phase I completed 10513 West 84th Terrace Metformin/Sulfonylurea GR combo Type II diabetes (oral) Preclinical NEUGENE product Undisclosed Preclinical Lenexa, KS 66214 Rifalazil GR GI Infection (oral) Preclinical Phone: (913) 685-8850 Fax: (913) 685-8856 email: [email protected] Contact: Thadd Vargas, (650) 462-5900 www.cydexinc.com DRUG DELIVERY TECHNOLOGIES Current Technologies/Platforms: Application(s): Current Partner(s): DOW CORNING CORPORATION CAPTISOL® (b-Cyclodextrin Sulfobutyl Parenteral, Oral, Inhalation, Ophthalmic, Other Allergan, Inc.; Bristol-Myers PO Box 994 Ethers, Sodium Salts) drug delivery Squibb; Daiichi Asubio Pharma Midland, MI 48686 technology Co., Ltd.; Merck & Co., Inc.; Phone: (989) 496-6000 Fax: (989) 496-6731 Pfizer Inc.; Pfizer Animal Health; Taisho Pharmaceutical Co., Ltd.; email: [email protected] TargeGen, Inc.; Teva www.dowcorning.com Pharmaceutical Industries, Ltd.; Genentech Inc.; AstraZeneca UK Current Technologies/Platforms: Application(s): Current Partner(s): Limited; Gilead Sciences, Inc.; Array BioPharma Inc. Transdermal Drug Delivery Pressure Sensitive (PSA) and Soft Skin (SSA) adhesives; excipients; elastomeric matrices; in situ film-forming materials; coatings; fluids; and emulsions Pipeline Technologies/Platforms: Application(s): Development stage: Controlled Release Devices Adhesives, Medical-Grade Elastomers Many Captisol-Enabled® Formulations: • Amiodarone – Licensed Worldwide -IV Antiarrhythmic Preclinical – Clinical; Seeking Excipients for Topical Ointments, Emulsions, Gels, Sprays, Sticks, • Budesonide – Licensed in the U.S. -Respiratory development/marketing Pharmaceutical Applications Delivery of Actives • Fexofenadine -Oral Antihistamine partners • Fosphenytoin -IV Anti-epilepsy Topical excipients Volatile excipients, fluids, blends, waxes and • Melphalan – Licensed in the U.S. -IV Oncology emulsifiers to aid the delivery of topical forms and • Propofol -IV Anesthetic actives • Sertraline -Oral Antidepressant Contact: Stacey Chapin
Contact: Jose L. Rodriguez DRUG DELIVERY TECHNOLOGIES DELSITE BIOTECHNOLOGIES,INC. 1505 Walnut Hill Lane Irving, TX 75038 Phone: (972) 717-5009 Fax: (972) 831-1132 email: [email protected] www.delsite.com Pipeline Technologies/Platforms: Application(s): Development stage: GelVac™ Nasal Powder System Vaccine delivery Phase I completed GelSite® Polymer Injectable System Injectable delivery of protein & peptide drugs Pre-clinical Contact: Jean Anne Mire, Director, Business Development, (972) 650-7320, email: [email protected] Drug Delivery Technology November/December 2006 Vol 6 No 10 77 * DDT Nov-Dec 2006 Round 5 11/10/06 8:18 PM Page 79
DRUG DELIVERY TECHNOLOGIES DRUG DELIVERY TECHNOLOGIES DPT LABORATORIES,LTD. E.I. DUPONT DE NEMOURS COMPANY 307 East Josephine Street DuPont Fluorochemicals, Chestnut Run Plaza San Antonio, TX 78215 Wilmington, DE 19880-0711 Phone: (210) 476-8159 Fax: (210) 829-8733 Phone: (302) 224-0426 Fax: (302) 224-0427 www.dupont.com/dymel e-mail: [email protected] www.dptlabs.com Current Technologies/Platforms: Application(s): Current Partner(s): Current Technologies/Platforms: Application(s): Current Partner(s): Technical Service Assistance (i.e. Metered Dose Inhalers, Dry Powder Inhalers and Confidential Advanced formulation expertise, Aerosols, Creams, Foams, Gels, Basic Propellant Properties and other medical aerosols including multivesicular Lotions, Ointments, Solutions, Characteristics, Formulation emulsions, liposomes, Suspensions, Nasal Sprays Properties Data, Formulation Testing, microemulsions, anhydrous See Company Profile Analytical Services, Toxicity aerosol foams, low surfactant and Information, Regulatory Assistance, surfactant-free formulations Safe Storage and Handling
Contact: Roxanne Barr Particle Science Technology, Metered Dose Inhalers, Dry Powder Inhalers and Confidential Engineering Evaluations for Heat, other medical aerosols DRUG DELIVERY TECHNOLOGIES Mass & Momentum Transfer, Quality Management and Technology, DURECT CORPORATION Chemical & Reaction Engineering, 10240 Bubb Road Electrical & Energy Engineering, Cupertino, CA 95014 Environmental and Process Safety Phone: (408) 777-1417 Fax: (408) 777-3577 email: [email protected] Contact: Mr. Joe Creazzo, email: [email protected] www.durect.com DRUG DELIVERY TECHNOLOGIES Current Technologies/Platforms: Application(s): Current Partner(s): EGALET DUROS® systemic and site-directed implantable Endo Pharmaceuticals Lejrvej 37- 41 Kirke Vaerlose DK – 3500 Vaerlose - Denmark SABER® parenteral, oral, dermal and others Cardinal Health, BioPartners, Phone: +45 4447 8080 Fax: +45 4447 2425 Pain Therapeutics www.egalet.com DURIN™ biodegradable implant Voyager Pharmaceuticals Current Technologies/Platforms: Application(s): Current Partner(s): MICRODUR™ microsphere injectables Egalet® Oral Sustained Release LACTEL® biodegradable polymers Various Parvulet® Pediatrics Contact: Schond Greenway, (408) 777-1417 Pipeline Technologies/Platforms: Application(s): Development stage:
Cardiovascular Phase III DRUG DELIVERY TECHNOLOGIES Morphine Phase II EASTMAN CHEMICAL COMPANY Contact: Ken Downie 200 S Wilcox Drive, Box 431 Kingsport, TN 37662 DRUG DELIVERY TECHNOLOGIES Phone: (800) 327-8626 Fax: (423) 229-2707 www.eastman.com ELAN DRUG TECHNOLOGIES Current Technologies/Platforms: Application(s): Current Partner(s): Monksland - Athlone, Co Westmeath - Ireland Phone: +353 90 64 95000 Fax: +353 90 64 95807 C-A-P NF Enteric coating e-mail: [email protected] Eastacryl™ 30D NF acrylic coating Enteric coating Website: www.elan.com/EDT material Current Technologies/Platforms: Application(s): Current Partner(s):
Eastman CA-398-10 NF Sustained/Controlled Release; Taste Masking; NanoCrystal® Technology Oral: enhanced bioavailability, rapid absorption, Number of clients including Semi-Permeable Films (for poorly water-soluble compounds) decreased fed/fasted variability. Solid oral dosage commercialized products forms, waterless tablets, oral liquids with Merck, Wyeth, Eastman CAB-171-15-PG Sustained/Controlled Release; Taste Masking; Fournier/Abbott and Par. Semi-Permeable Films Parenteral: low volume, high dose aqueous formula- tions for IV, IM and Sub-Q administration Eastman Vitamin E TPGS NF Absorption Enhancer, Solubilizer, Bioavailability Enhancer Respiratory: liquid and dry powder formulations for upper respiratory or deep lung delivery; sterile, Contact: Carolyn Baker, (423) 229-2987 preservative-free aqueous nasal spray suspensions Pipeline Technologies/Platforms: Application(s): Development stage: NanoCrystal® Technology IM formulation of NCE Phase III NanoCrystal® Technology Inhalation reformulation of marketed product Phase II NanoCrystal® Technology Oral liquid NCE Phase II NanoCrystal® Technology Tablet NCE Phase I NanoCrystal® Technology IM depot Phase I NanoCrystal® Technology Tablet reformulation of marketed product Phase I Contact: Sarah Carty, [email protected]
78 Drug Delivery Technology November/December 2006 Vol 6 No 10 * DDT Nov-Dec 2006 Round 5 11/10/06 8:18 PM Page 80
DRUG DELIVERY TECHNOLOGIES DRUG DELIVERY TECHNOLOGIES EMISPHERE TECHNOLOGIES,INC. FERRIS PHARMACEUTICALS INC. 765 Old Saw Mill River Road 16W300 83rd Street Tarrytown, NY 10591 Burr Ridge, IL 60527-5848 Phone: (914) 347-2220 Phone: (630) 734-7810 Fax: (630) 887-1008 www.emisphere.com Current Technologies/Platforms: Application(s): Current Partner(s): email: [email protected] www.FerrisCares.com Eligen Oral Drug Delivery Oral delivery of macromolecules and other non- Proprietary Technology Technology orally available therapeutics Current Technologies/Platforms: Application(s): Current Partner(s): Pipeline Technologies/Platforms: Application(s): Development stage: Polyurethane matrix (contains Wound dressings Marketed by Ferris Mfg. absorbent starch, glycerol, surfactant) Corp. Oral Heparin Solid Dose Cardiovascular Phase III - Self Developed drug free
Oral LMWH Solid Dose Cardiovascular Phase I - Undisclosed partner Polyurethane matrix containing Antimicrobial dressings Marketed by Ferris Mfg. antimicrobial (nanocrystalline silver) Corp. Oral Salmon Calcitonin Osteoporosis/Osteoarthritis Phase III - Novartis Pipeline Technologies/Platforms: Application(s): Development stage: Oral Recombinant Parathyroid Osteoporosis Phase I - Novartis Hormone 1-34 Loaded foam and gel formulations to Transdermal - healthy or injured skin/tissue which drugs, carriers, biologicals, or Mucosal - (mouth, nose, rectum) healthy/injured Oral Insulin Diabetes Phase II - Self Developed cosmetics (dry or liquid form) can be added without heat/shear Oral Cromolyn Sodium Asthma/Allergies Phase II - Self Developed degradation, sterile/non-sterile
Oral Recombinant Human Growth Growth disorders Phase I - Novartis Contact: Paul Kay Hormone (somatropin)
Oral Acyclolvir Anti-viral Phase I - Undisclosed DRUG DELIVERY TECHNOLOGIES FERTIN PHARMA A/S Oral Gallium Oncology Pre-clinical - Genta Industrivej 8 Other Feasibility Projects Various Pre-clinical DK-7120 Vejle Denmark Contact: Business Development (914) 347-2220 Phone: (+45) 72 15 13 00 Fax: (+45) 72 15 13 01 email: [email protected] DRUG DELIVERY TECHNOLOGIES www.fertin.com ETHYPHARM Current Technologies/Platforms: Application(s): Current Partner(s): 194 Bureaux de la Colline 92213 Saint-Cloud Cedex - France MediChew® Oral, Buccal Novartis, GlaxoSmithKline Phone: +33 1 41 12 17 20 www.ethypharm.com DRUG DELIVERY TECHNOLOGIES
ILTERTEK NC F I . See Company Current Technologies/Platforms: Application(s): Current Partner(s): 11411 Price Road Profile Oral Modified Release Oral, site-specific, sustained, delayed Biovail, Astra Hebron, IL 60034 Taste-Masking, Orodispersible Oral, rapid dispersion Jansen, BMS Oral Enhanced Absorption Oral, pulmonary (macromolecules) Novartis, Sanofi Phone: (800) 648-0791 Fax: Injectable Modified Release Parenteral / implantation parenteral (800) 648-2929 Vaccine Delivery/Cancer & Adjuvants Parenteral www.filtertek.com Current Technologies/Platforms: Application(s): Current Partner(s): Contact: Bruno Delie, Senior VP, Business Development, +33 1 41 12 17 20 Needles Access Products Drug Delivery/Transfer Various
Various Filters and Fluid Control Intravenous Drug Delivery Various DRUG DELIVERY TECHNOLOGIES Components EURAND,INC. 845 Center Drive Air and Liquid Filters Pharmaceutical/Laboratory Processing Various Vandalia, OH 45377 Contact: Bruce Daniels, VP Medical Marketing Phone: (937) 898-9669 Fax: (937) 898-1093 email: [email protected] DRUG DELIVERY TECHNOLOGIES www.eurand.com FLAMEL TECHNOLOGIES S.A. Current Technologies/Platforms: Application(s): Current Partner(s): Parc Club Du Moulin á Vent AdvaTab™ Taste-masking, Fast Dissolve 33, Avenue du Docteur Georges Lévy 69693 Vénissieux Cedex - France Biorise® Bioavailability Enhancement Multiple International Partners Phone: (+33) 4-72-78-34-34 Diffucaps® Customized Release www.flamel.com Current Technologies/Platforms: Application(s): Current Partner(s): Diffutabs® Customized Release MicroPump Oral (MicroPump) GSK, Servier Monde, Liquitard Taste-masking/Suspension MEDUSA Parenteral Merck & Co. (all with MicroPump) Microcaps® Taste-masking/Fast-dissolve Pipeline Technologies/Platforms: Application(s): Development stage: Minitabs® Customized Release See Company Profile Genvir (MicroPump) Oral Phase III Orbexa™ Customized Release Metformin XL (MicroPump) Oral Phase I Ace Inhibitor (MicroPump) Oral Confidential Pipeline Technologies/Platforms: Application(s): Development stage: Augmentin SR (MicroPump) Oral Confidential Basulin (MEDUSA) Parenteral Phase I (completed) Drug Targeting/Drug Conjugation Parenteral Pre-Clinical Various Drugs Various Preclinical
Contact: Troy Harmon Contact: Frederick Simonin, (+33) 4-72-78-34-34
Drug Delivery Technology November/December 2006 Vol 6 No 10 79 * DDT Nov-Dec 2006 Round 5 11/10/06 8:18 PM Page 81
DRUG DELIVERY TECHNOLOGIES DRUG DELIVERY TECHNOLOGIES
GENEREX BIOTECHNOLOGY CORPORATION HOVIONE 33 Harbour Square, Suite 202 40 Lake Drive Toronto, Ontario, Canada M5J 2G2 East Windsor, NJ 08520 Phone: (800) 391-6755 Fax: (416) 364-9363 Phone: 609-918-2600 Fax: 609-918-2615 email: [email protected] email: helloovione.com www.generex.com www.hovione.com Current Technologies/Platforms: Application(s): Current Partner(s): RapidMist™ Buccal Mucosa Not Disclosed Current Technologies/Platforms: Application(s): Current Partner(s): Pipeline Technologies/Platforms: Application(s): Development stage: Spray Drying Encapsulation, Aglomeration, Reduction Residual Particle Sizing and shaping Many Generex Oral-lyn™ - Oral insulin Approved in Ecuador Micronization Particle Size Control spray for the treatment of diabetes Buccal Mucosa Glucose RapidSprayTM Freeze Drying Processing Thermally Labile APIs Metformin Gum Not Disclosed Fentanyl Spray Pipeline Technologies/Platforms: Application(s): See Company Contact: Business Development (800) 391-6755, [email protected] Sonocrystallization Profile Other critical crystallization Manipulate degree of crystallinity DRUG DELIVERY TECHNOLOGIES Contact: Mr. Doug Hecker GLATT PHARMACEUTICAL SERVICES 20 Spear Road DRUG DELIVERY TECHNOLOGIES Ramsey, NJ 07446 INEOS FLUOR Phone: (201) 825-8700 The Heath - Runcorn www.glattpharmaceuticals.com Cheshire, WA7 4QX UK Current Technologies/Platforms: Application(s): Current Partner(s): Phone: +44 (0)1928 515525 Fax: +44 (0)1928 511418 CPS™ Proprietary Drug Delivery Technology, High Not Disclosed e-mail: [email protected] Potency Pellets, Uniformly Distributed Low www.ineosfluor.com Doses, Advantages over Extrusion/ Spheronization, Dense, Spherical, Uniform Pellets Current Technologies/Platforms: Application(s): Current Partner(s):
MicroPx™ Proprietary Drug Delivery Technology, High HFA 134a and HFA 227ea Medical Aerosols Supply 80% of world Potency Pellets, Pellets sizes of 50 microns See Company market and larger, Continuous Process, Dense, Profile Spherical, Uniform Medical Propellants
ZRx™ Zero-Order Release Tablet System, Extended Contact: Dr. Tim Noakes Release Tablet Matrix System, Zero or First- Order Release Characteristics Contact: Thomas M. Salus, (201) 818-3778 DRUG DELIVERY TECHNOLOGIES INNERCAP TECHNOLOGIES,INC. DRUG DELIVERY TECHNOLOGIES 5420 Bay Center Drive, Suite 100 HOSPIRA,INC. Tampa, FL 33609 One 2 One Phone: (813) 837-0796 Fax: (813) 837-0207 D988, H1 275 Northfield Drive email: [email protected] www.innercap.com Lake Forest, IL 60045 Phone: (224) 212-2267 Fax: (224) 212-3210 Pipeline Technologies/Platforms: Application(s): Development stage: email: [email protected] www.hospira.com NOVACAPS™ Multi-Phase, Multi-Compartment Capsules Actively seeking Multiple Dual Drug Delivery Licenseess Current Technologies/Platforms: Application(s): Current Partner(s): Controlled and Site Specific Drug Delivery and partner Pre-filled Syringes Plastic polymer and glass syringes available in Incompatible combination drugs luer cone, luer lock, and stacked in needle Pulsatile Drug Delivery configurations Contact: Fred H. Miller, (813) 837-0796 i-SecureTM Pre-filled cartridge syringe designed for DRUG DELIVERY TECHNOLOGIES compatibility with IV sets or needles INTELLIPHARMACEUTICS CORP. VisIVTM Ready-to-use IV medication delivery in a non- Multiple 30 Worcester Road PVC/non-DEHP container Toronto, Ontario M9W 5X2 - Canada Phone: (416) 798-3001, ext. 128 - Fax: (416) 798-3007 ADD-Vantage System® IV admixture system used when medication is not stable in a premix format e-mail: [email protected] www.intellipharmaceutics.com Ansyr Syringe® Pre-filled plastic syringe compatible with IV systems Current Technologies/Platforms: Application(s): Development stage:
Contact: Kevin Wess HyperMatrix™ Technology Platforms Oral Drug Delivery Par Pharmaceuticals, ratiopharm, Elite, Larasan
Contact: Joe Quinto, Director of Business Development
80 Drug Delivery Technology November/December 2006 Vol 6 No 10 * DDT Nov-Dec 2006 FINAL 11/15/06 9:01 PM Page 82
DRUG DELIVERY TECHNOLOGIES DRUG DELIVERY TECHNOLOGIES
INTERNATIONAL SPECIALTY PRODUCTS (ISP) KURVE TECHNOLOGY,INC 1361 Alps Road 19805 North Creek Pkwy Wayne, NJ 07470 Bothell, WA 98011 Phone: (973) 628-4000 Fax: (973) 628-4117 Phone: (425) 640-9249 Fax: (425) 673-5783 email: [email protected] e-mail: [email protected] www.ispcorp.com www.kurvetech.com Current Technologies/Platforms: Application(s): Current Partner(s): Current Technologies/Platforms: Application(s): Development stage: Solid Dispersions Bioavailability Enhancement Not Disclosed Controlled Particle Dispersion™ Nasal drug delivery Confidential Contact: Dr. Tim Bee ViaNase ID Intelligent nasal drug delivery with electronic DRUG DELIVERY TECHNOLOGIES controls & lockouts See Company INTRANASAL THERAPEUTICS,INC. Profile 201 Summit Ave, Ste C-2 Contact: Michael Rackley, VP Business Development, [email protected] Montvale, NJ 07645 Phone: (201) 307-9450 Fax: (201) 307-9455 DRUG DELIVERY TECHNOLOGIES www.intranasal.com LIPOCINE INC. 675 Arapeen Drive, Suite 202 Current Technologies/Platforms: Application(s): Current Partner(s): Salt Lake City, UT 84103 Nasal Drug Development Pain, CNS Confidential Phone: (801) 994-7383 Fax: (801) 994-7388 Aseptic, Preservative Free email: [email protected] www.lipocine.com Pipeline Technologies/Platforms: Application(s): Development stage: Current Technologies/Platforms: Application(s): Current Partner(s): Nasal Drug Development Metabolic Preclinical Lip’ral® Oral poorly water soluble compounds Schwarz Pharma Contact: Ralph S. Johnston Lip’ral® SSR Oral extended release for poorly water soluble Schwarz Pharma compounds DRUG DELIVERY TECHNOLOGIES Hydroance® Oral poorly permeable compounds N/A INYX,INC. See Company Profile 825 Third Avenue, 40th Floor LilV™ Parenteral delivery N/A New York, NY 10022 Phone: (212) 838-1111 Fax: (212) 838-0060 Contact: Jerry Simmons, Corporate Business Development Officer e-mail: [email protected] DRUG DELIVERY TECHNOLOGIES www.inyxgroup.com MACROMED,INC. Current Technologies/Platforms: Application(s): Current Partner(s): 2417 S. 3850W, Suite 150 Metered Dose Inhalers (CFC & HFA) Asthma, Systemic None West Valley City, UT 84120 Dry Powder Inhalers Asthma None T: (801) 433-2560 Fax: (801) 433-2561 Website: www.macromed.com Nasal/Sublingual/Buccal Sprays Allergy, Systemic None e-mail: [email protected] - www.macromed.com Topical Foams/Creams/Ointments/Gels Dermatological None Current Technologies/Platforms: Application(s): Current Partner(s): Aseptic Fill/Sterile Injectables Varied None ReGel Parenteral Depot Solid Dose Varied None HySolv Parenteral/Oral Solubilizer Not Disclosed Contact: Marc Couturier, Senior Vice President, Global Business Development (416) 250-0091 SQZgel Oral Sustained Release
DRUG DELIVERY TECHNOLOGIES Contact: Alex S. Kim, Executive Vice President, (801) 433-2560 IOMED, INC. DRUG DELIVERY TECHNOLOGIES 2441 South 3850 West Salt Lake City, Utah 84120 MEDPHARM LTD Phone: (800) 621-3347 Fax: (801) 972-9072 Business Centre - Sheep Street e-mail: [email protected] Charlbury 0X7 3RR www.iomed.com Oxfordshire, United Kingdom Current Technologies/Platforms: Application(s): Current Partner(s): Phone: +44 (0) 16 0881 9267 Fax: +44 (0) 16 0881 9268 Iontophoresis (non-invasive • Physical therapy email: [email protected] method of drug delivery into and/or • Local dermal anesthesia through biological membranes, www.medpharm.co.uk such as skin, mucosal membrane of the body cavity, or ocular tissue Pipeline Technologies/Platforms: Application(s): Development Stage: for local or systemic applications MedSpray™ A novel topical/transdermal spray Pre-clinical Pipeline Technologies/Platforms: Application(s): Development stage: MedNail® A novel ungual penetration system Pre-clinical Transscleral Iontophoresis (non- • AMD Preclinical MedFoam™ A novel cosmetically elegant stable/fast-breaking Pre-clinical invasive drug delivery into back of • Diabetic Retinopathy foam the eye) See Company Profile D3S™ A device for dermal drug delivery Seeking out-licensing Contact: Jim Isaacson partner
Contact: Carole Delauney, Head of Business Development
Drug Delivery Technology November/December 2006 Vol 6 No 10 81 * DDT Nov-Dec 2006 Round 5 11/10/06 8:18 PM Page 83
DRUG DELIVERY TECHNOLOGIES DRUG DELIVERY TECHNOLOGIES MERRION PHARMACEUTICALS,INC. NASTECH PHARMACEUTICAL COMPANY,INC. 219 Racine Drive, Suite D 3450 Monte Ville Parkway 45 Adams Avenue Wilmington, NC 28403-8702 Bothell, WA 98021 Haupauge, NY 11788 Phone: (910) 799-1847 Fax: (910) 395-1843 Phone: (212) 845-4268 email: [email protected] www.nastech.com www.merrionpharma.com Current Technologies/Platforms: Application(s): Current Partner(s): Current Technologies/Platforms: Application(s): Current Partner(s): Gastrointestinal Permeation Applicable to solid and liquid-filled dosage STAT-T™ - Systemic Transnasal Intranasal Pharmacia, Phol-Boskamp Enhancement Technology (GIPETTM) forms. Enhancer-based technology for oral Absorption Technology for poorly permeable compounds administration of small molecules, macromolecules, peptides, biologics, and PTS™ - Paracellular Transport Intranasal Seeking additional polysaccharides Confidential System partnerships for these technologies JAT™ - Junction Activator Intranasal Gastrointestinal Retention System Applicable to a wide range of drugs; there Technology (GIRESTM) - capsule containing a is no change in the chemical composition controlled-release tablet inside an of API. Targeted at once-a-day dosing for Contact: Robert Stanislaro, (212) 845-4268 inflatable pouch compounds with short biological half-lives, narrow absorption windows, narrow DRUG DELIVERY TECHNOLOGIES therapeutic indices, or which require local delivery to GIT. NEKTAR THERAPEUTICS 150 Industrial Road Pipeline Technologies/Platforms: Application(s): Development stage: San Carlos, CA 94070 Targeted Delivery Systems Targeted Delivery Preclinical Phone: (650) 631-3100 www.nektar.com Oral Vaccine Delivery Systems Oral Preclinical
Contact: Thomas W. Leonard, PhD, VP & CSO Current Technologies/Platforms: Application(s): Current Partner(s):
PEG-INTRON® Parenteral Schering-Plough DRUG DELIVERY TECHNOLOGIES MGLAS AG Neulasta™ (PEG-filgrastim) Parenteral Amgen Otto-Liebmann-Strasse 2 Münnerstadt, Germany 97702 Pipeline Technologies/Platforms: Application(s): Development stage: Phone: +49(0)9733 808-0 Fax: +49(0)9733 808-160 PEGASYS® (PEG-a-interferon) Parenteral Roche email: [email protected] Somavert® (PEG-hGHra) Parenteral Pharmacia Exubera® (inhaled insulin) Inhalation Pfizer www.mglas.de EYE001 (PEGylated aptumer) Parenteral Eyetech Current Technologies/Platforms: Application(s): Current Partner(s): SprayGel™ adhesion barrier Gel Confluent system (PEG) Containers made of tubular glass: Parenteral Pharmcos, among others: CDP870 (PEGylated antibody Parenteral Pharmacia Syringes, cartridges (one- and two- Nasal Apotex, Aradigm, AstraZeneca, fragment) chamber), vials, ampoules, specialties Oral Biotage, Chiron, Sanofi Aventis, Inhaled alpha I Inhalation Phase I upon on customer request Diagnostic Sanofi Pasteur, Baxter, GSK, Inhaled Forté (PTH) Inhalation Phase I Roche Diagnostics, Inhaled tobramycin Inhalation Phase I Schering-Plough, Vetter Inhaled leuprolide Phase I Pipeline Technologies/Platforms: Application(s): Development stage: PEGylated interferon beta Parenteral Phase I PEG-AXOKINE Parenteral Phase I Needle-free devices Transdermal Clinical Phase II PEG-TPO Parenteral Pre-clinical Innovative needles (V Bevel®/Spoon Parenteral Market PEG-prostacyclin Parenteral Pre-clinical Point®/Spoon Point Plus®) PEG proteins Parenteral Pre-clinical Inhaled dronabinol (MDI) Inhalation Pre-clinical Pre-washed/pre-sterilized Parenteral Development Inhaled small molecules Inhalation Pre-clinical cartridges for aseptic filling Single chain antibodies Inhalation Pre-clinical Laser technology Manufacture of containers for Market & Developmet PA2794 Inhalation Pre-clinical parenterals Contact: Joyce Strand, (650) 631-3138 Contact: Mr. Wolfgang Heidl, +49(0)9733 808-125
DRUG DELIVERY TECHNOLOGIES MISTRAL PHARMA INC. NEW- 2101 Halpern ELECTRONIC St-Laurent, Quebec H4S 1S3 - Canada Phone: (514) 920-0909 Fax: (514) 920-0404 EDITION www.mistralpharma.com e-mail: [email protected] All advertisers appearing Current Technologies/Platforms: Application(s): Current Partner(s): in our print edition will Procise Oral Drug Delivery also appear in the Savit Oral Drug Delivery Confidential electronic edition of Chronop Oral Drug Delivery
Contact: Alain Desjardins Drug Delivery Technology with active links to their Web site. The electronic edition also provides advertisers with global distribution of their message.
82 Drug Delivery Technology November/December 2006 Vol 6 No 10 * DDT Nov-Dec 2006 Round 5 11/10/06 8:18 PM Page 84
DRUG DELIVERY TECHNOLOGIES DRUG DELIVERY TECHNOLOGIES NEOPHARM INC. NUSIL TECHNOLOGY 1850 Lakeside Drive 1050 Cindy Lane Waukegan, IL 60085 Carpinteria, CA 93013 Phone: (847) 887-0800 Fax: (847) 887-9281 Phone: (805) 684-8780 Fax: (805) 566-9905 email: [email protected] email: [email protected] www.neophrnm.com www.nusil.com Current Technologies/Platforms: Application(s): Current Partner(s): Current Technologies/Platforms: Application(s): Current Partner(s):
NeoLipid® Technology Delivery of broad range of difficult to formulate silicone elastomers transdermal, mucosal, in-vitro drugs pressure sensitive adhesives NeoPhectin (In Vitro) Delivery of Nucleic acids (plasmid, antisense, silicone gels siRNA) silicone fluids NeoPhectin-AT (In Vivo) Delivery of Nucleic acids (plasmid, antisense, custom development siRNA) Contact: Mark Paulsen, (805) 684-8780 Pipeline Technologies/Platforms: Application(s): Development Stage:
NeoLipid® Technology Easy to use Liposome based drugs for treatment Liposome based SN-38 DRUG DELIVERY TECHNOLOGIES of cancer (LE-SN38), SN-38 is an OAKWOOD LABORATORIES, L.L.C. active metabolite of Campostar® - Phase II 7670 First Place, Suite A Oakwood Village, OH 44146 Liposome based Paclitaxel Phone: (440) 359-0000 Fax: (440) 359-0001 (LEP-ETU) - Phase I/II email: [email protected] www.Oakwoodlabs.com Liposome based raf antisense (LErafAONETU) - Current Technologies/Platforms: Application(s): Current Partner(s): Phase I CHRONIJECT™ Injectables Sustained Release of Parenteral Injectables Domestic & International Microsphere Technology NMEs, Peptides, Approved APIs DRUG DELIVERY TECHNOLOGIES Sterile Lyophilized Dosage Forms NOF CORPORATION 11 Martin Avenue, Suite 1170 Pipeline Technologies/Platforms: Application(s): Development stage: White Plains, NY 10606 Novel Advanced Drug Delivery Phone: (914) 681-9790 Fax: (914) 681-9791 Technologies Contact: Mark T. Smith, President See Company International: + 81-3-5424-6741 Profile email: [email protected] DRUG DELIVERY TECHNOLOGIES www.nof.co.jp/dds OSG NORWICH PHARMACEUTICALS,INC. Current Technologies/Platforms: Application(s): Current Partner(s): 6826 State Highway 12 PEG Derivitives Suitable & ideal for producing PEGylated drugs N/A Norwich, NY 13815 Phone: (607) 335-3000 Fax: (607) 335-3100 Phospholipids & Liposomes Ideal for screening tests and liposomal formulations N/A email: [email protected] HIghly Purified Oleic Acid Formulation development N/A www.norwichpharma.com Current Technologies/Platforms: Application(s): Current Partner(s): Cholesterol Pullulan Encapsulated antigen or protein can be delivered to N/A dendritic cells, so these nanoparticles can be Tablets Numerous suitable for stimulating immune system Capsules Numerous Non-sterile liquids Numerous Contact: [email protected] Contact Person: Bob Calabro DRUG DELIVERY TECHNOLOGIES DRUG DELIVERY TECHNOLOGIES NOVADEL PHARMA,INC. OWEN MUMFORD,LTD. 25 Minneakoning Road, Suite 101 Brook Hill Woodstock Flemington, New Jersey 08822 Oxford, OX20 1TU - England Phone: (908) 782-3431 Fax: (908) 782-2445 Phone: +44 (0) 1993 812021 Fax: +44 (0) 1993 813473 email: [email protected] e-mail: [email protected] www.novadel.com www.omdrugdelivery.com Current Technologies/Platforms: Application(s): Current Partner(s): Current Technologies/Platforms: Application(s): Current Partner(s): Customized Drug Delivery Devices Abbott, Amgen, Sanofi- Oral spray technology platform • Oral spray technology potentially achieves: Par Pharmaceuticals - Aventis, Berlex-Schering applicable to a broad range of - rapid delivery of drugs directly to bloodstream NitroMist™ (nitroglycerin Autoinjectors for plastic or glass- AG, Genentech, Lilly, therapeutic areas & product - quick onset of action lingual aerosol) prefilled syringes; Pen-cartridge Subcutaneous Delivery Serono, Teva, Cilag, categories: - Lower doses Hanna Biosciences - injectors many more • Currently marketed Rx and OTC - Avoids the GI tract and first pass liver metabolism Zensane™ (ondansetron drugs • Strong patent position oral spray) Re-usable/Re-loadable or • New molecular entities in Manhattan Pharmaceuticals Disposable Devices development for Diprivan (Propofol) Contact: Barry Cohen Contact Person: Sarah Massey
Drug Delivery Technology November/December 2006 Vol 6 No 10 83 * DDT Nov-Dec 2006 Round 5 11/10/06 8:18 PM Page 85
DRUG DELIVERY TECHNOLOGIES DRUG DELIVERY TECHNOLOGIES OXFORD LASERS INC. PFEIFFER OF AMERICA 29 King Street 742 Alexander Road, Suite 201 Littleton, MA 01460-1528 Princeton, New Jersey 08540 Phone: (978) 742-9000 Fax: (978) 742-9100 Phone: (609) 987-0223 Fax: (609) 987-1511 email: [email protected] e-mail: [email protected] www.oxfordlasers.com www.pfeiffer-group.com Current Technologies/Platforms: Application(s): Current Partner(s): Current Technologies/Platforms: Application(s): Current Partner(s): Metered Dose Dispensing Systems Nasal, Bucal, Topical & Dermal N/A EnVision System range (high quality Automatic measurements systems: One system Chiesi, Vectura, Bespak, for Aqueous Solutions & Suspensions high speed imaging system) for Nasal, MDI, DPI and softmist devices. GlaxoSmithKline EnVision QC system (information for Information obtained: Spray Pattern, Plume FDA submissions) geometry, Event duration and high speed imaging. Pipeline Technologies/Platforms: Application(s): Development Stage: EnVision R&D (Full suite of R&D application: additional information on flow Microhaler Pulmonary Undisclosed capability to provide detailed field velocity through the actuation of the device information on the device) Contact: Richard Sica
Micro-Machining Systems For machining of small hole and feature in a wide DRUG DELIVERY TECHNOLOGIES Micro-Machining Application Labs range of material PHARMACEUTICAL PROFILES Contact Person: Dr. Seamus D. Murphy, (978) 742-9000, email: [email protected] Mere Way, Ruddington Fields, Ruddington DRUG DELIVERY TECHNOLOGIES Nottingham, NG11 6JS, United Kingdom Phone: +44 115 974 9000 PARTICLE &COATING TECHNOLOGIES,INC www.pharmprofiles.com 5445 Highland Park Drive St. Louis, MO 63110 e-mail: [email protected] Current Technologies/Platforms: Application(s): Current Partner(s): Phone: (314) 535-1516 Fax: (314) 535-1514 ENTERION™ CAPSULE Oral drug development Many www.pctincusa.com TECHNECOAT™ Pulmonary drug development Current Technologies/Platforms: Application(s): Current Partner(s): Gamma Scintigraphy Nasal, drug development, rectal drug development, vaginal drug development Spinning-disk coating Many Several, confidential Contact: Dr. Gareth King, VP, Business Development Micro-capacity spray dryer Preformulation Biotechnology Samples Mini-Fluid-Bed Expensive Materials DRUG DELIVERY TECHNOLOGIES Forming narrow-size distributions Many PHARMAFORM L.L.C. Fluid-bed coating, spray-drying, Many 11400 Burnet Road, Bldg. 4 – Suite 4010 spray-chilling Austin, TX 78758 Bioavailability enhancement Hydrophobic drugs Phone: (512) 834-0449, ext. 201 Fax: (512) 834-2105 Fast-melt tablets Pharmaceuticals www.pharmaform.com Pipeline Technologies/Platforms: Application(s): Development stage: Current Technologies/Platforms: Application(s): Current Partner(s): Hot Melt Extrusion Controlled Release, Abuse Deterrent, Dosage Coating liquid droplets Widely applicable Forms, Transmucosal Films, Coating particles down to 1 micron Widely applicable Successful initial applications Enhanced Solubility Extended-release technology Fragrance, flavor, etc. Liquid Fill Hard Gel Capsules Enhanced Solubility, Enhanced Bioavailability, Contact: Person: Dr. Irwin Jacobs, [email protected] –Sustained and Immediate Release Improved Stability, Extended Product Family
DRUG DELIVERY TECHNOLOGIES Novel Drug Delivery Systems Poorly Soluble Drugs, Expanded Product Lines, Target Drug Delivery, Improved Safety, Enhanced PENWEST PHARMACEUTICALS CO. Patient Acceptance 39 Old Ridgebury Road, Suite 11 Danbury, CT 06810 Film Coating Tablets, Capsules, Multiparticulates, Improved Product Handling, Improved Stability, Phone: (203) 796-3700 Fax: (203) 794-1573 Aesthetics, Branding, Controlled Release e-mail: [email protected] Confidential www.penwest.com Powder Filled Capsules Capsules
Current Technologies/Platforms: Application(s): Current Partner(s): Oral Suspensions Liquids ® ® Timerex Oral controlled release Opana ER – Endo Pharm Sustained Release Matrix Tablets Tablets Procardia® XL – Mylan ® Slofedipine XL – Sanofi Micronization – API All Dosage Forms Synthelabo Cronodopin – E. Merck Immediate Release Tablets Tablets Procardia® – Ranbaxy ® Cystrin CR – Leiras Formulation Development All Dosage Forms Internal projects Preformulation Development All Dosage Forms Geminex® Dual Drug Release Internal projects Pipeline Technologies/Platforms: Application(s): Development Stage: SyncroDoseTM Site and time specific release Internal projects Contact Person: Diane D’Alessandro EDACS Abuse Deterrent Systems Controlled or abused substances
Films Transdermal and transmucosal drug delivery Confidential
Liquid Filled Hard Gelatin Capsules Sustained delivery
Contact Person: Michael M. Crowley, PhD, VP Business Development
84 Drug Delivery Technology November/December 2006 Vol 6 No 10 * DDT Nov-Dec 2006 Round 5 11/10/06 8:19 PM Page 86
DRUG DELIVERY TECHNOLOGIES DRUG DELIVERY TECHNOLOGIES POLYGENETICS,INC. REXAM PHARMA PO Box 33115 600 Deerfield Parkway Los Gatos, CA 95031 Buffalo Grove, IL 60089 Phone: (408) 356-1815 Fax: (408) 356-7094 Phone: (847) 541-9700 Fax: (847) 541-9201 email: [email protected] e-mail: [email protected] www.rexam.com/pharma www.polygenetics.com Current Technologies/Platforms: Application(s): Current Partner(s): Current Technologies/Platforms: Application(s): Current Partner(s):
Cavilink™ Porous Polymers Drug delivery, embolotherapy Boston Scientific Corp. The Sof’ Bag: 2 components delivered Dermal N/A by Rexam: a multilayer bag in a Cavilink™ Polymers Zero-order release Boston Scientific plastic bottle combined a metering pump to guarantee a maximum protection against contamination Pipeline Technologies/Platforms: Application(s): Development stage: and oxidation Cavilink™ Gene therapy Intermediate Cavilink™ Artificial organs Preliminary Pill jars & value added closures with Oral N/A or without tamper evidence, child Contact: Dr. James Benson, (408) 356-1815 resistance or dessicant
DRUG DELIVERY TECHNOLOGIES Patented Safe’n Sound safety Parenteral N/A system for prefilled syringes Transfer RESPIRICS,INC. sets, veterinary syringes, auto- 6008 Triangle Drive, Suite 101 injectors, implanters, injectable vials Raleigh, NC 27617 Phone: (919) 789-4220 Fax: (919) 789-4254 Diabolo: COC vials closed with a Parenteral Aseptic Technologies www.respirics.com TPE cap in a class 100A room and sterilized to avoid any additional step before filling
Current Technologies/Platforms: Application(s): Current Partner(s): DPIs and pMDIs Pulmonary N/A MD Turbo™ Breath-triggered device with electronic dose TEAMM Pharmaceuticals (U.S. Pumps, valves and applicators Nasal, Buccal & Auricular N/A counter for use with pMDIs Market Only) Pipeline Technologies/Platforms: Application(s): Development Stage: Medical Devices Various N/A
Acu-Breathe™ Single Dose Pulmonary DPI; for infrequent dosing; single Pre-Clinical Diagnostic Disposables Various N/A blister Pipeline Technologies/Platforms: Application(s): Development Stage: Acu-Breathe™ 15-Dose Pulmonary DPI; for chronic dosing; replaceable Pre-Clinical Preservative Free solutions, Ophthalmics cartridge Contact: Michael Cullen Acu-Breathe™ 30-Dose Pulmonary DPI; for chronic dosing; disposable Pre-Clinical DRUG DELIVERY TECHNOLOGIES Acu-Breathe™ Twin Pulmonary DPI; for two or more drugs Design Development SAFC Contact: Gilbert S. Mott, Jr., President & CEO 3050 Spruce Street St. Louis, MO 63103 DRUG DELIVERY TECHNOLOGIES Phone: (800) 336-9719 RESPIRONICS RESPIRATORY DRUG DELIVERY www.sigmaaldrich.com 41 Canfield Road Current Technologies/Platforms: Application(s): Current Partner(s): Cedar Grove, NJ 07009 Phone: (800) 962-1266 Fax: (724) 387- 5270 Polyamineo Acids Carrier/excipient e-mail: [email protected] Lipids Liposomes Lipisomes Carrier/excipient www.respironics.com Tween 20/80 GMP,Low Peroxide Detergent/surfactant Current Technologies/Platforms: Application(s): Current Partner(s): Pipeline Technologies/Platforms: Application(s): Development stage: The I-neb® AAD® System Pulmonary Drug Delivery CoTherix Inc, Schering AG, The I-neb is the third generation Profile Pharma Ltd PEGylation Stability, solubility Prototype AAD (Adaptive Aerosol Delivery) system. It is a small, battery- Contact: Tom Gelineau, (314) 301-2077, email: [email protected] powered, lightweight, and virtually silent drug delivery device designed to significantly reduce the inconvenience of conventional nebulizer/compressor therapy while delivering a precise, reproducible dose of drug.
Contact: Mark Elphick
Drug Delivery Technology November/December 2006 Vol 6 No 10 85 * DDT Nov-Dec 2006 Round 5 11/10/06 8:19 PM Page 87
DRUG DELIVERY TECHNOLOGIES DRUG DELIVERY TECHNOLOGIES SAFETY SYRINGES SENSIRION - THE SENSOR COMPANY 2875 Loker Avenue East Laubisruetistr. 50 Carlsbad, CA 92010 Staefa, Zurich CH-8712, Switzerland Phone: (760) 918-9908 Fax: (760) 918-0565 Phone: +41 44 306 4000 Fax: +41 44 306 4030 e-mail: [email protected] email: [email protected] www.safetysyringes.com www.sensirion.com Current Technologies/Platforms: Application(s): Current Partner(s): Current Technologies/Platforms: Application(s): Current Partner(s): UltraSafe Passive® Delivery System Drug delivery devices for prefilled syringes; pharmaceutical presentations that offer passive Microfluidic flow sensors and Dosing and metering of liquid drugs in the Medical device manufacturers safety features and improved drug delivery Amgen, AstraZeneca systems based on digital CMOS chips micro liter and nano liter range and bio-tech companies Eisai, Johnson & Johnson ® Tamper-Evident UltraSafe Passive Anti-counterfeiting of drugs; tamper evidence (Ortho Clinical Diagnostics) CMOSens Technology - The combina- Calibrated, digital, ready to use sensor solutions Delivery System Merck, Pfizer, tion of sensor elements and digital Talecris Biotherapeutics signal processing on one single micro Ypsomed Autoinjector with the Self-administration chip UltraSafe Passive® Delivery System Pipeline Technologies/Platforms: Application(s): Development stage:
See Company Disposable Flow Sensors Dosing and metering of liquid drugs in the Functional samples available Profile micro liter and nano liter range Contact: Matthew Klimjack, Director of Marketing Contact: Ulf Kanne +41 44 306 4000 DRUG DELIVERY TECHNOLOGIES DRUG DELIVERY TECHNOLOGIES SCIARRA LABORATORIES,INC. 485-09 S. Broadway SHARMATEK, Inc. Hicksville, NY 11801 12 Walnut Drive Phone: (516) 933-7853 Fax: (516) 933-7807 Long Valley, NJ 07853 email: [email protected] Phone: (908) 852-5087 www.sciarralabs.com email: [email protected] www.stk-inc.net Current Technologies/Platforms: Application(s): Current Partner(s):
Metered Dose Inhalers Asthma Medication Current Technologies/Platforms: Application(s): Current Partner(s): Pharmaceutical Aerosols Foams, Solutions Pulsatile Macroparticulate Drug Diltiazem ER Capsules, qd (90,120 mg) Marketed as KaizemTM CD Contact: John J. Sciarra Delivery System (PMDDS™) in India by Wockhardt Diffusion Controlled Drug Delivery Diltiazem ER Capsules, qd (120, 180, 240, 300 Available DRUG DELIVERY TECHNOLOGIES System (DCDDS™) 360 mf); bioequivalent to Tiazac®, fasted SCOLR Pharma, Inc. Hydrophilic Matrix Drug Delivery Quinidine sulfate ER Tablets (300 mg); Currently manufactured and 3625 132nd Avenue SE, Suite 400 System (HMDDS™) bioequivalent to Quinidex; sold by TEVA Pharms Bellevue, WA 98006 Phone: (425) 373-0171 Fax: (425) 373-0181 Felodipine ER tablets, qd (2.5, 5, 10mg) Available email: [email protected] Delayed Release Drug Delivery Omeprazole EC capsules (10, 20, 40 mg), qd Licensed to Wockhardt www.scolr.com System (DRDDS™) capsules, qd for international markets
Current Technologies/Platforms: Application(s): Current Partner(s): Micro Emulsion Drug Delivery Cyclosporine Marketed by Panacea System (MEDDS™) Biotec in India CDT® Controlled Delivery Technologies Solid Oral Delivery, Small Molecule Platform consists of Four Issued Predictive Modeling Tool RE: MR product design Available Patents: See Company Profile (FRT/IVIVC™) “Dual Polymer” technology BCS class 1 & 2 Microfluidization Processing Low solubility, high permeability drugs, such as Available “Salt” technology BCS class 1 & 2 Wyeth, Perrigo Technology (MPT™) Cyclosporine
“Amino Acid” technology BCS class 2, 3 Pipeline Technologies/Platforms: Application(s): Development stage: Pipeline Technologies/Platforms: Application(s): Development stage: Biphasic HMDDS™ Drugs absorbed at upper GI tract Early stage development
CDT® “Asymmetrical” technology #4 Combinatition, Cocktail Therapies, Gastric Pre-Clinical, Patent pending Programmable Tabsule™ Drug Oral, multi-phasic release, site-specific Early stage development Retention and Site Specific Delivery System (PTDDS™) Tabsules™ (mini-tablets)
Contact: Stephen Turner Contact: Vinay K. Sharma, PhD , Chairman, (908) 852-5087, Mobile: (908) 616-3319
DRUG DELIVERY TECHNOLOGIES QUALICAPS 6505 Franz Warner Parkway Whitsett, NC 27377 Phone: (336) 449-3900 www.qualicaps.com Current Technologies/Platforms: Application(s): Current Partner(s):
Quali-V® capsules Empty two-piece capsule of non-gelatin origin
F/S Machine Combination filling and sealing encapsulation
Contact: Tamara Smith, (336) 449-3953
86 Drug Delivery Technology November/December 2006 Vol 6 No 10 * DDT Nov-Dec 2006 Round 5 11/10/06 8:19 PM Page 88
DRUG DELIVERY TECHNOLOGIES DRUG DELIVERY TECHNOLOGIES SMITHS MEDICAL ASD, INC, TRANSPHARMA MEDICAL LTD. 2231 Rutherford Road 2 Yodfat Street, Northern Industrial Zone Carlsbad, CA 92008 Lod, Israel 71291 Phone: (866) 286-6226 Fax: (760) 929-0147 Phone: +972-8-915-2201 Fax: +972-8-915-2202 www.smiths-medical.com e-mail: [email protected] www.transpharma-medical.com Current Technologies/Platforms: Application(s): Current Partner(s): Pipeline Technologies/Platforms: Application(s): Development Stage:
Safety Devices for Hypodermic Injection Medication Delivery Many ViaDerm Drug Delivery System Transdermal Teva Pharmaceutical Injections Industries (undisclosed high molecular weight protein), Syringe Pumps and Infusion Infusion Medication Delivery Many seeking partner (hPTH Accessories (1-34) for osteoporosis)
Contact: Mark Baumgartner, Business Development Manager Contact: Judith Kornfeld, Vice President, Business Development
DRUG DELIVERY TECHNOLOGIES DRUG DELIVERY TECHNOLOGIES SOLIQS TRAVANTI PHARMA INC.(FORMERLY BIRCH POINT MEDICAL INC.) SOLIQS Business Unit 2520 Pilot Knob Road, Suite 100 ABBOTT GmbH & Co. KG St. Paul, MN 55120 PO Box 21 08 05 Phone: (651) 730-1008 Fax: (651) 730-1013 67008 Ludwigshafen, Germany Phone: +49-621 589 2427 Fax: +49-621 589 3092 e-mail: [email protected] email: [email protected] www.travantipharma.com www.soliqs.com Current Technologies/Platforms: Application(s): Current Partner(s): Pipeline Technologies/Platforms: Application(s): Development stage: WEDD® (Wearable Electronic Pain, Inflammation Undisclosed Meltrex™ Melt extrusion technology n/a Disposable Drug Delivery) Technology - Proprietary active transdermal Xellux™ Polymeric film technology n/a (iontophoretic) drug delivery system NanoMorph™ Amorphous nanoparticle technology n/a that is self-contained, portable & disposable SoliScreen™ Qualitative & quantitative screening systems n/a Contact: [email protected] Pipeline Technologies/Platforms: Application(s): Development Stage: WEDD® Active Transdermal Drug Pain, Inflammation, Nausea/Emesis, Thrombosis, DRUG DELIVERY TECHNOLOGIES Delivery System Osteoporosis, Cosmetics, among others SPI PHARMA Contact: Robert Arnold 321 Cherry Lane New Castle, Delaware 19720 DRUG DELIVERY TECHNOLOGIES Phone: (302) 576-8500 x 8554 TRIS PHARMA,INC. Fax: (302) 576-8567 Brunswick Business Park - 2033 Route 130, Suite D www.spipharma.com Monmouth Junction, NJ 08852 Current Technologies/Platforms: Application(s): Current Partner(s): Phone: (732) 940-2800 - Fax:(732) 940-2855 Pharmaburst™ Fast Melt Excipient Oral Dispersible Tablet Generic & Brand Rx System e-mail: [email protected] - www.trispharma.com Pharmafreeze™ Fast Melt Lyophilized ODT, Sublingual Tablet Brand Rx Current Technologies/Platforms: Application(s): Current Partner(s): System LipisolTM Bioavailability/Solubility Enhancement Pharmasperse™ Dry Powder Reconstitutable Syrup Generic Rx, OTC Suspension eXolTM Bioavailability/Solubility Enhancement Pharmagum™ DC Chewing Gum Buccal Gum Tablet Rx, OTC, Nutraceutical maxsolTM Bioavailability/Solubility Enhancement Not Disclosed Powder PerpetuRateTM Controlled Release Taste-masking/Controlled release Solid Oral Dose Rx, OTC LiquiXRTM Taste-masking/Controlled Release/Liquid Suspension Custom Processing Granulation, Chilsonation Micronizing, Extrusion Rx, OTC delibRateTM Controlled Release Pipeline Technologies/Platforms: Application(s): Development Stage: ProRateTM Controlled Release Pharmachew™ Excipient System Chewable Tablet Platform OTC, Nutraceutical Pharmatab™ Excipient System Swallow Tablet Platform Rx, OTC ODTXRTM Orally Disintegrating Tablet /Controlled Release/ Fast Dissolve Contact: Sarat Chandar Contact: Anish Parikh
DRUG DELIVERY TECHNOLOGIES TEXMAC INC. 3001 Stafford Drive Charlotte, NC 28208 Phone: (704) 393-6555 Fax: (704) 392-1621 email: [email protected] www.texmac.com Pipeline Technologies/Platforms: Application(s): Development Stage:
Soluble Microneedle Technology Drug delivery Distribute sample micro- needles for customer’s evaluation
Cosmeceutical Distribute sample micro- needles for customer’s evaluation
Contact: Yashi Osaka
Drug Delivery Technology November/December 2006 Vol 6 No 10 87 * DDT Nov-Dec 2006 Round 5 11/10/06 8:19 PM Page 89
DRUG DELIVERY TECHNOLOGIES DRUG DELIVERY TECHNOLOGIES UPM PHARMACEUTICALS,INC. VECTURA GROUP PLC 6200 Seaforth Street 1 Prospect West Baltimore, MD 21224 Chippenham Phone: (410) 843-3738 Fax: (410) 633-4438 Wiltshire, UK SN14 6FH [email protected] Phone: +44 1249 667700 Fax: +44 1249 667701 www.upm-inc.com e-mail: [email protected] Current Technologies/Platforms: Application(s): Current Partner(s): www.vectura.com
Cushioning Beads™ Pediatric, geriatric, HIV patients undisclosed
Accomodates high and low dose drugs, quick Current Technologies/Platforms: Application(s): Current Partner(s): dissolve form ASPIRAIR Pulmonary (Active DPI Device) Available - Non-exclusive
Trap & Trigger™ Pediatric, geriatric, HIV, cancer patients undisclosed GYROHALER Pulmonary (Passive DPI Device) Available - Non-exclusive Current Technologies/Platforms: Application(s): Current Partner(s): POWDERHALE Pulomnary (Formulation System) Available - Non-exclusive Cushioning Beads™ Oral quick dissolve tab early Contact: Doug Smalley, Director of Business Development Trap & Trigger™ Oral SR suspension for electrolytic drugs early DRUG DELIVERY TECHNOLOGIES Contact: Rich Ryzenga VENTAIRA PHARMACEUTICALS,INC. DRUG DELIVERY TECHNOLOGIES 1801 Watermark Drive, Suite 100 VALERITAS Columbus, OH 43215 1000C Lake Street Phone: (614) 340-2325 Fax: (614) 340-2320 Ramsey, NJ 07446 email: [email protected] Phone: (847) 604-8005 Fax: (847) 604-8006 www.ventaira.com E-mail: [email protected] Current Technologies/Platforms: Application(s): Current Partner(s): Website: www.valeritas.com Mystic drug inhalation technology Pulmonary Contact Person: Peter Larsen, VP Business Development (uses electrostatic energy to form a Current Technologies/Platforms: Application(s): Current Partner(s): uniform fine particle spray) Mini-JectTM Pre-Filled Needle-Free Delivery System Drug formulation technology Pulmonary Seeking qualified strategic (allowing the company to optimize partners for co-develop h-PatchTM Single-Use, Disposable Basal-Bolus the delivery of drugs - small opportunities Delivery System molecules and are expanding to biomolecules) e-PatchTM Control Release Disposable Micro Pump Undisclosed Internal Pipeline Delivery System Technologies Partners: Application(s): Development stage:
TM Micro-Trans Microneedle Intradermal Delivery System Fluticasone Propionate Asthma Completed Phase I clinical trial
Undisclosed Asthma Formulation
Undisclosed Pain Formulation
Contact: Peter Larsen, VP, Business Development, (847) 604-8005, [email protected] Undisclosed Undisclosed Formulation
Contact: Leslie Williams, (614) 340-2338 DRUG DELIVERY TECHNOLOGIES DRUG DELIVERY TECHNOLOGIES VALOIS VYTERIS,INC. 50 Avenue de l’Europe 13-01 Pollitt Drive Marly-le-Roi, France 78164 Fair Lawn, NJ 07410 Phone: +33 (0) 1 39 17 20 20 Fax: +33 (0) 1 39 58 12 98 Phone: (201) 703-2299 www.valoispharma.com www.vyteris.com Current Technologies/Platforms: Application(s): Current Partner(s): Current Technologies/Platforms: Application(s): Current Partner(s): Metering Spray Pumps Nasal, Throat, Dermal/Transdermal, Ear Active Transdermal Systems Transdermal B. Braun Metering Valves for pMDIs Pulmonary (Asthma, COPD) Unit-Dose Nasal Spray Devices Nasal Pipeline Technologies/Platforms: Application(s): Development stage:
Pipeline Technologies/Platforms: Application(s): Development Stage: Lidocaine System Transdermal NDA filed on Lidocaine System Dose Indicator for pMDIs Dry Powder Inhaler Electronic Devices New Pumps, Valves and Unit-Doses
Contact: Pierre Carlotti - VP Marketing
88 Drug Delivery Technology November/December 2006 Vol 6 No 10 * DDT Nov-Dec 2006 Round 5 11/10/06 8:19 PM Page 90
DRUG DELIVERY TECHNOLOGIES YPSOMED AG Brunnmattstrasse 6 Burgdorf, Switzerland 3401 Phone: +41 34 424 41 11 Fax: +41 34 424 41 22 email: [email protected] www.ypsomed.com
Current Technologies/Platforms: Application(s): Current Partner(s):
Reusasble injection pens Regular subcutaneous self-injections Aventis (insulin), Dongbao (insulin), Pfizer (hGH), Eli Lilly (hGH), Genentech (hGH) and Roche (EPO and alfa-interferon)
Disposable injection pens Regular subcutaneous self-injections Aventis (insulin) and Serono (FSH)
Semi-Disposable injection pens Regular subcutaneous self-injections Aventis (insulin) Pipeline Technologies/Platforms: Application(s): Development stage:
Reusable and disposable auto- Subcutaneous and intramuscular self- Ongoing development injector systems injection of bio-molecules programs with a number of partners Contact: Ian Thompson, Manager Business Development
DRUG DELIVERY TECHNOLOGIES DEGUSSA CORPORATION DEGUSSA AG - PHARMA POLYMERS Pharma Polymers Röhm GmbH 2 Turner Place Kirschenallee 45 Piscattaway, NJ 08855 64293 Darmstadt, Germany T: (732) 981-5383 Option 4 T: +49-6151-18-4019 F: (732) 981-5371 F: +49-6151-18-3520 E: [email protected] E: [email protected] Current Technologies/Platforms: Application(s): Current Partner(s): EUDRACOL™ Colon-targeted-sustained-release oral drug delivery technology
EUDRAPULSE™ Pulsatile oral drug delivery technology with variable lag times See Company EUDRAMODE™ Oral drug delivery platform technology Profile providing a broad range of release profiles NEW- ELECTRONIC EDITION All advertisers appearing in our print edition will also Contact: Dr. Gerhard Renner, +49 6151 184810, [email protected] appear in the electronic edition of Drug Delivery DRUG DELIVERY TECHNOLOGIES Technology with active links to their Web site. The GENZYME PHARMACEUTICALS 675 West Kendall Street electronic edition also provides advertisers with global Cambridge, MA 02142 Phone: (800) 868-8208 or (617) 374-7248 distribution of their message. Fax: (617) 768-9765 E-mail: [email protected] www.genzymepharmaceuticals.com Current Technologies/Platforms: Application(s): Current Partner(s):
LipoBridge® CNS, blood brain barrier, Alzheimer’s, stroke, Undisclosed trauma, Parkinson’s, Multiple Sclerosis
LipoMaskTM Extended circulation time of drug particles in Undisclosed blood
Pipeline Technologies/Platforms: Application(s): Development stage:
CerenseSM Deliver and assess poorly brain-penetrant Undisclosed drug compounds in the CNS
Design for Peptide DeliverySM Customized solutions for peptide formulations Undisclosed
See Company Profile
Drug Delivery Technology November/December 2006 Vol 6 No 10 89 * DDT Nov-Dec 2006 Round 5 11/10/06 8:24 PM Page 91
EXCIPIENTS, POLYMERS, LIPSOMES, LIPIDS, COATINGS EXCIPIENTS, POLYMERS, LIPSOMES, LIPIDS, COATINGS AKINA,INC. BROOKWOOD PHARMACEUTICALS,INC. Business & Technology Center 756 Tom Martin Drive 1291 Cumberland Avenue, E130 Phone: (205) 917-2239 West Lafayette, IN 47906-1385 Fax: (205) 917-2205 www.brookwoodpharma.com Phone: (765) 464-0501 Fax: (765) 464-0820 e-mail: [email protected] - www.akinainc.com Current Technologies/Platforms: Application(s): Current Partner(s): Biodegradable poly(lactide-co- -cGMP commercial synthesis of PLGs at lot sizes Current Technologies/Platforms: Application(s): Current Partner(s): glycolide) (PLG) polymers up to 30 kg Highly Plastic Granules Fast melting tablets Samyang Corp. -cGMP contract manufacturing of other biodegradable biomaterials excipients
Contact: Yourong Fu, (765) 464-0501, ext. 1 Designed for companies developing the next Undisclosed Contract manufacturing and scale- generation of novel biomaterials that require EXCIPIENTS, POLYMERS, LIPSOMES, LIPIDS, COATINGS up of custom biomaterials technical expertise, synthesis, characterization, process development, and scale-up A.P. PHARMA 123 Saginaw Drive -Covalently linking moieties, such as peptides, Modified Polymer Surfaces proteins, and polysaccharides, to biodegradable Redwood City, California 94063 polymer matrices, such as microparticle rods, Phone: (650) 366-2626 Fax: (650) 365-6490 fibers, meshes, and other 3-D shapes E-mail: [email protected] -Applicable to drug delivery formulations or www.appharma.com medical devices Pipeline Technologies/Platforms: Application(s): Development Stage: Current Technologies/Platforms: Application(s): Current Partner(s): Injectable Microparticles Wide range of therapeutic areas Phase I, II and III
® MICROSPONGE Topical J&J (Retin-A-Micro®), Phase I and II Injectable Solid Implants Wide range of therapeutic areas Aventis (Carac™) BIOCHRONOMER™ Parenteral Actively seeking partners Advanced Preclinical Drug-eluting Devices Local delivery BIOERODIMER™ Parenteral Actively seeking partners ALGINATES Oral Actively seeking partners Contact: Kelly Arlint, (205) 917-2239
Pipeline Technologies/Platforms: Application(s): Development Stage EXCIPIENTS, POLYMERS, LIPSOMES, LIPIDS, COATINGS APF112 Parenteral, Post-operative Pain Relief CARDINAL HEALTH OSTEOARTHRITIS Parenteral, Local Anti-inflammatory 14 Schoolhouse Road ANTI-NAUSEA/VOMITING Parenteral, Post-chemotherapy Relief ANTI-ADHESIONS Parenteral, Post-surgical Somerset, New Jersey 08873 Phone: (732) 537-6200 Fax: (732) 537-5949 Contact: Mike O’Connell, (650) 366-2626 email: [email protected] www.cardinal.com/pts EXCIPIENTS, POLYMERS, LIPSOMES, LIPIDS, COATINGS Current Technologies/Platforms: Application(s): Current Partner(s): AQUALON DIVISION,HERCULES INCORPORATED 1313 North Market Street Matrix Tablets All are for oral applications for functional release N/A Wilmington, DE 19894 Tablet Coating N/A Drug Layering N/A Phone: (800) 345-0447 Fine-Particle Coating N/A www.aqualon.com Contact: (866) 720-3148, email: [email protected] See Company Current Technologies/Platforms: Application(s): Current Partner(s): Profile
Klucel® hydroxypropylcellulose (HPC) Applications for all 4 products/technologies: Natrosol® hydroxyethylcellulose (HEC) solid dosage (immediate and controlled Aqualon® ethylcellulose (EC) release), film coatings, liquid system thickeners Aqualon® carboxymethylcellulose (oral, topical, nasal) (CMC) NEW- Contact: Richard Salzstein, PhD, Pharmaceutical Sales Manager, (302) 995-3173 ELECTRONIC EXCIPIENTS, POLYMERS, LIPSOMES, LIPIDS, COATINGS EDITION BASF 100 Campus Drive All advertisers appearing Florham Park, NJ 07932 Phone: (800) 443-0627, Fax: (973) 245-6763 in our print edition will email: [email protected] also appear in the www.pharma-solutions.basf.com Current Technologies/Platforms: Application(s): Current Partner(s): electronic edition of Kollicoat® Coatings & Coating Systems Drug Delivery Technology Kollidon® Binders & disintegrants with active links to their Ludipress® Direct compression aids See Company Profile Web site. The electronic Lutrol® & Lutrol® Micro Solubilizers edition also provides Solutol® Solubilizer advertisers with global Cremophor® Solubilizer & emulsifier
Contact: BASF Pharma Solutions, (800) 443-0627 distribution of their message.
90 Drug Delivery Technology November/December 2006 Vol 6 No 10 DDTNov-Dec2006Round511/10/068:24PMPage92 * urn ehooisPafrs plcto() CurrentPartner(s): Contact CORPLEX™ Hydrogel Application(s): Current Technologies/Platforms: Pharma-Carb urn ehooisPafrs plcto() CurrentPartner(s): Compressible excipients: Foremost Gel-Klear™ Chroma-Seal™, GDF™, Chroma- Chroma-SRF™, Teric™, Chroma- Chroma-Kote™, Tone™, Chroma- Dri-Klear™, Chroma-Tone™, Pigmented andclear coatingsystems: Application(s): Current Technologies/Platforms: ats,Nu-Tab Lactose, Opadry Contact Opaglos Surelease Starch 1500 Opadry urn ehooisPafrs plcto() CurrentPartner(s): Acryl-EZE Application(s): Current Technologies/Platforms: ® ® e o,PD PBsns eeomn,(0)7572,[email protected] (203)775-7124, VPBusinessDevelopment, PhD, DebFox, : on aao (215)661-2630 DonnaMarano, : ® AMB II ® 2 ® ® ® ® Cal-Carb , XIINS OYES ISMS IIS COATINGS LIPIDS, LIPSOMES, POLYMERS, EXCIPIENTS, XIINS OYES ISMS IIS COATINGS LIPIDS, LIPSOMES, POLYMERS, EXCIPIENTS, XIINS OYES ISMS IIS COATINGS LIPIDS, LIPSOMES, POLYMERS, EXCIPIENTS, hn:(0)5800 a:(414)607-5959 (800)558-0802Fax: Phone: ® , ® etPit PAWest 19486-0024 Point, Oral, High Gloss, complete film coating system completefilmcoating HighGloss, Oral, atal rgltnzdMieSac,excipient Partially MaizeStarch, Pregelatinized Film coating ModifiedRelease, Oral, Film coating ModifiedRelease, Enteric, Oral, coating system coating completefilm AqueousMoistureBarrier, Oral, completefilmcoating HighPerformance, Oral, system and diagnostic products and diagnostic device, woundcare, mucosal, Transdermal, solid dosage forms solid dosage solid dosage forms solid dosage hn:(215)699-7733 Phone: iwue,WI53214 Milwaukee, 415 Mayer Boulevard www.chr-hansen.com 9015 W. Maple Street Maple 9015 W. www.colorcon.com C C HR hn:(5)2885 Fx (650)298-8012 (650)298-8255Fax: Phone: OLORCON .H ANSEN mi:[email protected] email: 66MdlfedRa,Suite G 2686 Middlefield Road, C ewo iy CA94063 Redwood City, ORIUM www.coriumgroup.com I NTERNATIONAL companies andevice wound care, generic, specialty, Pharma, ,I NC . Contact Crodamols (Fatty Esters) Medilan™ (Medium-GradeLanolin) cholesterol) Cholesterol HP(High-purity Crillet HP(High-puritypolysorbate) CurrentPartner(s): PEG 600NF Super Refined Application(s): Current Technologies/Platforms: Refined Super Refined Super Refined triglycerides Super Refined Contact: NYMCEL GENU GENU GELRITE ieieTcnlge/ltom:Apiains:DevelopmentStage: KELCOGEL Application(s): Pipeline Technologies/Platforms: CurrentPartner(s): KELTROL Application(s): Current Technologies/Platforms: KELCOGEL XANTURAL GENU GENU *Add flexibility andpowertoyourdevelopmentprocesswith CurrentPartner(s): Application(s): Current Technologies/Platforms: Contact your todesignreleaseprofile. Polymers EUDRAGIT EUDRAGIT EUDRAGIT :[email protected] E: ® ® ® ® T: (732) 981-5383 Option 4 (732)981-5383Option T: Pectin Gum RefinedLBG Carrageenan Pectin ® ie age,(3)4700,et 4281 ext. (732)417-0800, NigelLangley, : S:Ade .Hnyhc,(3)9158;Gray oa d,+49-6151-18-3567 JonasIde, (732)981-5383;Germany: Honeycheck, AndrewS. USA: : ® D ® ® E 0 F Super Refined PEG 400NF, ictaa,NJ08855 Piscattaway, Gellan gum Xanthan gum neSna (858)467-6615 Anne Sinha, ® ® ® ® ® Carmellose Sodium EGUSSA ® Gellan Gum Gellan gum RL /RSandNEanNM Polymers E L/S andFSPolymers :(732)981-5371 F: Pharma PolymersPharma Xanthan gum ® ® Turner Place 2 ® ® (High-Purity Polysorbate 80 E 0 F Super PEG 300NF, Oleic AcidNF XIINS OYES ISMS IIS COATINGS LIPIDS, LIPSOMES, POLYMERS, EXCIPIENTS, XPET,PLMR,LPSMS IIS COATINGS LIPIDS, LIPOSOMES, POLYMERS, EXIPIENTS, XPET,PLMR,LPSMS IIS COATINGS LIPIDS, LIPOSOMES, POLYMERS, EXIPIENTS, C ORPORATION Drug DeliveryTechnology hn:(5)2240 Fx (858)292-4901 (858)292-4900Fax: Phone: mi:[email protected] email: ® oia,Oa,Parenteral Oral, Topical, Topical Parenteral Parenteral Oral, Topical, oia,Oa,Parenteral Oral, Topical, Transdermal (TDD) Oral, Topical, oia,Oa,Parenteral Oral, Topical, Biotech & OralTopical, Opthalmic, Parenteral, Tablet Coating Edible FilmSystems Delivery Creams&Lotions Ointments, Tablet coatings Pharmaceutical Emulsions Encapsulation Ophthalmic Compositions Wound CareProducts Ostomy & utie,andpulsedrelease. sustained, Polymers fordelayed, Sustained Release: moistureprotection. odor-masking, Polymers fortaste-and Protective Coatings: colon. fromtheduodenumto drug delivery Polymers forpH-dependent Enteric Coatings: a ig,CA92123 San Diego, www.cpkelco.com 8355 AeroDrive :[email protected] E: D hn:(3)4700 Fx (732)417-0804 (732)417-0800Fax: Phone: CP K EGUSSA 49 amtd,Germany 64293 Darmstadt, mi:[email protected] email: :+49-6151-18-4019 T: :+49-6151-18-3520 F: ELCO November/December 2006 Kirschenallee 45 AG -P Röhm GmbH EUDRAGIT 300-A Columbus Circle www.crodausa.com dsn NJ08837 Edison, HARMA C ® RODA Ourwiderange ofpolymersallows . P OLYMERS I NC N/A .
e CompanySee Vol 6No 10
Profile 91 Drug Delivery Technology November/December 2005 Vol 5 No 10 * DDT Nov-Dec 2006 Round 5 11/10/06 8:24 PM Page 93
EXCIPIENTS, POLYMERS, LIPSOMES, LIPIDS, COATINGS EXCIPIENTS, POLYMERS, LIPSOMES, LIPIDS, COATINGS DELSITE BIOTECHNOLOGIES,INC. ETHYPHARM 1505 Walnut Hill Lane 194 Bureaux de la Colline Irving, TX 75038 92213 Saint-Cloud Cedex - France Phone: (972) 717-5009 Fax: (972) 831-1132 Phone: +33 1 41 12 17 20 email: info@delsite www.ethypharm.com www.delsite.com Pipeline Technologies/Platforms: Application(s): Development Stage: Current Technologies/Platforms: Application(s): Current Partner(s):
® GelSite® Polymer Mucosal DMF Spherulites Vaccines GelSite® Polymer Injectable Preclinical Multiparticles, Sustained Release Enhanced Absorption Forms Contact: Jean Anne Mire - Director, Business Development, (972) 650-7320, email: [email protected] Contact: Bruno Delie, Senior VP - Business Development, +33 1 41 12 17 20 EXCIPIENTS, POLYMERS, LIPSOMES, LIPIDS, COATINGS DEPOMED,INC. EXCIPIENTS, POLYMERS, LIPSOMES, LIPIDS, COATINGS 1360 O’Brien Drive FLAMEL TECHNOLOGIES Menlo Park, CA 94025 33 Avenue Du Drive Georges Levy Venissieux, France 69693 Phone: (650) 462-5900 Phone: +33 472-783-434 Fax: +33 472-783-435 www.depomedinc.com E-mail: [email protected] www.flamel.com Current Technologies/Platforms: Application(s): Current Partner(s): Current Technologies/Platforms: Application(s): Current Partner(s):
Gastric Retention Diffusional Oral, Liquid, Controlled release of soluble drugs Biovail, Inc. MEDUSA Parenteral Bristol-Myers Squibb & other Technology undisclosed partners Gastric Retention Erosional Oral, Constant delivery rate of insoluble drugs Technology MICROPUMP Oral Biovail, Merck, Servier GlaxoSmithKline & others Gastric Retention Bi-Layer Oral, Controlled release of 2 drugs with different undisclosed Technology characteristics Pipeline Technologies/Platforms: Application(s): Development Stage Gastric Retention Combination Oral, Controlled release of 2 drugs Biovail, Inc. Technology simultaneously or in sequence Genvir (MICROPUMP) Oral Phase III
Contact: Thadd Vargas, (650) 462-5900 Basulin (MEDUSA) Parenteral Phase I
EXCIPIENTS, POLYMERS, LIPSOMES, LIPIDS, COATINGS Metformin XL (MICROPUMP) Oral Phase I DOW CORNING CORPORATION P.O. Box 994 Augmentin SR (MICROPUMP) Oral Confidential Midland, MI 48686 Ace Inhibitor (MICROPUMP) Oral Confidential Phone: (989) 496-6000 Fax: (989) 496-6731 e-mail: [email protected] Various MEDUSA & MICROPUMP Oral & Parenteral Preclinical www.dowcorning.com Projects Current Technologies/Platforms: Application(s): High-purity, Volatile Silicone Fluids Carrier for sprays, spreading agent, solvent, lubricant, emollient, skin Contact: Federick Simonin, +33 472-783-434 protectant, and excipient for hydrophilic actives Blends Lubricant, emollient, carrier for sprays, spreading agent EXCIPIENTS, POLYMERS, LIPSOMES, LIPIDS, COATINGS Unique, silky aesthetics (smooth, dry feel); rheology modifier; thickener for GRAIN PROCESSING CORPORATION Gels silicone-containing formulations 1600 Oregon Street Semi-occlusive formulations, lubricant, detackifier, emollient, water-repellent, Muscatine, IA 52761 Waxes thickener, moisturizer Phone: (563) 264-4265 Emulsifiers Room temperature emulsification www.grainprocessing.com Lipids Vegetable oil, evening primrose oil, camelina oil, borage oil, blackcurrent oil, Current Technologies/Platforms: Application(s): Current Partner(s): shea butter, cocoa butter, jojoba oil, mango olein, mango butter, and several silicone and lipid blend emulsions ® Lecithin Stabilized Liposome MALTRIN Maltodextrins NF Aqueous Film Coating, Bulking, Carrying, Blending, Capsules, Creams & Lotions, Dry Delivery Solution Based on a high content of dilinoleic phosphatidylcholine PURE-DENT® Corn Starches USP/NF Granulation, Film Forming, Liquid Contact: Stacey Chapin Pharmaceuticals, Medical Nutritionals, Soaps & PURE-COTE®, INSTANT PURE-COTE® Cleansers, Spray Drying, Tableting, Throat EXCIPIENTS, POLYMERS, LIPSOMES, LIPIDS, COATINGS Modified Starches Lozenges, Wet Granulation EASTMAN CHEMICAL COMPANY Spress® Pregelatinized Starches NF 200 S. Wilcox Drive Kingsport, TN 37662 WATER LOCK® Superabsorbent Phone: (800) 327-8621 Polymers www.eastman.com Current Technologies/Platforms: Application(s): Current Partner(s): Contact: Bob Bahn, (563) 264-4281
Eastman CAP Enteric Coating
Eastman Eastacryl® 30D Acrylic Enteric Coating Coating Material
Eastman CA-398-10 NF Sustained/Controlled Release; Taste Masking
Eastman CAB-171-15-PG Sustained/Controlled Release
Eastman Vitamin E TPGS Absorption Enhancer, Solubilizer, Bioavailability Enhancer
Contact: Carolyn Baker, (423) 229-2987
92 Drug Delivery Technology November/December 2006 Vol 6 No 10 DDTNov-Dec2006Round511/10/068:25PMPage94 * Contact CurrentPartner(s): Application(s): Current Technologies/Platforms: Hubersorb silica RxCIPIENTS Zeopharm HuberCal RxCIPIENTS urn ehooisPafrs plcto() CurrentPartner(s): Contact matrix technology Patented lipid-binding novel Application(s): Current Technologies/Platforms: urn ehooisPafrs plcto() CurrentPartner(s): Contact: Advantia™ CoatingSystems Application(s): Current Technologies/Platforms: ieieTcnlge/ltom:Apiains:DevelopmentStage Contact: CurrentPartner(s): interactions withcananddrug Electrostatic effectsfrompropellant Application(s): Pipeline Technologies/Platforms: CFC11 andCFC12medicalpropellants medical propellants ZEPHEX 134aand227eaHFA Application(s): Current Technologies/Platforms: KarlMattson-Boze : acCuuir eirVc rsdn,GlobalBusinessDevelopment(416)250-0091 Senior Vice President, MarcCouturier, : ® Ann Druffner ® Tim Noakes calcium carbonate ® ® calcium silicate GL 100&200 FM1000 ® & hn:+4()12 152 Fx +44(0)1928511418 +44(0)1928515525Fax: Phone: XIINS OYES ISMS IIS COATINGS LIPIDS, LIPSOMES, POLYMERS, EXCIPIENTS, XIINS OYES ISMS IIS COATINGS LIPIDS, LIPSOMES, POLYMERS, EXCIPIENTS, XIINS OYES ISMS IIS COATINGS LIPIDS, LIPSOMES, POLYMERS, EXCIPIENTS, XIINS OYES ISMS IIS COATINGS LIPIDS, LIPSOMES, POLYMERS, EXCIPIENTS, hn:(1)8811 a:(212)838-0060 (212)838-1111Fax: Phone: www.ineosfluor.com •www.zephex.com 2 hr vne 40thFloor 825 Third Avenue, -al [email protected] e-mail: mi:[email protected] email: eie leadingMDIcompanies propelledones from CFCpropelledMDIstoHFA tosupportthesmoothtransition Made available ofthe Supplymany World’sdevices othermedicalaerosolsand Metered DoseInhalers, medications Earlyresearch ofpulmonary Enhancing reproducibilityanddelivery rlSld NotDisclosed Oral Solids Carrier Inert filler Glidants tablets Fast-dissolve excipientfororaldosage combination inhalation therapy drugs therapy inhalation combination butalso not onlysinglemolecule, of enhancedelivery drug substancesthat For orunstable deliveringincompatible hsie UK WA7 4QX Cheshire, New York, NY 10022 NY New York, h et,Runcorn The Heath, www.inyxgroup.com www.rxcipients.com orwww.hubermaterials.com INEOS F H hn:(7)6840 Fx (973) 628-4117 (973) 628-4000Fax: Phone: UBER I NYX -al [email protected] e-mail: International Specialty Products Specialty International (ISP) ..H J.M. ,I E ar eGae MD21078 Havre deGrace, NGINEERED NC LUOR 907 Revolution Street . :(410)939-7228 T: mi:[email protected] email: UBER www.ispcorp.com an,NJ07470 Wayne, 1361 Alps Road 1361 Alps C M ORPORATION ATERIALS Various
e Company See , ATOF PART
Profile VIVASTAR Contact Vegetable Oil LUBRITAB EXPLOTAB PRUV urn ehooisPafrs plcto() CurrentPartner(s): PROSOLV Application(s): Current Technologies/Platforms: EMCOCEL VIVAPUR urn ehooisPafrs plcto() CurrentPartner(s): Contact: Silicone-Coated Papers &Films Application(s): Current Technologies/Platforms: urn ehooisPafrs plcto() CurrentPartner(s): Contact: HySolv™ Application(s): Current Technologies/Platforms: distribution oftheir message. advertisers withglobal edition alsoprovides Web site.Theelectronic with activelinkstotheir Drug DeliveryTechnology electronic edition of also appearinthe in ourprintedition will All advertisersappearing EDITION ELECTRONIC NEW- ® Sodium Stearyl Fumarate Sodium Stearyl ee il (845)878-8380 ReneeMill, : ® ® ® ® tv anes MarketingManager Steve Saunders, lxS i,EeuieVc rsdn (801)433-2560 Executive Vice President, Kim, Alex S. ® ® Microcrystalline Cellulose Microcrystalline Microcrystalline Cellulose Microcrystalline Sodium StarchGlycolate Sodium StarchGlycolate Hydrogenated -al [email protected] -www.macromed.com e-mail: XIINS OYES ISMS IIS COATINGS LIPIDS, LIPSOMES, POLYMERS, EXCIPIENTS, XIINS OYES ISMS IIS COATINGS LIPIDS, LIPSOMES, POLYMERS, EXCIPIENTS, XIINS OYES ISMS IIS COATINGS LIPIDS, LIPSOMES, POLYMERS, EXCIPIENTS, Drug DeliveryTechnology hn:(0)4125 Fx (845)878-3484 (800)431-2457Fax: Phone: hn:(3)7420 a:(630)734-2690 (630)734-2700Fax: Phone: :(0)4326 a:(801)433-2561 (801)433-2560Fax: T: est:www.macromed.com Website: mi:[email protected] email: West UT84120 Valley City, Release linersformedicaldevices rl aetrlSlblzrNotDisclosed Parenteral Solubilizer Oral, Superdisintegrant Tablet Lubricant Tablet Binder Lubricant High FunctionalityExcipients Superdisintegrant Tablet Binder 47S 80,Suite 150 3850W, 2417 S. mi:[email protected] email: 91Rue2,Suite 1 2981 Route 22, ilwro,IL60527 Willowbrook, atro,NY12563 Patterson, www.jrspharma.com www.loparex.com M JRS P 7700 Griffin 7700 Griffin Way ACRO L OPAREX HARMA M November/December 2006 ED ,I LP NC . Vol 6No 10
e Company See
Profile 93
Drug Delivery Technology November/December 2005 Vol 5 No 10 * DDT Nov-Dec 2006 Round 5 11/10/06 8:25 PM Page 95
EXCIPIENTS, POLYMERS, LIPSOMES, LIPIDS, COATINGS EXCIPIENTS, POLYMERS, LIPSOMES, LIPIDS, COATINGS NEOPHARM INC. PARTICLE AND COATING TECHNOLOGIES,INC. 150 Field Drive, Suite 195 5445 Highland Park Drive Lake Forest, IL 60045 St. Louis, MO 63110 Phone: (847) 295-8678 Fax: (847) 295-8854 Phone: (314) 535-1516 Fax: (314) 535-1514 www.neophrm.com email: [email protected] www.pctincusa.com Current Technologies/Platforms: Application(s): Current Partner(s):
NeoLipid™ Technology Delivery of broad range of difficult to formulate Current Technologies/Platforms: Application(s): Current Partner(s): drugs Very viscous coatings Better barriers Burst-release coatings Delayed release NeoPhectin™ (In Vitro) Delivery of Nucleic acids (siRNA, plasmids, antisense) Pipeline Technologies/Platforms: Application(s): Development Stage: NeoPhectin-AT™ (In Vivo) Delivery of Nucleic acids (siRNA, plasmids, New barrier coatings antisense) Contact: Robert Sparks Pipeline Technologies/Platforms: Application(s): Development Stage: EXCIPIENTS, POLYMERS, LIPSOMES, LIPIDS, COATINGS NeoLipid™ Technology Easy to use Liposome-based drugs for treatment Liposome-based SN38 of Cancer (LE-SN38), SN-38 is an PAULAUR CORPORATION active metabolite of 105 Melrich road Camptosar® - Phase I/II Cranbury, NJ 08512 Liposome-based Paclitaxel Phone: (609) 395-8844 Fax: (609) 395-8850 (LEP-ETU) - Phase I/II email: [email protected] Liposome-based raf anti- www.paulaur.com sense (LE-rafAON) - Phase I Current Technologies/Platforms: Application(s): Current Partner(s): Sugar Spheres USP/NF Oral, Solid Dosage, Sustained, Controlled & Extended Release
EXCIPIENTS, POLYMERS, LIPSOMES, LIPIDS, COATINGS DURO-TAB® Direct Compacting & Tableting Sugar
NOVEON,INC. ® 9911 Brecksville Road MEGATAB Direct Compacting & Tableting Sucrose Cleveland, OH 44141 MEGADEX® Direct Compacting & Tableting Dextrose Phone: (216) 447-5000 www.pharma.noveon.com Current Technologies/Platforms: Application(s): Current Partner(s): EXCIPIENTS, POLYMERS, LIPSOMES, LIPIDS, COATINGS Carbobol® Polymers Controlled release solid dosage forms (tabs, caps); topical lotions, creams and gels PHARMAFORM L.L.C. 11400 Burnet Road, Bldg. 4 - Suite 4010 Pemulen® Polymeric Emulsifiers Topical lotions, creams and gels Austin, TX 78758 Noveon® Polycarbophils Bioadhesion in vaginal, buccal and ophthalmic Phone: (512) 834-0449, ext. 201 - Fax: (512) 834-2105 applications; taste masking www.pharmaform.com
EXCIPIENTS, POLYMERS, LIPSOMES, LIPIDS, COATINGS Current Technologies/Platforms: Application(s): Current Partner(s): Film Coating Controlled Release, Modified Release, Delayed OSG NORWICH PHARMACEUTICALS,INC. Release 6826 State Highway 12 Norwich, NY 13815 Hot Melt Extrusion Controlled Release, Abuse Deterrent, Dosage Forms, Transmucosal Films, Phone: (607) 335-3000 Fax: (607) 335-3100 Enhanced Solubility email: [email protected] Pipeline Technologies/Platforms: Application(s): Development Stage: www.norwichpharma.com EDACS Abuse Deterrent Systems Controlled or abused substances Current Technologies/Platforms: Application(s): Current Partner(s): Contact: Michael M. Crowley, PhD, VP Business Development Aqueous and solvent tablet coating Tablets Numerous Contact: Bob Calabro EXIPIENTS, POLYMERS, LIPOSOMES, LIPIDS, COATINGS POLYMUN SCIENTIFIC GMBH EXCIPIENTS, POLYMERS, LIPSOMES, LIPIDS, COATINGS Nussdorfer Laende 11 OXFORD LASERS INC. Vienna, Austria A-1190 2 Shaker Road, Unit D201 Phone: +43-1-36006-6203 Fax: +43-1-3697615 Shirley, MA 01464 e-mail: [email protected] Phone: (978) 425 0755 or (800) 222-3632 Fax: (978) 425-4487 www.oxfordlasers.com www.polymun.com e-mail: [email protected] Current Technologies/Platforms: Application(s): Current Partner(s): Current Technologies/Platforms: Application(s): Current Partner(s): Liposome Production Technology Continuous and aseptic one-step process EnVision Pharma Systems - Short MDI & nasal devices, generation of spray pattern Bespak resulting in sterile liposomes of defined pulsed light source imaging and plume geometry information. Also Vectura size distribution and long- term stability. Allows development of DPI, nebulizer, and transdermal/ Chiesi scale-up to any desired production size at high needle-free devices GlaxoSmithKline drug incorporation rates and excellent batch-to- batch consistency in GMP-compliant quality. VisiSizer System Particle size analysis for medical devices Bang & Olufsen Medicom Contact: Dr. Dietmar Katinger development
Laser micro-machining Wide range of medical device and controlled/calibrated leak testing Contact: Dr. Séamus D Murphy, [email protected], (978) 425 0755
94 Drug Delivery Technology November/December 2006 Vol 6 No 10 DDTNov-Dec2006Round511/10/068:25PMPage96 * PURASORB PURASAL urn ehooisPafrs plcto() CurrentPartner(s): PURAC Application(s): Current Technologies/Platforms: Contact ieieTcnlge/ltom:Apiains:DevelopmentStage: Contact: Conjugation CurrentPartner(s): PEGylation Application(s): Pipeline Technologies/Platforms: Keyhole limpethemocyanin (KLH) Synthetic Cholesterol Tween LowPeroxide 20/80GMP, Liposomes Lipids Polyamino Acids Application(s): Current Technologies/Platforms: urn ehooisPafrs plcto() CurrentPartner(s): Contact: Sorbitol Powder Sorbogem™ Spray-dried Powder Mannitol Granular, 2080, Mannogem™ EZ, Application(s): Current Technologies/Platforms: WECOBEE Triglycerides urn ehooisPafrs plcto() CurrentPartner(s): NEOBEE Application(s): Current Technologies/Platforms: Contact: hn:(0)2417 (1-3-90 Fx (800)368-4661(314-652-0000) (800)244-1173(314-534-4900)Fax: Phone: ® ClaudiaBratrude : ® ® Medium Chain ® o eieu 34 0-07 mi:[email protected] email: (314)301-2077, Tom Gelineau, ® aa Chandar Sarat ae .Butterwick James M. Triglycerides (Biodegradable Polymers) XPET,PLMR,LPSMS IIS COATINGS LIPIDS, LIPOSOMES, POLYMERS, EXIPIENTS, XIINS OYES ISMS IIS COATINGS LIPIDS, LIPSOMES, POLYMERS, EXCIPIENTS, XIINS OYES ISMS IIS COATINGS LIPIDS, LIPSOMES, POLYMERS, EXCIPIENTS, XIINS OYES ISMS IIS COATINGS LIPIDS, LIPSOMES, POLYMERS, EXCIPIENTS, www.purac.com orwww.puracbiomaterials.com hn:(4)6463 Fx (847)634-1992 (847)634-6330Fax: Phone: hn:(0)7274 a:(201)712-7648 (201)712-7642Fax: Phone: mi:[email protected] email: rlMany Parenteral Oral aetrl mlns Microspheres Implants, Parenteral, tblt,slblt Prototype solubility Stability, Carrier/adjuvant Emulsifier/liposomes Detergent/surfactant Carrier/excipient Liposomes Carrier/excipient oi rlDs x OTCNutraceutical Rx, OTCNutraceutical Rx, Solid OralDose Solid OralDose mi:[email protected] email: ovn,carrier Solvent, Suppository base Suppository 100 WestHunter Avenue iclsie IL60069 Lincolnshire, 111 Barclay Boulevard t oi,MO63103 Louis, St. awo,NJ07607 Maywood, P www.safcglobal.com 3050 Spruce Street 3050 Spruce URAC S www.stepan.com TEPAN A SAFC MERICA C OMPANY hn:(302)576-8500x8554 Phone: e ate Delaware 19720 New Castle, ,I NC www.spipharma.com a:(302)576-8567 Fax: 2 hryLane 321 Cherry P P SPI HARMA distribution oftheir message. advertisers withglobal edition alsoprovides Web site.Theelectronic with activelinkstotheir Drug DeliveryTechnology electronic edition of also appearinthe in ourprintedition will All advertisersappearing EDITION ELECTRONIC NEW- urn ehooisPafrs plcto() CurrentPartner(s): Contact: modification Micro-/Nan particle surface coating, Application(s): Current Technologies/Platforms: standard lipidsavailable Custom manufactured and LipoMask urn ehooisPafrs plcto() CurrentPartner(s): LipoBridge Application(s): Current Technologies/Platforms: POLYOX METHOCEL Contact: urn ehooisPafrs plcto() CurrentPartner(s): ETHOCEL Application(s): Current Technologies/Platforms: TM Melissa Bressette TM TM Water-Soluble ResinsNF ae .Butterwick James M. ® TM Ethylcellulose Cellulose Ethers XIINS OYES ISMS IIS COATINGS LIPIDS, LIPSOMES, POLYMERS, EXCIPIENTS, XIINS OYES ISMS IIS COATINGS LIPIDS, LIPSOMES, POLYMERS, EXCIPIENTS, XIINS OYES ISMS IIS COATINGS LIPIDS, LIPSOMES, POLYMERS, EXCIPIENTS, Drug DeliveryTechnology hn:(9)8216 Fx (898)832-1465 (898)832-1560Fax: Phone: T HE rgdlvr,cseisNaraMachinery cosmetics Drug delivery, xeddcruaintm fprnr nbodUndisclosed Undisclosed timeofpartnersinblood Extended circulation MultipleSclerosis Parkinson’s, trauma, stroke, Alzheimer’s, bloodbrainbarrier, CNS, onrle ees,tabletcoating Colntrolled release, rlfls hot-meltextrusion oral films, granulation, tabletcoating, Colntrolled release, onrle ees,hot-meltextrusion Colntrolled release, iln,Michigan 48642 Midland, www.dowexcipients.com D OW hn:(0)3365 Fx (704)392-1621 (704)393-6555 Fax: Phone: ..Box 1206 P.O. C hn:(800)868-8208or(617)374-7248 Phone: -al [email protected] E-mail: HEMICAL www.genzymepharmaceuticals.com mi:[email protected] email: November/December 2006 G ENZYME 675 West Kendall Street abig,MA02142 Cambridge, hrot,NC28208 Charlotte, C a:(617)768-9765 Fax: 3001 Stafford Drive www.texmac.com OMPANY T EXMAC P HARMACEUTICALS I NC . Vol 6No 10
e CompanySee
Profile 95 Drug Delivery Technology November/December 2005 Vol 5 No 10 * DDT Nov-Dec 2006 Round 5 11/10/06 8:25 PM Page 97
CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES AKINA,INC. Business & Technology Center Bldg 275-3E-10 1291 Cumberland Avenue, E130 St. Paul, MN 55110 See Company West Lafayette, IN 47906-1385 Profile Phone: (800) 643-8086 Fax: 651-737-5265 Phone: (765) 464-0501 - Fax: (765) 464-0820 www.3m.com/ddsadv e-mail: [email protected] - www.akinainc.com Please check the categories in which your company provides the service. Please check the categories in which your company provides the service. ❏ Drug Discovery ❏ Analytical Development ❏✔Formulation Development ❏ Stability Testing ❏ ❏✔✔❏✔ ❏ Drug Discovery Analytical Development Formulation Development Stability Testing ❏ Clinical Trial MFG/Scale-up ❏✔Technology/Transfer ❏ Manufacturing ❏ Packaging ❏✔ ❏✔ ❏✔✔❏ Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging ❏ Other: ❏✔ Laboratory Testing ❏ Current Partnerships: Samyang Corp., Boston Scientific, Endovasc ❏ Other: Contact: Kinam Park, PhD, (765) 464-0390, [email protected] Contact: Brian Gabrio; [email protected] CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES AAIPHARMA INC. AKORN,INC. 2320 Scientific Park Drive 2500 Millbrook Drive Wilmington, NC 28405 Buffalo Grove, IL 60089 Phone: (800) 575-4224 or (910) 254-7000 Phone: (800) 932-5676 Fax: 800-943-3694 Fax: (910) 815-2300 e: [email protected] - www.aaipharma.com/aaiportal/ Website: www.akorn.com Please check the categories in which your company provides the service. Please check the categories in which your company provides the service. ❏ Drug Discovery ❏✔✔Analytical Development ❏ Formulation Development ❏ ✔Stability Testing ❏✔ Drug Discovery ❏✔Analytical Development ❏✔Formulation Development ❏✔Stability Testing ❏✔ Clinical Trial MFG/Scale-up ❏✔✔Technology/Transfer ❏ Manufacturing ❏ ✔Packaging ❏✔ Clinical Trial MFG/Scale-up ❏✔Technology/Transfer ❏✔ Manufacturing ❏✔ Packaging ❏✔ Other: Phase I-IV Clinical Trials, Clinical trial packaging and distribution ✔❏ Labroatory Testing ❏ Other: ❏ Current Partnerships:
CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES Contact: JAY STERN VP SALES & MARKETING
ABC LABORATORIES,INC. CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES 7200 East ABC Lane Columbia, MO 65202 Alcoa Flexible Packaging Phone: (573) 443-9000 Fax: (573) 443-9033 6603 West Broad Street email: [email protected] Richmond, VA 23230 www.abclabs.com Phone: (804) 281-2603 Fax: (804) 281-2238 www.alcoa.com Please check the categories in which your company provides the service. Please check the categories in which your company provides the service. ❏✔Drug Discovery ❏✔✔Analytical Development ❏ Formulation Development ❏ Stability Testing ❏ Clinical Trial MFG/Scale-up ❏ Technology/Transfer ❏ Manufacturing ❏ Packaging ❏ Drug Discovery ❏ Analytical Development ❏ Formulation Development ❏ Stability Testing ❏ Clinical Trial MFG/Scale-up ❏ Technology/Transfer ❏ Manufacturing ❏✔ Packaging Contact: Nancy Berrey Contact: Victoria C. Welch, (804) 281-2262 CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES ADVION BIOSCIENCES CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES 15 Catherwood Road American Peptide Company, Inc. Ithaca, New York 14850 777 East Evelyn Avenue Phone: (607) 266-0665 Fax: (607) 266-0749 Sunnyvale, CA 94086 email: [email protected] Phone: (408) 733-7604, x204 www.advion.com www.americanpeptide.com
Please check the categories in which your company provides the service. Please check the categories in which your company provides the service. ❏ ❏ ❏ ❏ Drug Discovery Analytical Development Formulation Development Stability Testing ❏ Drug Discovery ❏ Analytical Development ❏ Formulation Development ❏ Stability Testing ❏ ❏ ❏ ❏ Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging ❏ Clinical Trial MFG/Scale-up ❏ Technology/Transfer ❏✔Manufacturing ❏ Packaging ❏✔ Analytical Testing & Analysis ❏✔ Other: Peptides, cGMP, Process Development ❏✔ Other: LC/MS Bioanalytical Services; Sample Management Services
Contact: Gary Hu, (800) 926-8272, ext. 204 Contact: Gaye Martin
96 Drug Delivery Technology November/December 2006 Vol 6 No 10 DDTNov-Dec2006Round511/10/068:25PMPage98 * ❏ ❏ Contact ❏ theservice. provides Please checkthecategoriesinwhichyourcompany ✔ Contact ❏ ❏ ❏ theservice. provides Please checkthecategoriesinwhichyourcompany ❏ ❏ Contact ❏ theservice. provides Please checkthecategoriesinwhichyourcompany ❏ ❏ ❏ Contact ❏ theservice. provides Please checkthecategoriesinwhichyourcompany ✔ ✔ ✔ ✔ Other: Clinical TrialMFG/Scale-up Drug Discovery Other: Clinical TrialMFG/Scale-up Drug Discovery te:Education&Training: Other: Clinical TrialMFG/Scale-up Drug Discovery Other: Clinical TrialMFG/Scale-up Drug Discovery Laboratory TestingLaboratory AFPam,(800)443-0627 BASFPharma, : : Kim Thomas, (847) 270-5072 (847) KimThomas, : : Dr. Angeline Zakrzewski, email: [email protected] 203-312-0682 [email protected] email: AngelineZakrzewski, Dr. : ai ree,VPSalesandMarketing Greeley, David : CONTRACT PHARMACEUTICAL &BIOLOGICAL DEVELOPMENT SERVICES CONTRACT PHARMACEUTICAL &BIOLOGICAL DEVELOPMENTSERVICES CONTRACT PHARMACEUTICAL &BIOLOGICAL DEVELOPMENTSERVICES CONTRACT PHARMACEUTICAL &BIOLOGICAL DEVELOPMENTSERVICES Solid and semi-solid dosage formcontractmanufacturing Solid andsemi-soliddosage assa tt nltcltcnqe.Seiial,assa: Specifically, analyticaltechniques. state Alsooffersawiderangeof • X-RayPowder onPolymorph Screening, offersspecializedcourses for pharmaceuticalapplications • organizesin-depth • Characterization Services, Synthesis, Preformulation Preformulation Synthesis, Services, Characterization oyop cenn rgas We forExpert areavailable Witness services. Polymorph Screeningprograms. Diffraction, Near IR and Terahertz Spectroscopy, and Patent related issues. andPatent related NearIRand Terahertz Spectroscopy, Diffraction, Pharmaceutical area. international A ZOPHARMA hn:(0)3208 Fx (203)312-0722 (203)312-0682Fax: Phone: hn:(5)4378 Fx (954)432-9015 (954)433-7480Fax: Phone: ® is a training and consulting company specialized on pharmaceutical applications ofsolid- specializedonpharmaceuticalapplications is atrainingandconsultingcompany mi:[email protected] email: mi:[email protected] email: ❏ ❏ ❏ ❏ ❏ ❏ ❏ ❏ Interna ✔ ✔ Technology/Transfer Analytical Development Technology/Transfer Analytical Development Technology/Transfer Analytical Development Technology/Transfer Analytical Development
e CompanySee www.assainternational.com tional ,C Analytical Ser SAINTERNATIONAL ASSA
Profile 10320 USAToday Way www.azopharma.com ONTRACT abr,CT06811 Danbury, iaa,FL33025 Miramar, 3B EastLake Road W orkshops T: (800) 422-9837 (domestic) or(847)948-4770 (800)422-9837(domestic) T: vices www.baxterbiopharmasolutions.com hn:(0)4302,Fx (973) 245-6763 Fax: (800)443-0627, Phone: P and Conferences on Solid State Characterization inthe Characterization and ConferencesonSolidState B HARMACEUTICAL AXTER o hraetclSldSaepolm,including four problems, for PharmaceuticalSolidState -al [email protected] e-mail: ❏ ❏ ❏ ❏ ❏ ❏ ❏ ❏ ✔✔ ✔ ✔✔ ✔ Route 120& Wilson Roads mi:[email protected] email: www.pharma-solutions.basf.com Manufacturing Formulation Development Manufacturing Formulation Development Manufacturing Formulation Development Manufacturing Formulation Development on ae IL60073 Round Lake, H :(847)948-3642 F: lra ak NJ07932 Park, Florham I NC EALTHCARE 100 CampusDrive
e CompanySee S ERVICES BASF Profile C ORPORATION ❏ ❏ ❏ ❏ ❏ ❏ ❏ ❏ ✔ Packaging Stability Testing Packaging Stability Testing Packaging Stability Testing Packaging Stability Testing
e CompanySee e CompanySee Contact ❏ ❏ ❏ theservice. provides Please checkthecategoriesinwhichyourcompany Contact ❏ ❏ ❏ theservice. provides Please checkthecategoriesinwhichyourcompany ✔ Contact ❏ ❏ ❏ ❏ theservice. provides Please checkthecategoriesinwhichyourcompany ✔ Contact ❏ ❏ ❏ theservice. provides Please checkthecategoriesinwhichyourcompany ✔ ✔ ✔ Profile Profile Analytical Testing& Analysis Other: Clinical TrialMFG/Scale-up Drug Discovery Other: Clinical TrialMFG/Scale-up Drug Discovery Other: Clinical TrialMFG/Scale-up Drug Discovery Other: Clinical TrialMFG/Scale-up Drug Discovery o enn [email protected] JoeKeenan, : Sales : e tr,(858)450-4676 LeeStarr, : JenniferWinders : CONTRACT PHARMACEUTICAL &BIOLOGICAL DEVELOPMENTSERVICES CONTRACT PHARMACEUTICAL &BIOLOGICAL DEVELOPMENTSERVICES Analytical Chemistry &Microbiological Analytical Chemistry Testing Services CONTRACT PHARMACEUTICAL &BIOLOGICAL DEVELOPMENTSERVICES CONTRACT PHARMACEUTICAL &BIOLOGICAL DEVELOPMENTSERVICES Lyphilization GPmtrasmngmn soae ipnig apig oitc) consulting logistics), sampling, dispensing, (storage, management cGMP materials Drug DeliveryTechnology hn:(5)40313Fx (858)450-0785 (858)450-34123Fax: Phone: ❏ ❏ ❏ ❏ ✔ ❏ ❏ ❏ ❏ ❏ ✔ ✔ Technology/Transfer Analytical Development Technology/Transfer Analytical Development Process Development Technology/Transfer Analytical Development Technology/Transfer Analytical Development mi:[email protected] email: San Diego, California 92121 California San Diego, hn:+4010 560-Fx +44(0)1908552613 +44(0)1908552600-Fax: Phone: B www.bioservcorp.com -al [email protected] -www.bespak.com e-mail: IOSERV 5340 Eastgate Mall itnKye,Buckinghamshire MK125TS Milton Keynes, hn:(1)2404 a:(310)370-3642 (310)214-0043Fax: Phone: lchl rv,Featherstone Road, Blackhill Drive, C hn:(1)9110 Fx (812)961-1733 (812)961-1700Fax: Phone: B ORPORATION November/December 2006 IO -al [email protected] e-mail: ❏ ❏ S ❏ ❏ ✔✔ ✔ ✔ ❏ ❏ ❏ ❏ ✔✔ ✔✔ ✔ Wolverton Mill South CREEN Manufacturing Formulation Development Manufacturing TestingLaboratory Manufacturing Formulation Development Manufacturing Formulation Development United Kingdom www.bioscreen.com orne CA90503 Torrance, 94DlAmo Blvd 3904 Del loigo,IN47404 Bloomington, 4320 West ZenithDrive B B SA PLC ESPAK IO mi:[email protected] email: T ESTING C www.bioc.us ONVERGENCE S ERVICES Vol 6No 10 LLC ,I ❏ ❏ ❏ ❏ ❏ ❏ ❏ ❏ ✔ ✔ NC Packaging Stability Testing Packaging Stability Testing Packaging Stability Testing Packaging Stability Testing . 97 Drug Delivery Technology November/December 2005 Vol 5 No 10 * DDT Nov-Dec 2006 Round 5 11/10/06 8:59 PM Page 99
CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES BIOVAIL CONTRACT RESEARCH CAPSUGEL 460 Comstock Road 535 North Emerald Road Toronto, Ontario, Canada MIL4S4 Greenwood, SC 29646 Phone: (416) 752-3636 Fax: (416) 752-7610 Phone: (888) 783-6361 Fax: (888) 783-6360 See Company email: [email protected] email: [email protected] Profile www.biovail-cro.com www.capsugel.com Please check the categories in which your company provides the service. Please check the categories in which your company provides the service. ❏ Drug Discovery ❏ Analytical Development ❏ Formulation Development ❏✔ Stability Testing ❏ ❏ ❏✔ ❏ ❏ Clinical Trial MFG/Scale-up ❏ Technology/Transfer ❏ Manufacturing ❏ Packaging Drug Discovery Analytical Development Formulation Development Stability Testing ❏✔ ❏ ❏ ❏ ❏ Laboratory Testing Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging ❏ ❏✔ ❏✔ Other: Clinical Trials & Bioanalysis, Analytical Testing & Analysis Analytical Testing & Analysis Laboratory Testing
Contact: Tamar Aghamanoukian, Director, Marketing & Sales Contact: Glenda Oliver-Smith CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES CELSION CORPORATION BROOKWOOD PHARMACEUTICALS,INC. 756 Tom Martin Drive 10220-L Old Columbia Road Phone: (205) 917-2239 Columbia, MD 21046 Fax: (205) 917-2205 Phone: (410) 290-5390 Fax: (410) 290-5394 www.brookwoodpharma.com email: [email protected] www.celsion.com Please check the categories in which your company provides the service. Please check the categories in which your company provides the service. ✔ ❏✔ Drug Discovery ❏✔Analytical Development ❏ Formulation Development ❏✔ Stability Testing ❏ Drug Discovery ❏ Analytical Development ❏ Formulation Development ❏ Stability Testing ✔ ✔ ❏ Clinical Trial MFG/Scale-up ❏✔Technology/Transfer ❏ Manufacturing ❏ Packaging ❏ Clinical Trial MFG/Scale-up ❏ Technology/Transfer ❏ Manufacturing ❏ Packaging ✔ ❏ Laboratory Testing ❏ Analytical Testing & Analysis ❏ Process Development ❏✔ Other: Cancer Drug Development Contact: Kelly Arlint, (205) 917-2239
CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES Contact: Anthony P. Deasey, EVP & COO, (410) 290-5390 x4899 CALORIMETRY SCIENCES CORPORATION CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES 890 West 410 North, Suite A Lindon, UT 84042 CENTER FOR ADVANCED DRUG DEVELOPMENT Phone: (801) 763-1500 Fax: (801) 763-1414 100 Oakdale Campus Room 1 PRL email: [email protected] Iowa City, Iowa 52242-5000 www.calorimetrysciences.com Phone: (319) 335-4096 Fax: (319) 335-4374 email: [email protected] Please check the categories in which your company provides the service. www.pharmacy.uiowa.edu/rxserve/index.htm ❏ Drug Discovery ❏ Analytical Development ❏ Formulation Development ❏✔ Stability Testing Please check the categories in which your company provides the service. ❏ Clinical Trial MFG/Scale-up ❏ Technology/Transfer ❏ Manufacturing ❏ Packaging ❏ Laboratory Testing ❏ Drug Discovery ❏✔Analytical Development ❏✔Formulation Development ❏✔ Stability Testing ❏✔ Clinical Trial MFG/Scale-up ❏✔Technology/Transfer ❏✔ Manufacturing ❏ Packaging Contact: Peter Zumbrennen ❏✔ Other: Method development and validation according to ICH guidelines, development of dissolution procedures and CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES validation of the analytical method, pre-formulation, development of formulations, API, excipient and drug product testing according to official monographs. CARDINAL HEALTH 14 Schoolhouse Road Contact: Dr. Alta Botha Somerset, New Jersey 08873 CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES Phone: (732) 537-6200 Fax: (732) 537-5949 email: [email protected] CERILLIANT CORPORATION 811 Paloma Drive www.cardinal.com/pts Round Rock, Texas 78664 Phone: (800) 848-7837 Fax: (800) 654-1458 Please check the categories in which your company provides the service. email: [email protected] www.cerilliant.com ❏ Drug Discovery ❏✔✔Analytical Development ❏ Formulation Development ❏ ✔Stability Testing ✔❏ Clinical Trial MFG/Scale-up ❏✔✔Technology/Transfer ❏ Manufacturing ❏ ✔Packaging Please check the categories in which your company provides the service. ❏✔ Analytical Testing & Analysis ❏✔Process Development ❏ Drug Discovery ❏✔Analytical Development ❏ Formulation Development ❏✔ Stability Testing ❏✔ Other: Product Launch Services, Medical Education, Post-Launch Services ❏✔ Clinical Trial MFG/Scale-up ❏✔Technology/Transfer ❏✔ Manufacturing ❏✔ Packaging See Company ❏✔ Analytical Testing & Analysis ❏✔Process Development Contact: (866) 720-3148 (toll-free) or [email protected] Profile
Contact: Debbie Palmon, Account Manager/Tradeshow Coordinator
98 Drug Delivery Technology November/December 2006 Vol 6 No 10 DDTNov-Dec2006Round511/10/068:25PMPage100 * ❏ ❏ ❏ theservice. provides Please checkthecategoriesinwhichyourcompany ✔ ✔ Contact ❏ ❏ ❏ theservice. provides Please checkthecategoriesinwhichyourcompany Contact ❏ ❏ ❏ theservice. provides Please checkthecategoriesinwhichyourcompany ❏ theservice. provides Please checkthecategoriesinwhichyourcompany Contact ❏ ❏ Contact Development & Validation ❏ ❏ ❏ ❏ theservice. provides Please checkthecategoriesinwhichyourcompany ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ Other: Clinical TrialMFG/Scale-up Drug Discovery Other: Clinical TrialMFG/Scale-up Drug Discovery Other: Clinical TrialMFG/Scale-up Analytical Testing Drug Discovery Other: Clinical TrialMFG/Scale-up Other: TestingLaboratory Clinical TrialMFG/Scale-up Drug Discovery MilesHutchingsandDeanHamel : : April Ladd, Manager ofSales & Marketing Manager Ladd, April : rdShle (817)477-2766 Fred Schulze, : MichaelBranciforti(919)321-4043 : CONTRACT PHARMACEUTICAL &BIOLOGICAL DEVELOPMENTSERVICES CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES CONTRACT PHARMACEUTICAL &BIOLOGICAL DEVELOPMENTSERVICES CONTRACT PHARMACEUTICAL &BIOLOGICAL DEVELOPMENTSERVICES CONTRACT PHARMACEUTICAL &BIOLOGICAL DEVELOPMENTSERVICES Supplies probiotics (capsules, tablets and powders), phytonutrients, colors, flavors andmaskants flavors colors, phytonutrients, tabletsandpowders), Supplies probiotics(capsules, ecalsadEtatbe nlss ult aaeet ieCceCnutto,EH&StestingandConsulting LifeCycle Consultation, QualityManagement, Leachables andExtractables Analysis, amla elcluesrie,Cl iedvlpet elbnig ProcessDevelopment Cellbanking, Celllinedevelopment, Mammalian cellcultureservices, hscl&Ceia hrceiain atceSz nlss iePril eeain AnalyticalMethod Fine Particle Generation, Particle Size Analysis, Physical &ChemicalCharacterization, hn:(0)5800 Fx (414)607-5959 (800)558-0802Fax: Phone: hn:(1)7523 Fx (914)785-4241 (914)785-2533Fax: Phone: hn:(1)8426 Fx (919)884-2075 (919)884-2064Fax: Phone: eerhTinl ak NC27709-4748 Research Triangle Park, mi:[email protected] email: ❏ ❏ ❏ ❏ ❏ ❏ ❏ ❏ ✔✔ ✔ ❏ ❏ ✔ ✔✔ ✔✔ ✔✔ ✔ Technology/Transfer Analytical Development Technology/Transfer Analytical Development Process Development Analytical Development Analytical Development Technology/Transfer Technology/Transfer Analytical Development 0 al tet POBox 930310 200 Paoli Street, C mi:[email protected] email: mi:[email protected] email: IRRUS www.cirruspharm.com hn:(608)845-9521 Phone: C iwue,WI53214 Milwaukee, 540 White PlainsRoad artw,NY10591 Tarrytown, www.chr-hansen.com 9015 W. Maple Street Maple 9015 W. www.cibasc.com/cxs C IBA eoa WI53593 Verona, OATING P www.encap.com ..Box 14748 P.O. C ®E HARMACEUTICALS hn:(7)32CO Fx (812)336-7167 Fax: (877)312-COOK Phone: HR XPERT .H P ANSEN LACE mi:[email protected] email: ❏ ❏ ❏ ❏ ❏ ❏ ✔ ❏ ❏ ❏ ❏ S ERVICES Manufacturing Formulation Development Manufacturing Formulation Development Manufacturing Formulation Development Formulation Development Manufacturing Manufacturing Formulation Development ,I www.cookpharmica.com loigo,IN47403 Bloomington, 30S Paterson Drive 1300 S. NC C OOK . ,I NC P . HARMICA LLC
e Company See ❏ ❏ ❏ ❏ ❏ ❏ ❏ ❏ ❏ ❏ ✔ ✔ ✔
Profile Packaging Stability Testing Packaging Stability Testing Packaging Stability Testing Stability Testing Packaging Packaging Stability Testing Contact ❏ ❏ ❏ ❏ theservice. provides Please checkthecategoriesinwhichyourcompany ✔ ✔ ✔ ✔ Contact ❏ ❏ ❏ theservice. provides Please checkthecategoriesinwhichyourcompany Contact ❏ ❏ ❏ ❏ theservice. provides Please checkthecategoriesinwhichyourcompany ✔ ❏ ❏ ❏ theservice. provides Please checkthecategoriesinwhichyourcompany ✔ Current Partnerships: Other: Clinical TrialMFG/Scale-up Laboratory TestingLaboratory Other: Clinical TrialMFG/Scale-up Drug Discovery Current Partnerships: Other: Clinical TrialMFG/Scale-up Drug Discovery Analytical Testing& Analysis Clinical TrialMFG/Scale-up Drug Discovery e o,PD PBsns eeomn,(0)7572,[email protected] (203)775-7124, VPBusinessDevelopment, PhD, DebFox, : oeL Rodriguez JoseL. : neSna (858)467-6615 AnneSinha, : CONTRACT PHARMACEUTICAL &BIOLOGICAL DEVELOPMENTSERVICES CONTRACT PHARMACEUTICAL &BIOLOGICAL DEVELOPMENTSERVICES CONTRACT PHARMACEUTICAL &BIOLOGICAL DEVELOPMENTSERVICES CONTRACT PHARMACEUTICAL &BIOLOGICAL DEVELOPMENTSERVICES C-eeomn,Cnrc eeomn,ProductRe-engineering) ContractDevelopment, (Co-Development, Fermentation Capability Drug DeliveryTechnology hn:(8)CVNE Fx (608)241-7227 (888)COVANCE Fax: Phone: hn:(1)6585 Fx (913) 685-8856 (913)685-8850Fax: Phone: hn:(5)2240 Fx (858)292-4901 (858)292-4900Fax: Phone: ❏ ❏ ✔✔ ✔✔ ✔ ❏ ❏ ❏ ❏ ❏ ❏ ❏ ✔ Technology/Transfer Analytical Development Technology/Transfer Analytical Development Technology/Transfer Analytical Development Process Development Technology/Transfer Analytical Development mi:[email protected] email: mi:[email protected] email: -al [email protected] e-mail: 10513 West 84thTerrace a ig,CA92123 San Diego, C www.cydexinc.com www.cpkelco.com OVANCE eea KS66214 Lenexa, aio,WI53704 Madison, 3301 Kinsman Blvd. 8355 AeroDrive www.covance.com hn:(5)2885 Fx (650)298-8012 (650)298-8255Fax: Phone: C CP K Y D November/December 2006 EX L mi:[email protected] email: 66MdlfedRa,Suite G 2686 Middlefield Road, ELCO ABORATORIES ,I C ❏ ❏ ewo iy CA94063 Redwood City, ORIUM ❏ ❏ ✔✔ NC ❏ ❏ ✔ ❏ ❏ www.coriumgroup.com Manufacturing Formulation Development Manufacturing Formulation Development Manufacturing Formulation Development Manufacturing Formulation Development . I NTERNATIONAL ,I Vol 6No 10 NC ❏ ❏ ❏ ❏ ❏ ❏ ❏ ❏ ✔ . Packaging Stability Testing Packaging Stability Testing Packaging Stability Testing Packaging Stability Testing 99
Drug Delivery Technology November/December 2005 Vol 5 No 10 * DDT Nov-Dec 2006 Round 5 11/10/06 8:25 PM Page 101
CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES
DE DIETRICH PROCESS SYSTEMS,INC. DOW PHARMACEUTICAL SCIENCES,INC. 244 Sheffield Street 1330 Redwood Way Mountainside, NJ 07092 Petaluma, CA 94954 Phone: (908) 317-2585 Fax: 908-889-4960 Phone: (707) 793-2600 e-mail: [email protected] Fax: (707) 793-0145 www.ddpsinc.com www.dowpharmsci.com
Please check the categories in which your company provides the service. Please check the categories in which your company provides the service. ❏ Drug Discovery ❏✔Analytical Development ❏✔✔Formulation Development ❏ Stability Testing ❏ Drug Discovery ❏ Analytical Development ❏ Formulation Development ❏ Stability Testing ❏✔ Clinical Trial MFG/Scale-up ❏✔Technology/Transfer ❏ Manufacturing ❏✔Packaging ❏ Clinical Trial MFG/Scale-up ❏ Technology/Transfer ❏✔Manufacturing ❏ Packaging ❏✔ Laboratory Testing ❏ Other: ❏✔ Other: In vitro permeation studies; human skin, bovine eye, sheep vaginal, and porcine buccal tissues, clinical labeling Contact: Jennifer Kubiak (any dosage form), regulatory consulting and submissions, and dermatology and vaccine clinical trials. CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES Contact: Steve Smith, VP Marketing & Business Development (707) 793-2600
DEGUSSA CORPORATION DEGUSSA AG - PHARMA POLYMERS Pharma Polymers Röhm GmbH CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES 2 Turner Place Kirschenallee 45 Piscattaway, NJ 08855 64293 Darmstadt, Germany DPT LABORATORIES,LTD. T: (732) 981-5383 Option 4 T: +49-6151-18-4019 307 East Josephine Street F: (732) 981-5371 F: +49-6151-18-3520 San Antonio, TX 78215 E: [email protected] See Company E: [email protected] Profile Phone: (210) 476-8159 - Fax: (210) 829-8733 Please check the categories in which your company provides the service. e-mail: [email protected] www.dptlabs.com ❏ Drug Discovery ❏ Analytical Development ❏✔Formulation Development ❏ Stability Testing See Company ❏ Clinical Trial MFG/Scale-up ❏ Technology/Transfer ❏ Manufacturing ❏ Packaging Please check the categories in which your company provides the service. Profile ❏ Other: ❏ Drug Discovery ❏✔Analytical Development ❏✔ Formulation Development ❏✔Stability Testing ❏✔ Clinical Trial MFG/Scale-up ❏✔Technology/Transfer ✔❏ Manufacturing ❏✔ Packaging Contact: USA: Dr. Nasser Nyamweya, (732) 981-5366; Germany: Dr. Thomas Fürst, +49-6151-18-4452 Contact: Roxanne Barr CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES DELSITE BIOTECHNOLOGIES,INC. EGALET 1505 Walnut Hill Lane Lejrvej 37- 41 Kirke Vaerlose Irving, TX 75038 DK – 3500 Vaerlose - Denmark Phone: (972) 717-5009 Fax: (972) 831-1132 Phone: +45 4447 8080 Fax: +45 4447 2425 email: info@delsite www.egalet.com www.delsite.com Please check the categories in which your company provides the service. Please check the categories in which your company provides the service. ❏ Drug Discovery ❏✔Analytical Development ❏✔ Formulation Development ❏✔ Stability Testing ❏ ❏✔ ❏✔✔❏ Drug Discovery Analytical Development Formulation Development Stability Testing ❏✔ Clinical Trial MFG/Scale-up ❏✔✔Technology/Transfer ❏ Manufacturing ❏ Packaging ❏ ❏✔ ❏ ❏ Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging ❏✔ Laboratory Testing ❏ Other: Contact: Ken Downie Contact: Jean Anne Mire, (972) 650-7320, email: [email protected] CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES ELAN DRUG TECHNOLOGIES DEPOMED,INC. Monksland 1360 O’Brien Drive Athlone, Co Westmeath, Ireland Menlo Park, CA 94025 Phone: +353 90 64 95000 Fax: +353 90 64 95807 Phone: (650) 462-5900 www.elan.com/EDT www.depomedinc.com Please check the categories in which your company provides the service. Please check the categories in which your company provides the service. ❏ Drug Discovery ❏✔Analytical Development ❏✔ Formulation Development ❏✔ Stability Testing ❏ Drug Discovery ❏ Analytical Development ❏✔Formulation Development ❏ Stability Testing ❏✔ Clinical Trial MFG/Scale-up ❏✔✔Technology/Transfer ❏ Manufacturing ❏ ✔Packaging ❏ Clinical Trial MFG/Scale-up ❏ Technology/Transfer ❏ Manufacturing ❏ Packaging ❏ Laboratory Testing ❏ Other: Contact: Sarah Carty, Associate Director, European Business Development, +353 1 7094046 ❏✔ Current Partnerships: Biovail, Inc., ActivBiotics, AVI Biopharma CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES Contact: Thadd Vargas, (650) 462-5900 E.I. DUPONT DE NEMOURS COMPANY DuPont Fluorochemicals, Chestnut Run Plaza Wilmington, DE 19880-0711 Phone: +1-302-224-0426 Fax: +1-302-224-0427 www.dupont.com/dymel
Please check the categories in which your company provides the service.
❏ Drug Discovery ❏ Analytical Development ❏ Formulation Development ❏ Stability Testing ❏ Clinical Trial MFG/Scale-up ❏✔Technology/Transfer ❏✔✔Manufacturing ❏ Packaging ❏✔ Laboratory Testing Contact: Mr. Joseph Creazzo, Technical Service Manager, email: [email protected]
100 Drug Delivery Technology November/December 2006 Vol 6 No 10 DDTNov-Dec2006Round511/10/068:25PMPage102 * Contact: requirements. Qualitysystemaccreditedtointernational degradation. formulas withoutheat/shear ❏ ❏ ❏ theservice. provides Please checkthecategoriesinwhichyourcompany Contact: ❏ ❏ ❏ theservice. provides Please checkthecategoriesinwhichyourcompany ✔ ❏ theservice. provides Please checkthecategoriesinwhichyourcompany Contact ❏ ✔ Contact ❏ ❏ ❏ ❏ theservice. provides Please checkthecategoriesinwhichyourcompany ❏ theservice. provides Please checkthecategoriesinwhichyourcompany ❏ ✔ ✔ ✔ Analytical Testing& Analysis Other: Transdermal Clinical TrialMFG/Scale-up Drug Discovery Other: Clinical TrialMFG/Scale-up Drug Discovery Drug Discovery Clinical TrialMFG/Scale-up Other: Clinical TrialMFG/Scale-up Drug Discovery Drug Discovery Clinical TrialMFG/Scale-up Walter Strathy : MichaelFlater : Paul Kay rc ail,VPMedicalMarketing Bruce Daniels, CONTRACT PHARMACEUTICAL &BIOLOGICAL DEVELOPMENTSERVICES CONTRACT PHARMACEUTICAL &BIOLOGICAL DEVELOPMENTSERVICES CONTRACT PHARMACEUTICAL &BIOLOGICAL DEVELOPMENTSERVICES CONTRACT PHARMACEUTICAL &BIOLOGICAL DEVELOPMENTSERVICES CONTRACT PHARMACEUTICAL &BIOLOGICAL DEVELOPMENTSERVICES Dosage DeviceDevelopmentandMfg. Dosage and hn:(1)2975 Fx (610)292-9722 (610)279-7450Fax: Phone: hn:(3)7471 Fx (630)887-1008 (630)734-7810Fax: Phone: hn:(7)7784 Fx (770)767-7320 (770)767-8344Fax: Phone: mucosal ❏ ❏ ❏ ❏ ❏ ❏ ❏ ❏ ❏ ❏ ❏ ✔ ✔ ✔✔ ✔✔ ✔ mi:[email protected] email: mi:[email protected] email: Technology/Transfer Analytical Development Technology/Transfer Analytical Development Analytical Development Technology/Transfer Process Development Technology/Transfer Analytical Development Analytical Development Technology/Transfer mi:[email protected] email: patches/pads/inserts, with/without adhesive. Materials addedto Materials with/withoutadhesive. patches/pads/inserts, 80PrwyPae Suite 900 1850 Parkway Place, F www.emersonresources.com www.facettechnologies.com E ERRIS urRde IL60527-5848 Ridge, Burr MERSON orson PA 19401 Norristown, F www.FerrisCares.com aita GA30067 Marietta, 600 Markley Street 16W300 83rd Street ACET P hn:(3)8896 Fx (937) 898-1093 (937) 898-9669Fax: Phone: HARMACEUTICALS hn:(0)6809 Fx (815)648-2929 (800)648-0791Fax: Phone: T R ECHNOLOGIES ESOURCES mi:[email protected] email: ❏ ❏ ❏ ❏ ❏ ❏ ❏ ❏ ❏ ❏ ✔ ✔ ✔ ✔✔ Manufacturing Formulation Development Manufacturing Formulation Development Formulation Development Manufacturing Manufacturing Formulation Development Formulation Development Manufacturing adla OH45377 Vandalia, www.eurand.com 845 Center Drive ,I ern IL60034 Hebron, www.filtertek.com 11411 Price Road E NC F URAND ILTERTEK I . NC .
e CompanySee ,I NC Profile I NC . . ❏ ❏ ❏ ❏ ❏ ❏ ❏ ❏ ❏ ❏ ✔ ✔ foam e CompanySee Packaging Stability Testing Packaging Stability Testing Stability Testing Packaging Packaging Stability Testing Stability Testing Packaging
or Profile gel Contact (AceInhibitor) Servier (1Product), Merck &Co. Current Partnerships: ❏ ❏ ❏ ❏ theservice. provides Please checkthecategoriesinwhichyourcompany ✔ ✔ Contact ❏ Contact ❏ ❏ ❏ ❏ theservice. provides Please checkthecategoriesinwhichyourcompany ❏ theservice. provides Please checkthecategoriesinwhichyourcompany ✔ ❏ ❏ theservice. provides Please checkthecategoriesinwhichyourcompany ✔ Contact ✔ ❏ ❏ ❏ theservice. provides Please checkthecategoriesinwhichyourcompany ✔ Other: Process Development Clinical TrialMFG/Scale-up Drug Discovery Other: Other: Clinical TrialMFG/Scale-up Clinical TrialMFG/Scale-up Drug Discovery Drug Discovery Analytical Testing& Analysis Clinical TrialMFG/Scale-up Drug Discovery Clinical TrialMFG/Scale-up Drug Discovery rdrc ioi,(+33)472-783-434 Frederick Simonin, : uiesDvlpet 80 9-75 [email protected] (800)391-6755, BusinessDevelopment, : hmsM au,(201)818-3778 Salus, ThomasM. : efe enr,DirectorofBusinessDevelopment JeffreyBernard, : CONTRACT PHARMACEUTICAL &BIOLOGICAL DEVELOPMENTSERVICES Drug Delivery Drug Delivery CONTRACT PHARMACEUTICAL &BIOLOGICAL DEVELOPMENTSERVICES CONTRACT PHARMACEUTICAL &BIOLOGICAL DEVELOPMENTSERVICES CONTRACT PHARMACEUTICAL &BIOLOGICAL DEVELOPMENTSERVICES CONTRACT PHARMACEUTICAL &BIOLOGICAL DEVELOPMENTSERVICES Drug delivery feasibilitystudies Drug delivery mi:smnnfae.o est:www.flamel.com [email protected] /website: email: hn:(3)427344 a:(+33)472-783-435 (+33)472-783-434Fax: Phone: ivi Gni) rso-yr qib(aui) GlaxoSmithKline(2Products), Bristol-MyersSquibb(Basulin), Biovail (Genvir), hn:(0)3165 Fx (416)364-9363 (800)391-6755Fax: Phone: hn:(3)8110 Fx (630)851-1244 (630)851-1200Fax: Phone: hn:(7)7597 a:978-725-9078 (978) 725-9077Fax: Phone: Drug DeliveryTechnology G ❏ ❏ ❏ ❏ ❏ ❏ ✔✔ ✔✔ ✔✔ ✔✔ ❏ ❏ ❏ ❏ ❏ ✔ ✔ ✔ 3 Avenue duDocteur GeorgesLévy 33, ENEREX Technology/Transfer Analytical Development Technology/Transfer Technology/Transfer Analytical Development Analytical Development Technology/Transfer Analytical Development Process Development Technology/Transfer Analytical Development 69693 Vénissieux Cedex -France est:pharmproservices.com Website: oot,O,CanadaM5J2G2 ON, Toronto, 3HrorSur,Suite 202 33 Harbour Square, -al [email protected] e-mail: Parc ClubDuMoulin á Vent F -al [email protected] E-mail: mi:[email protected] email: LAMEL Arr,Illinois60504 SAurora, 2550 White OakCircle B www.formatech.com noe,MA01810 Andover, 0 ufnhDrive 200 Bulfinch www.generex.com IOTECHNOLOGY F F ORMATECH LUID T ECHNOLOGIES A IR ❏ ❏ ❏ ❏ ❏ ❏ ,I ✔ November/December 2006 ❏ ❏ ✔ ✔ ✔ ❏ ❏ ✔ ✔ ,I G Manufacturing Formulation Development Manufacturing Manufacturing Formulation Development Formulation Development NC Manufacturing Formulation Development www.glattpharmaceuticals.com Manufacturing Formulation Development NC LATT C . . ORPORATION hn:(201)825-8700 Phone: S.A. P asy NJ07446 Ramsey, HARMACEUTICAL 20 SpearRoad
e CompanySee
Profile ❏ ❏ ❏ ❏ ❏ ❏ ❏ ❏ ✔ S ❏ ❏ Vol 6No 10 ERVICES Packaging Stability Testing Packaging Packaging Stability Testing Stability Testing Packaging Stability Testing Packaging Stability Testing
101 Drug Delivery Technology November/December 2005 Vol 5 No 10 * DDT Nov-Dec 2006 Round 5 11/10/06 8:25 PM Page 103
CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES HAUSER CONTRACT RESEARCH ORGANIZATION INEOS FLUOR 6880 N. Broadway, Suite H The Heath, Runcorn Cheshire, UK WA7 4QX Denver, CO 80221 Phone: +44 (0) 1928 51 5525 Fax: +44 (0) 1928 51 1418 Phone: (720) 406-4700 email: [email protected] www.hausercro.com www.ineosfluor.com • www.zephex.com
Please check the categories in which your company provides the service.
❏✔ Drug Discovery ❏✔Analytical Development ❏ Formulation Development ❏✔Stability Testing Please check the categories in which your company provides the service. ❏✔ ❏✔ ❏✔✔❏ Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging ❏ Drug Discovery ❏ Analytical Development ❏ Formulation Development ❏ Stability Testing ❏✔ Other: Compliance Consulting ❏ Clinical Trial MFG/Scale-up ❏ Technology/Transfer ❏ Manufacturing ❏ Packaging ❏✔ Contact: Rod McKeever, (720) 406-4700 Laboratory Testing ❏✔ Other: Specliazed medical propellant testing CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES Contact: Tim Noakes HILL TOP RESEARCH CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES P.O. Box 429501 Cincinnati, OH 45242 INTELLIPHARMACEUTICS CORP. 30 Worcester Road Phone: (800) 785-2693 Fax: (513) 831-1217 Toronto, Ontario M9W 5X2 email: [email protected] Canada www.hill-top.com Phone: (416) 798-3001, ext. 128 Fax: (416) 798-3007 e-mail: [email protected] Please check the categories in which your company provides the service. www.intellipharmaceutics.com ❏ Drug Discovery ❏ Analytical Development ❏ Formulation Development ❏ Stability Testing ❏ Clinical Trial MFG/Scale-up ❏ Technology/Transfer ❏ Manufacturing ❏ Packaging Please check the categories in which your company provides the service. ❏✔ Other: Clinical Research ❏ Drug Discovery ❏✔Analytical Development ❏✔ Formulation Development ✔❏ Stability Testing ✔✔✔✔ Contact: Bryan Reynolds ❏ Clinical Trial MFG/Scale-up ❏ Technology/Transfer ❏ Manufacturing ❏ Packaging ❏✔Laboratory Testing CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES ❏ Other: HOVIONE Contact: Joe Quinto, Director of Business Development 40 Lake Drive East Windsor, NJ 08520 CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES Phone: 609-918-2600 Fax: 609-918-2615 INTERNATIONAL SPECIALTY PRODUCTS (ISP) See Company Profile email: helloovione.com 1361 Alps Road www.hovione.com Wayne, NJ 07470 Phone: (973) 628-4000 Fax: (973) 628-4117 Please check the categories in which your company provides the service. email: [email protected] www.ispcorp.com ❏ Drug Discovery ❏ Analytical Development ❏ Formulation Development ❏✔ Stability Testing Please check the categories in which your company provides the service. ❏✔ Clinical Trial MFG/Scale-up ❏✔Technology/Transfer ❏✔Manufacturing ❏ Packaging ❏ Drug Discovery ❏ Analytical Development ❏✔ Formulation Development ❏ Stability Testing CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES ❏✔ Clinical Trial MFG/Scale-up ❏ Technology/Transfer ❏✔ Manufacturing ❏ Packaging HOSPIRA,INC. ❏ Laboratory Testing One 2 One Contact: Ann Druffner D988, H1 275 Northfield Drive Lake Forest, IL 60045 CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES Phone: (224) 212-2267 Fax: (224) 212-3210 INTRANASAL THERAPEUTICS,INC. email: [email protected] 201 Summit Ave, Ste C-2 www.hospira.com Montvale, NJ 07645 Please check the categories in which your company provides the service. Phone: (201) 307-9450 Fax: (201) 307-9455 www.intranasal.com ❏ Drug Discovery ❏✔✔Analytical Development ❏ Formulation Development ❏✔ Stability Testing ❏✔ Clinical Trial MFG/Scale-up ❏✔Technology/Transfer ❏✔Manufacturing ❏✔Packaging Please check the categories in which your company provides the service. ❏ Analytical Testing & Analysis ❏ Process Development ❏✔ Other: Parenteral Manufacturing: vials, cartridges, pre-filled syringes, IV containers, and ampoules. Impurity Identification, ❏ Drug Discovery ❏✔Analytical Development ❏✔ Formulation Development ❏✔ Stability Testing Lyopholization Cycle Development, and Sterilization Cycle Development. ❏✔✔Clinical Trial MFG/Scale-up ❏ Technology/Transfer ❏✔ Manufacturing ❏✔Packaging ❏ ❏ ❏✔ Contact: Kevin Wess Analytical Testing & Analysis Process Development Other: Provided as a service to ITI partners Contact: Ralph S. Johnston
CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES INYX,INC. 825 Third Avenue, 40th Floor New York, NY 10022 Phone: (212) 838-1111 Fax: (212) 838-0060 e-mail: [email protected] www.inyxgroup.com
Please check the categories in which your company provides the service.
❏ Drug Discovery ❏ Analytical Development ❏✔ Formulation Development ❏✔ Stability Testing ❏ Clinical Trial MFG/Scale-up ❏✔Technology/Transfer ❏✔ Manufacturing ❏✔Packaging ❏ Analytical Testing & Analysis ❏ Process Development ❏ Other:
Contact: Marc Couturier, Senior Vice President, Global Business Development (416) 250-0091
102 Drug Delivery Technology November/December 2006 Vol 6 No 10 DDTNov-Dec2006Round511/10/068:26PMPage104 *
e Company See Contact ❏ ❏ ❏ ❏ theservice. provides Please checkthecategoriesinwhichyourcompany Contact ❏ ❏ theservice. provides Please checkthecategoriesinwhichyourcompany ✔ ✔ Contact: ❏ ❏ ❏ theservice. provides Please checkthecategoriesinwhichyourcompany ✔ Contact ❏ ❏ ❏ theservice. provides Please checkthecategoriesinwhichyourcompany Contact On-site Training Services, Regulatory Qualityand Troubleshooting, Consulting, Finished Product Testing, Preparation, ClinicalMaterial Process Optimization, ❏ ❏ ❏ theservice. provides Please checkthecategoriesinwhichyourcompany ✔ ✔ Laboratory Laboratory Testing Other: TestingLaboratory Clinical TrialMFG/Scale-up Drug Discovery Clinical TrialMFG/Scale-up Drug Discovery Clinical TrialMFG/Scale-up Drug Discovery Other: Clinical TrialMFG/Scale-up Drug Discovery Other: Clinical TrialMFG/Scale-up Drug Discovery Profile ReneeMill : er Simmons Jerry : tv anes MarketingManager SteveSaunders, : ChristineAdams : CONTRACT PHARMACEUTICAL &BIOLOGICAL DEVELOPMENTSERVICES CONTRACT PHARMACEUTICAL &BIOLOGICAL DEVELOPMENTSERVICES CONTRACT PHARMACEUTICAL &BIOLOGICAL DEVELOPMENTSERVICES Doug Hostetler CONTRACT PHARMACEUTICAL &BIOLOGICAL DEVELOPMENTSERVICES CONTRACT PHARMACEUTICAL &BIOLOGICAL DEVELOPMENTSERVICES xiins idr,Dsnerns urcn,HighFunctionalityExcipient Lubricant, Disintegrants, Binders, Excipients, ypiiain hra nlssSrie,Vldto-auatrn,DvlpetSrie,ProcessEngineering, DevelopmentServices, Validation-Manufacturing, Thermal Analysis Services, Lyophilization, hn:(0)4125 Fx (845)878-3484 (800)431-2457Fax: Phone: hn:(3)7420 a:(630)734-2690 (630)734-2700Fax: Phone: hn:(1)6620 Fx (717)656-3772 (717)656-2300Fax: Phone: hn:(1)3687 Fx (215)396-8375 (215)396-8373Fax: Phone: ❏ ❏ ❏ ❏ ❏ ❏ ✔ ✔ ❏ ❏ ✔ ❏ ❏ ✔ Technology/Transfer Analytical Development Technology/Transfer Analytical Development Technology/Transfer Analytical Development Technology/Transfer Analytical Development L Technology/Transfer Analytical Development YOPHILIZATION L mi:[email protected] email: mi:[email protected] email: ANCASTER mi:[email protected] email: 2425 New Holland Pike 91Rue2,Suite 1 2981 Route 22, www.lyotechnology.com www.lancasterlabs.com mi:[email protected] email: atro,NY12563 Patterson, ilwro,IL60527 Willowbrook, www.jrspharma.com acse,PA 17601 Lancaster, vln,PA 18974 Ivyland, JRS P www.loparex.com 7700 Griffin 7700 Griffin Way 30 Indian Drive hn:(0)94833 a:(801)994-7388 (801)994-87383Fax: Phone: L L HARMA ABORATORIES OPAREX T ECHNOLOGY ❏ ❏ ❏ ❏ ❏ ❏ ✔ ❏ ❏ ✔ ❏ ❏ ✔ ✔ 7 rpe rv,Suite 202 675 Drive, Arapeen Manufacturing Formulation Development Manufacturing Formulation Development Manufacturing Formulation Development LP Manufacturing Formulation Development Manufacturing Formulation Development mi:[email protected] email: atLk iy UT84103 Salt Lake City, www.lipocine.com ,I L NC ,I IPOCINE NC . . I NC . ❏ e CompanySee ❏ ❏ ❏ ❏ ❏ ❏ ❏ ✔ ❏ ❏ ✔ Packaging Stability Testing Packaging Stability Testing Packaging Stability Testing Packaging Stability Testing Packaging Stability Testing
Profile Contact ❏ ❏ ❏ theservice. provides Please checkthecategoriesinwhichyourcompany Contact ❏ ❏ theservice. provides Please checkthecategoriesinwhichyourcompany ✔ ✔ Contact efficacy andperformancetesting ❏ ❏ ❏ theservice. provides Please checkthecategoriesinwhichyourcompany Contact ❏ ❏ ❏ theservice. provides Please checkthecategoriesinwhichyourcompany ✔ ✔ ✔ ✔ Other: Analytical Testing& Analysis Clinical TrialMFG/Scale-up Drug Discovery Clinical TrialMFG/Scale-up Drug Discovery Other: Clinical TrialMFG/Scale-up Drug Discovery Clinical TrialMFG/Scale-up Drug Discovery lxS i,EeuieVc rsdn (801)433-2560 Executive Vice President, Kim, AlexS. : : Thomas W. Leonard, PhD, VP &CSO VP PhD, Leonard, ThomasW. : aoeDlue,HeadofBusinessDevelopment CaroleDelauney, : efe ahm [email protected] JeffreyBasham, : CONTRACT PHARMACEUTICAL &BIOLOGICAL DEVELOPMENTSERVICES CONTRACT PHARMACEUTICAL &BIOLOGICAL DEVELOPMENTSERVICES CONTRACT PHARMACEUTICAL &BIOLOGICAL DEVELOPMENTSERVICES CONTRACT PHARMACEUTICAL &BIOLOGICAL DEVELOPMENTSERVICES Drug Delivery ahmtclmdln fDu bopin rdciemdlfrfruainotmzto n cenn,invitro andscreening, optimization predictivemodelforformulation modelingofDrug Mathematical Absorption, -al [email protected] -www.macromed.com e-mail: Drug DeliveryTechnology hn:(1)7914 Fx (910) 395-1843 (910)799-1847Fax: Phone: hn:(5)7230 Fx (252)758-8522 (252)752-3800Fax: Phone: :(0)4326 a:(801)433-2561 (801)433-2560Fax: T: ❏ ❏ ❏ ❏ ✔ ✔ ❏ ❏ ❏ ❏ ❏ ✔✔ ✔ ✔ ✔✔ ✔✔ Technology/Transfer Analytical Development mi:[email protected] email: Technology/Transfer Analytical Development Technology/Transfer Analytical Development Process Development Technology/Transfer Analytical Development mi:[email protected] email: M est:www.macromed.com Website: imntn NC28403-8702 Wilmington, hn:+4()1 8196 Fx +44(0)1608819268 +44(0)1608819267Fax: Phone: ERRION West UT84120 Valley City, www.merrionpharma.com revle North Carolina Greenville, 1 aieDie Suite D 219 Racine Drive, 47S 80,Suite 150 3850W, 2417 S. www.metricsinc.com 1240 Sugg Parkway M M P ACRO HARMACEUTICALS ETRICS mi:[email protected] email: M uiesCnr,Sheep Street Business Centre, November/December 2006 ED ,I www.medpharm.co.uk ❏ ❏ ❏ ❏ ❏ ❏ ❏ ❏ ✔ ✔ ,I Charlbury 0X73RR Charlbury NC Manufacturing Formulation Development Manufacturing Formulation Development Manufacturing Formulation Development Manufacturing Formulation Development NC M . Oxfordshire ED . P ,I HARM NC . L TD Vol 6No 10 ❏ ❏ ❏ ❏ ❏ ❏ ✔ ❏ ❏ Packaging Stability Testing Packaging Stability Testing Packaging Stability Testing Packaging Stability Testing 103 Drug Delivery Technology November/December 2005 Vol 5 No 10 * DDT Nov-Dec 2006 Round 5 11/10/06 8:26 PM Page 105
CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES MGLAS AG NORTHWEST KINETICS INC. Otto-Liebmann-Strasse 2 3615 Pacific Avenue Tacoma, Washington 98418 Münnerstadt, Germany 97702 Phone: (253) 593-5304 Fax: (253) 593-5181 Phone: +49(0)9733 808-0 Fax: +49(0)9733 808-160 [email protected] email: [email protected] www.nwkinetics.com www.mglas.de Please check the categories in which your company provides the service.
Please check the categories in which your company provides the service. ❏ Drug Discovery ❏ Analytical Development ❏ Formulation Development ❏ Stability Testing ❏ Clinical Trial MFG/Scale-up ❏ Technology/Transfer ❏✔ Manufacturing ❏ Packaging ❏ Drug Discovery ❏ Analytical Development ❏ Formulation Development ❏ Stability Testing ❏ Analytical Testing & Analysis ❏ Process Development ❏ Clinical Trial MFG/Scale-up ❏ Technology/Transfer ❏✔ Manufacturing ❏✔Packaging ❏✔ Other: Phase I & II Clinical Trials Contact: Mr. Wolfgang Heidl, +49(0)9733 808-125 Contact: Lisa Rehberger CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES MICRON TECHNOLOGIES INC. 435 Creamery Way OAKWOOD LABORATORIES, L.L.C. 7670 First Place, Suite A Exton, PA 19341 Oakwood Village, OH 44146 Phone: (610) 425-5100 Fax: (610) 425-5104 Phone: (440) 359-0000 Fax: (440) 359-0001 www.microntech.com email: [email protected] www.Oakwoodlabs.com Please check the categories in which your company provides the service. Please check the categories in which your company provides the service. ❏ Drug Discovery ❏✔ Analytical Development ❏ Formulation Development ❏✔ Stability Testing ❏ Drug Discovery ❏✔Analytical Development ❏✔Formulation Development ❏ Stability Testing ❏ Clinical Trial MFG/Scale-up ❏ Technology/Transfer ❏✔ Manufacturing ❏ Packaging ❏✔ Clinical Trial MFG/Scale-up ❏✔Technology/Transfer ❏✔Manufacturing ❏ Packaging ❏✔Other: Analytical Testing & Analysis ❏✔ Laboratory Testing
CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES Contact: Mark T. Smith, President MISTRAL PHARMA INC. 2101 Halpern CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES St-Laurent, Quebec H4S 1S3 - Canada OCTOPLUS Phone: (514) 920-0909 Fax: (514) 920-0404 Zernikedreef 12 www.mistralpharma.com 2333 CL Leiden Netherlands e-mail: [email protected] Phone: +31 71 5244044 Fax: +31 71 5244043 Please check the categories in which your company provides the service. email: [email protected] www.octoplus.nl ❏ Drug Discovery ❏✔ Analytical Development ❏✔ Formulation Development ❏ Stability Testing ❏ ❏ ❏✔ ❏ Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging Please check the categories in which your company provides the service. Contact: Bertrand Bolduc ❏ Drug Discovery ❏✔Analytical Development ❏✔Formulation Development ❏✔Stability Testing CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES ❏✔ Clinical Trial MFG/Scale-up ❏ Technology/Transfer ❏✔Manufacturing ❏ Packaging ✔ MYLAN TECHNOLOGIES,INC. ❏ Other: Special expertise in pharmaceutical development and cGMP clinical trial manufacturing of biopharmaceuticals 110 Lake Street and low-soluble compounds St. Albans, Vermont 05478 Contact: Dr. Henrik Luessen, Director Business Development, +31 71 5244044 Phone: (800) 532-5226 (U.S.) International: 1-802-527-7792 Fax: (802) 527-8151 CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES email: [email protected] OSG NORWICH PHARMACEUTICALS,INC. www.mylantech.com 6826 State Highway 12 Please check the categories in which your company provides the service. Norwich, NY 13815 ❏ Drug Discovery ❏ Analytical Development ❏ Formulation Development ❏ Stability Testing Phone: (607) 335-3000 Fax: (607) 335-3100 ❏ Clinical Trial MFG/Scale-up ❏ Technology/Transfer ❏✔ Manufacturing ❏ Packaging email: [email protected] ❏ Analytical Testing & Analysis ❏ Process Development www.norwichpharma.com Please check the categories in which your company provides the service. Contact: Tom Campbell ❏ Drug Discovery ❏✔Analytical Development ❏✔Formulation Development ❏✔Stability Testing CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES ❏✔ Clinical Trial MFG/Scale-up ❏✔Technology/Transfer ❏✔Manufacturing ❏✔Packaging ❏✔ Laboratory Testing NEXT BREATH LLC 1450 South Rolling Road Contact: Bob Calabro Baltimore, MD 21227 Phone: (410) 455-5904 www.nextbreath.net
Please check the categories in which your company provides the service.
❏ Drug Discovery ❏ Analytical Development ❏✔✔Formulation Development ❏ Stability Testing ❏ Clinical Trial MFG/Scale-up ❏ Technology/Transfer ❏ Manufacturing ❏ Packaging ❏✔ Other: Nasal, Pulmonary Development, & Analytical Testing
Contact: Julie Suman, PhD, (410) 455-5904
104 Drug Delivery Technology November/December 2006 Vol 6 No 10 DDTNov-Dec2006Round511/10/068:26PMPage106 * Contact NasalSpraydelivery Sterileinjectables, Lyophilization, ❏ ❏ ❏ theservice. provides Please checkthecategoriesinwhichyourcompany Contact ❏ ❏ ❏ theservice. provides Please checkthecategoriesinwhichyourcompany ✔ ✔ Contact ❏ ❏ ❏ theservice. provides Please checkthecategoriesinwhichyourcompany ✔✔✔ ✔ Contact ❏ ❏ ❏ theservice. provides Please checkthecategoriesinwhichyourcompany ❏ theservice. provides Please checkthecategoriesinwhichyourcompany Contact ❏ ❏ ✔ Other: Clinical TrialMFG/Scale-up Drug Discovery Laboratory TestingLaboratory Clinical TrialMFG/Scale-up Drug Discovery Laboratory TestingLaboratory Clinical TrialMFG/Scale-up Drug Discovery Other: Clinical TrialMFG/Scale-up Drug Discovery Drug Discovery Laboratory TestingLaboratory Clinical TrialMFG/Scale-up Pam Shirto : : Larry Toscano Larry : RobertSparks : r emsD upy 98 4-00 mi:[email protected] email: (978)742-9000, Murphy, SeamusD. Dr. : SarahMassey : CONTRACT PHARMACEUTICAL &BIOLOGICAL DEVELOPMENTSERVICES CONTRACT PHARMACEUTICAL &BIOLOGICAL DEVELOPMENTSERVICES CONTRACT PHARMACEUTICAL &BIOLOGICAL DEVELOPMENT SERVICES CONTRACT PHARMACEUTICAL &BIOLOGICAL DEVELOPMENTSERVICES CONTRACT PHARMACEUTICAL &BIOLOGICAL DEVELOPMENTSERVICES mgn,Mcoahnn,Photonics Micromachining, Imaging, ihptnymnfcuig otoldRlaepout,Cnrle usacs Over-encapsulation, Controlledsubstances, ControlledReleaseproducts, High-potency manufacturing, hn:+4()19 101 Fx +44(0)1993813473 +44(0)1993 812021Fax: Phone: hn:(0)3584 Fx (609)395-8850 (609)395-8844Fax: Phone: hn:(1)5511 a:(314)535-1514 (314)535-1516Fax: Phone: hn:(7)7290 Fx (978) 742-9100 (978) 742-9000Fax: Phone: hn:(0)8140 a:(905)812-6709 (905)821-4001Fax: Phone: P -al [email protected] e-mail: RIL AND ARTICLE ❏ ❏ ❏ ❏ ✔✔ ❏ ❏ ❏ ❏ ✔ ❏ ❏ mi:[email protected] email: issag,O,CanadaL5N7J8 ON, Mississauga, Technology/Transfer Analytical Development Technology/Transfer Analytical Development Technology/Transfer Analytical Development Technology/Transfer Analytical Development Analytical Development Technology/Transfer 00MsisuaRa,Suite 350 7070 Mississauga Road, mi:[email protected] email: mi:[email protected] email: mi:[email protected] email: xod OX20 1TU-England Oxford, 5445 Highland Park5445 Highland Drive iteo,MA01460-1528 Littleton, www.omdrugdelivery.com P www.oxfordlasers.com O Brook Hill Woodstock rnuy NJ08512 Cranbury, AULAUR t oi,MO63110 Louis, St. www.pctincusa.com O www.paulaur.com www.patheon.com WEN 105 Melrich road XFORD C 29 King Street P OATING ATHEON M C UMFORD L ORPORATION ASERS T ❏ ❏ ❏ ❏ ❏ ❏ ✔ ❏ ❏ ✔ ❏ ❏ I ✔ ✔ ECHNOLOGIES NC Manufacturing Formulation Development Manufacturing Formulation Development Manufacturing Formulation Development Manufacturing Formulation Development Formulation Development Manufacturing ,L I . NC TD . . ,I NC . ❏ ❏ ❏ ❏ ✔ ❏ ❏ ✔ ❏ ❏ ❏ ❏ Packaging Stability Testing Packaging Stability Testing Packaging Stability Testing Packaging Stability Testing Stability Testing Packaging ❏ ❏ ❏ Contact and topicaldrugadministration. ❏ ❏ ❏ theservice. provides Please checkthecategoriesinwhichyourcompany ❏ theservice. provides Please checkthecategoriesinwhichyourcompany Contact ❏ ❏ ❏ ❏ theservice. provides Please checkthecategoriesinwhichyourcompany Contact ❏ ❏ ❏ theservice. provides Please checkthecategoriesinwhichyourcompany ✔ ✔ ✔ Current Partnerships: Other: Clinical TrialMFG/Scale-up Other: Clinical TrialMFG/Scale-up Drug Discovery Drug Discovery Current Partnerships: Other: Clinical TrialMFG/Scale-up Drug Discovery Laboratory Laboratory Testing Clinical TrialMFG/Scale-up Drug Discovery RichardSica : ihe .Coly h,VPBusinessDevelopment PhD, Crowley, MichaelM. : DianeD’Alessandro : CONTRACT PHARMACEUTICAL &BIOLOGICAL DEVELOPMENTSERVICES CONTRACT PHARMACEUTICAL &BIOLOGICAL DEVELOPMENT SERVICES CONTRACT PHARMACEUTICAL &BIOLOGICAL DEVELOPMENTSERVICES CONTRACT PHARMACEUTICAL &BIOLOGICAL DEVELOPMENTSERVICES ehncladeetoi eie o utds n ntoedu ipnigapiain,fruei aa,oral foruseinnasal, Mechanical andelectronicdevicesformultidoseunitdosedrugdispensingapplications, Drug DeliveryTechnology hn:(0)7630 a:(203)794-1573 (203)796-3700Fax: Phone: hn:(0)9702 Fx (609)987-1511 (609)987-0223Fax: Phone: eeWy udntnFed,Ruddington Ruddington Way, Fields, Mere otnhm G16S ntdKingdom United NG116JS, Nottingham, -al [email protected] e-mail: ❏ ❏ ❏ ❏ ❏ ❏ ❏ ❏ ❏ ✔ ✔ ✔ ✔ Technology/Transfer Analytical Development Technology/Transfer Analytical Development Technology/Transfer Analytical Development Other: Out-licensing proprietary drug delivery technolgiesforproductformulations drugdelivery Out-licensingproprietary Other: Technology/Transfer Analytical Development 9OdRdeuyRa,Suite 11 Road, 39 OldRidgebury -al [email protected] e-mail: P 4 lxne od Suite 201 742 Alexander Road, hn:(1)8404,et 0 a:(512)834-2105 201Fax: ext. (512)834-0449, Phone: ENWEST rneo,New Jersey 08540 Princeton, P hn:+44115974 9000 Phone: www.pharmprofiles.com www.pfeiffer-group.com HARMACEUTICAL P abr,CT06810 Danbury, www.penwest.com EFE OF FEIFFER 10 untRa,Bd.4-Suite 4010 Bldg. Road, 11400 Burnet P HARMACEUTICALS November/December 2006 www.pharmaform.com A P ❏ ❏ ❏ ❏ ❏ ❏ ❏ ❏ ✔ ✔ ✔ ✔ ✔ MERICA HARMA utn TX78758 Austin, P Manufacturing Formulation Development Manufacturing Formulation Development Manufacturing Formulation Development Manufacturing Formulation Development ROFILES F ORM C O . L.L.C. Vol 6No 10 ❏ ❏ ❏ ❏ ✔ ❏ ❏ ❏ ❏ ✔ ✔ Packaging Stability Testing Packaging Stability Testing Packaging Stability Testing Packaging Stability Testing 105 Drug Delivery Technology November/December 2005 Vol 5 No 10 * DDT Nov-Dec 2006 Round 5 11/10/06 8:26 PM Page 107
CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES PHARMATEK LABORATORIES INC. PRECISION PHARMA SERVICES 5626 Oberlin Drive, Suite 100 155 Duryea Road San Diego, CA 92121 Melville, New York 11747 Phone: (858) 587-8783 Fax: (858) 587-8771 T: 631-845-6244 F: 631-752-7354 email: [email protected] www.precisionpharma.com www.pharmatek.com Please check the categories in which your company provides the service. Please check the categories in which your company provides the service.
❏ Drug Discovery ❏✔Analytical Development ❏✔Formulation Development ❏✔ Stability Testing ❏ Drug Discovery ❏✔Analytical Development ❏ Formulation Development ❏✔Stability Testing ❏ Clinical Trial MFG/Scale-up ❏ Technology/Transfer ❏✔Manufacturing ❏ Packaging ❏✔ Clinical Trial MFG/Scale-up ❏ Technology/Transfer ❏✔Manufacturing ❏✔Packaging ❏ Laboratory Testing ❏✔Analytical Testing & Analysis ❏ Process Development ❏ Other: ❏✔Other: Aseptic parenteral manufacturing Contact: Elizabeth Hickman, [email protected], (858) 587-8783 Contact: Neil L. Coles CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES PHARMPRO®(DIVISION OF FLUID AIR) REMMELE ENGINEERING,INC.- AUTOMATION DIVISION 2550 White Oak Circle 677 Transfer Road Aurora, IL 60504 St. Paul, MN 55114 Phone: (630) 851-1200 Phone: (651) 643-3700 Fax: (651) 642-5665 www.pharmpro.com email: [email protected] www.remmeleautomation.com Please check the categories in which your company provides the service. Please check the categories in which your company provides the service. ❏ Drug Discovery ❏ Analytical Development ❏✔Formulation Development ❏ Stability Testing ❏ Drug Discovery ❏ Analytical Development ❏ Formulation Development ❏ Stability Testing ❏ Clinical Trial MFG/Scale-up ❏✔✔Technology/Transfer ❏ Manufacturing ❏ Packaging ❏ Clinical Trial MFG/Scale-up ❏ Technology/Transfer ❏✔ Manufacturing ❏✔Packaging ❏ Other: ❏ Laboratory Testing Contact: Tom Tappen, (630) 851-1200 Contact: Brian Raehsler
CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES POLYMUN SCIENTIFIC GMBH Nussdorfer Laende 11 RESPIRONICS RESPIRATORY DRUG DELIVERY 41 Canfield Road Vienna, Austria A-1190 Cedar Grove, NJ 07009 Phone: +43-1-36006-6203 Fax: +43-1-3697615 Phone: (800) 962-1266 Fax: (724) 387- 5270 e-mail: [email protected] e-mail: [email protected] www.polymun.com www.respironics.com Please check the categories in which your company provides the service. Please check the categories in which your company provides the service. ❏ Drug Discovery ❏ Analytical Development ❏✔Formulation Development ❏✔ Stability Testing ❏ Drug Discovery ❏✔ Analytical Development ❏✔Aerosol Formulation Development ❏ Stability Testing ❏✔ Clinical Trial MFG/Scale-up ❏✔✔Technology/Transfer ❏ Manufacturing ❏ Packaging ❏✔ Clinical Trial MFG/Scale-up ❏✔Technology/Transfer ❏✔ Manufacturing ❏ Packaging ❏ Other: ❏✔ Laboratory Testing Contact: Dr. Dietmar Katinger Contact: Mark Elphick CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES POLYPEPTIDE LABORATORIES 365 Maple Avenue REXAM PHARMA 600 Deerfield Parkway Torrance, California 90503 Buffalo Grove, IL 60089 Phone: (800) 770-0557 or (310) 782-3569 Phone: (847) 541-9700 Fax: (847) 541-9201 Fax: (310) 782-3645 e-mail: [email protected] www.polypeptide.com www.rexam.com/pharma
Please check the categories in which your company provides the service. Please check the categories in which your company provides the service. ❏ ❏ ❏ ❏ ❏ Drug Discovery ❏ Analytical Development ❏ Formulation Development ❏ Stability Testing Drug Discovery Analytical Development Formulation Development Stability Testing ❏ ❏ ❏ ❏✔ ❏ Clinical Trial MFG/Scale-up ❏ Technology/Transfer ❏✔Manufacturing ❏ Packaging Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging ❏ ❏ Analytical Testing & Analysis ❏ Process Development ❏✔ Other: Peptide API Manufacturing Laboratory Testing
Contact: Jane Salik, (310) 782-3569 Contact: Michael Cullen CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES PRACS INSTITUTE,LTD. SAFC 4801 Amber Valley Parkway 3050 Spruce Street Fargo, North Dakota 58104 St. Louis, MO 63103 Phone: (701) 239-4750 Fax: (701) 239-4955 Phone: (800) 244-1173 (314-534-4900) Fax: (800) 368-4661 (314-652-0000) Email: [email protected] email: [email protected] Website: www.pracs.com www.safcglobal.com Please check the categories in which your company provides the service. Please check the categories in which your company provides the service. ❏ Drug Discovery ❏✔Analytical Development ❏ Formulation Development ❏✔Stability Testing ❏ Drug Discovery ❏ Analytical Development ❏✔ Formulation Development ❏ Stability Testing ❏✔Clinical Trial MFG/Scale-up ❏✔Technology/Transfer ❏✔ Manufacturing ❏✔Packaging ❏ Clinical Trial MFG/Scale-up ❏ Technology/Transfer ❏ Manufacturing ❏ Packaging ❏ Laboratory Testing ❏✔Analytical Testing & Analysis ❏ Process Development ✔ ❏ Other: Clinical Research Services Contact: Tom Gelineau, (314) 301-2077, email: [email protected] Contact: John Pottier, Director, Business Development
106 Drug Delivery Technology November/December 2006 Vol 6 No 10 * DDT Nov-Dec 2006 FINAL 12/5/06 10:18 AM Page 108
CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES
SCIARRA LABORATORIES,INC. SPRAY ANALYSIS AND RESEARCH SERVICES 485-09 S. Broadway P.O. Box 7900 Hicksville, NY 11801 Wheaton, IL 60187 Phone: (516) 933-7853 Fax: (516) 933-7807 Phone: (800) 95-Spray Fax: (630) 260-7593 email: [email protected] e-mail: [email protected] www.sciarralabs.com www.sprayconsultants.com
Please check the categories in which your company provides the service. Please check the categories in which your company provides the service.
J Drug Discovery J Analytical Development JFormulation Development J Stability Testing J Drug Discovery JLaboratory Testing J Formulation Development J Stability Testing J Clinical Trial MFG/Scale-up JTechnology/Transfer JManufacturing J Packaging J Clinical Trial MFG/Scale-up J Technology/Transfer J Manufacturing J Packaging
Contact: John J. Sciarra Contact: Elizabeth Kucharz CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES SCOLR Pharma, Inc. CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES 3625 132nd Avenue SE, Suite 400 SRI INTERNATIONAL Bellevue, WA 98006 333 Ravenswood Avenue Phone: (425) 373-0171 Fax: (425)-373-0181 Menlo Park, CA 94025 email: [email protected] Phone: (866-451-5998) Fax: (650) 859-3041 www.scolr.com any email: [email protected] Comp See e www.sri.com/biosciences Profil Please check the categories in which your company provides the service. Please check the categories in which your company provides the service. J Drug Discovery J Analytical Development JFormulation Development J Stability Testing J Clinical Trial MFG/Scale-up JTechnology/Transfer J Manufacturing J Packaging J Drug Discovery JAnalytical Development J Formulation Development J Stability Testing J Clinical Trial MFG/Scale-up JTechnology/Transfer J Manufacturing J Packaging Contact: Stephen Turner Contact: Client Services CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES SMITHS MEDICAL ASD, INC, STEPAN COMPANY 2231 Rutherford Road 100 West Hunter Avenue Carlsbad, CA 92008 Maywood, NJ 07607 Phone: (866) 286-6226 Fax: (760) 929-0147 Phone: (201) 712-7642 Fax: (201) 712-7648 www.smiths-medical.com email: [email protected] www.stepan.com Please check the categories in which your company provides the service. Please check the categories in which your company provides the service. J Drug Discovery J Analytical Development J Formulation Development J Stability Testing J Drug Discovery J Analytical Development J Formulation Development J Stability Testing J Clinical Trial MFG/Scale-up J Technology/Transfer J Manufacturing J Packaging J Clinical Trial MFG/Scale-up J Technology/Transfer JManufacturing J Packaging J Analytical Testing & Analysis J Process Development J Other: Safety Devices for Injection, Syringe Pumps & Accessories for Infusion Contact: James M. Butterwick Contact: Mark Baumgartner, Business Development Manager CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES TEXMAC INC. 3001 Stafford Drive SPI PHARMA Charlotte, NC 28208 321 Cherry Lane Phone: (704) 393-6555 Fax: (704) 392-1621 New Castle, Delaware 19720 email: [email protected] Phone: (302) 576-8500 x 8554 www.texmac.com Fax: (302) 576-8567 www.spipharma.com Please check the categories in which your company provides the service. J Drug Discovery J Analytical Development J Formulation Development J Stability Testing Please check the categories in which your company provides the service. J Clinical Trial MFG/Scale-up JTechnology/Transfer J Manufacturing J Packaging J Drug Discovery JAnalytical Development JFormulation Development J Stability Testing J Other: Machinery distribution - Transdermal patch film coating - Hirano Coating machine distribtion J Clinical Trial MFG/Scale-up JTechnology/Transfer J Manufacturing J Packaging Contact: Yashi Osaka
Contact: Sarat Chandar CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES TUNNELL CONSULTING, INC. 900 East Eighth Avenue, Suite 106 King of Prussia, PA 19406 Phone: (610) 337-0820 Fax: (610) 337-1884 e-mail: [email protected] www.tunnellconsulting.com Please check the categories in which your company provides the service.
J Drug Discovery JAnalytical Development JFormulation Development JStability Testing J Clinical Trial MFG/Scale-up JTechnology/Transfer JManufacturing J Packaging J Laboratory Testing
Contact: Stephanie A. Haase
Drug Delivery Technology November/December 2006 Vol 6 No 10 107 * DDT Nov-Dec 2006 Round 5 11/10/06 8:26 PM Page 109
CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES UNIVERSITY OF IOWA/COLLEGE OF PHARMACY/ VETTER PHARMA-FERTIGUNG GMBH&CO.KG CENTER FOR ADVANCED DRUG DEVELOPMENT Schuetzenstr. 87 100 Oakdale Campus, Room 1 PRL Ravensburg, Germany 88212 Iowa City, IA 52242-5000 Phone: +49 751 3700 0 Fax: +49 751 3700 4000 Phone: (319) 335-4096 Fax: (319) 335-4374 e-mail: [email protected] email: [email protected] www.pharmacy.uiowa.edu/service/index.htm www.vetter-pharma.com
Please check the categories in which your company provides the service. Please check the categories in which your company provides the service. ❏ ❏ ❏ ❏✔ ❏✔Laboratory Testing ❏✔Analytical Development ❏✔ Formulation Development ❏✔ Stability Testing Drug Discovery Analytical Development Formulation Development Stability Testing ❏✔ ❏✔ ❏✔ ❏✔ ❏✔Clinical Trial MFG/Scale-up ❏✔Technology/Transfer ❏✔ Manufacturing ✔❏ Packaging Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging ❏✔ Other: Contract Manufacturing, Process Development/Scale-Up, Aseptic Filling of Syringes/Vials/Cartridges, ✔ ❏ Other: Manufacturing of tablets, capsules, injectables and lyophilized drug products, clinical trial blinding or over- Lyophilization encapsulation; capable of handling potent material, licensed to handle controlled substances; method development, Contact: Suzan Frohmann validation according to ICH guidelines, development of dissolution procedures and validation of the analytical method, preformulation, development of formulations, API, excipients and drug product testing according to official monographs Contact: Alta Botha, D.Sc. CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES WEST PHARMACEUTICAL SERVICES,INC. UPM PHARMACEUTICALS,INC. 101 Grodon Drive 6200 Seaforth Street Lionville, PA 19341 Baltimore, Maryland 21224 Phone: (800) 231-3000 Fax: (610) 594-3000 Phone: (410) 843-3738 Fax: (410) 633-4438 www.westpharma.com email: [email protected] www.upm-inc.com Please check the categories in which your company provides the service. Please check the categories in which your company provides the service. ❏ Drug Discovery ❏ Analytical Development ❏ Formulation Development ❏ Stability Testing ❏ Clinical Trial MFG/Scale-up ❏ Technology/Transfer ❏ Manufacturing ❏ Packaging ❏ Drug Discovery ❏✔Analytical Development ❏✔ Formulation Development ❏✔ Stability Testing ❏ Analytical Testing & Analysis ❏ Process Development ❏✔ Clinical Trial MFG/Scale-up ❏✔Technology/Transfer ❏✔ Manufacturing ✔❏ Packaging ✔❏ Other:
Contact: Rich Ryzenga Prefillable Syringe Systems – [email protected] CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES Custom Injection Molding for drug delivery systems: [email protected] Package Testing: West Monarch Analytical Laboratories, [email protected] VALOIS 50 Avenue de l’Europe Reconstitution Systems: Medimop Projects Ltd; [email protected] Marly-le-Roi, France 78164 CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES Phone: +33 (0) 1 39 17 20 20 Fax: +33 (0) 1 39 58 12 98 www.valoispharma.com XEMPLAR PHARMACEUTICALS,LLC 200 Riggenbach Road Please check the categories in which your company provides the service. Fall River, MA 02720 Phone: (508) 676-6726 Fax: (508) 676-6546 ❏ Drug Discovery ❏✔Analytical Development ❏✔Formulation Development ❏✔ Stability Testing email: [email protected] ❏✔ Clinical Trial MFG/Scale-up ❏✔Technology/Transfer ❏ Manufacturing ❏✔ Packaging www.xemplarpharm.com ❏✔ Laboratory Testing Please check the categories in which your company provides the service. ❏ Drug Discovery ✔❏ Analytical Development ❏✔ Formulation Development ❏✔ Stability Testing Contact: Guillaume Brouet - Lab Manager ❏✔ Clinical Trial MFG/Scale-up ✔❏ Technology/Transfer ❏ Manufacturing ❏ Packaging CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES ✔❏ Analytical Testing & Analysis ❏✔ Process Development ✔❏ Other: Aerosol Delivery Systems, Double Blind Masking Devices VECTURA LIMITED One Prospect West Contact: Charles R. Eck Chippenham CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES Wiltshire, SN14 6FH United Kingdom YPSOMED AG Phone: (+)44 (0)1249 667667 Brunnmattstrasse 6 Burgdorf, Switzerland 3401 www.vectura.co.uk Please check the categories in which your company provides the service. T: +41 34 424 41 11 Fax: +41 34 424 41 22 www.ypsomed.com ❏ Drug Discovery ❏✔✔Analytical Development ❏ Formulation Development ❏ ✔Stability Testing e-mail: [email protected] ❏✔ Clinical Trial MFG/Scale-up ❏✔Technology/Transfer ❏ Manufacturing ❏ Packaging Please check the categories in which your company provides the service. ❏✔ Other: Inhalers ❏ Drug Discovery ❏ Analytical Development ❏ Formulation Development ❏ Stability Testing ❏✔ Current Partnerships: Various ❏ Clinical Trial MFG/Scale-up ❏ Technology/Transfer ❏✔Manufacturing ❏✔Packaging ❏ Analytical Testing & Analysis ❏ Process Development Contact: Doug Smalley, Director of Business Development, (+) 44 (0) 1249 667667 ❏ Other: CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES Contact: Ian Thompson, Manager Business Development Genzyme Pharmaceuticals 675 West Kendall Street - Cambridge, MA 02142 Phone: (800) 868-8208 or (617) 374-7248 Fax: (617) 768-9765 E-mail: [email protected] See Company www.genzymepharmaceuticals.com Profile Please check the categories in which your company provides the service. ❏ Drug Discovery ❏✔ Analytical Development ❏✔ Formulation Development ❏ Stability Testing ❏✔ Clinical Trial MFG/Scale-up ❏ Technology/Transfer ❏✔Manufacturing ❏ Packaging ❏ Analytical Testing & Analysis ❏ Process Development ❏ Other:
108 Drug Delivery Technology November/December 2006 Vol 6 No 10 * DDT Nov-Dec 2006 Round 5 11/10/06 8:26 PM Page 110
MACHINERY & LABORATORY EQUIPMENT AND SOFTWARE MACHINERY & LABORATORY EQUIPMENT AND SOFTWARE THE AEGIS TECHNOLOGIES GROUP EMERSON RESOURCES,INC. 13062 Highway 290 West 600 Markley Street Austin, TX 78737 Norristown, PA 19401 Phone: (800) 647-2275 Fax: (512) 615-3574 Phone: (610) 279-7450 Fax: (610) 292-9722 email: [email protected] email: [email protected] www.aegisxcellon.com www.emersonresources.com Type of Software & Brand Name: Application(s): Type & Brand Name of Instrument/System: Application: acsIXtreme acsIXtreme is a modeling, execution and analysis HPLC Formulation Development environment for continuous dynamic systems and TOC Analytical Methods Development & Testing processes. Versatile and powerful enough to address the GC most challenging simulation problems. IR UV ascIXtreme acsIXtreme is a powerful application for fast, efficient Dissolution simulation execution and analysis. It allows users to Texture analyzer conduct sophisticated model analysis without having to be DSC a model developer. Contact: Walter Strathy Contact: Mark Green MACHINERY & LABORATORY EQUIPMENT AND SOFTWARE MACHINERY & LABORATORY EQUIPMENT AND SOFTWARE ERWEKA AMERICA CORP. ARIZONA INSTRUMENT 70 Church Street, Suite 102 1912 West 4th Street Flemington, NJ 08822 Tempe, AZ 85281 Phone: (908) 788-4666 Fax: (908) 788-4667 Phone: (602) 470-1414 Fax: (480) 804-0656 email: [email protected] email: [email protected] www.erweka.com www.azic.com Type & Brand Name of Instrument/System: Application: Type & Brand Name of Instrument/System: Application: Inhaler Testers MDI and DPI models consisting of Anderson Type Moisture/Solids/Ash Analyzer - Computrac MAX, Computrac Used in R&D, quality control, and industrial process control. Cascade, Astra Draco Multi-Stage Liquid Impinger, as Vappor Pro Durable and easy to use, these anlayzers aer equally well as Single Stage Impinger’s are available, in suitable for production floor or laboratory environments. accordance with all testing procedures within the USP.
Contact: Julie Driver or Terri Thomas DT Series Dissolution Testers Complete range of apparatus in two versions, standard High Head and Low Head model designed to reduce MACHINERY & LABORATORY EQUIPMENT AND SOFTWARE evaporation loss. Complete on-line & off-line systems, in addition to integration with external HPLC units. ASSURXINC. 305 Vineyard Town Center, Suite 374 ZT Series Disintegration Testers From manually controlled units to fully automated Morgan Hill, CA 95037 systems, available with either single or multiple test baskets, either 6 cell and 3 cell test basket Phone: (408) 778-1376 Fax: (408) 776-1267 configurations. email: [email protected] www.assurx.com TBH Series & MC Series Tablet Tester Commencing with a hand-held unit designed for hardness measurement; up to fully automated units Type of Software & Brand Name: Application(s): which can be integrated with an external computer for compliance with CFR 21 Part 11. Enterprise Quality Tracking-CATSWeb AssurX offers CATSWeb, a browser-based corrective-action tracking system that complies to FDA 21 CFR Part 11 Friability Testers Three different models, available with either a single or regulations. The software helps manufacturers track and dual drum configuration. The TA operates with a fixed manage issues, customer complaints, supplier returns, and speed of 25 RPM, whereas the TAR and TDR is variable other corrective actions. Customization and extensibility from 20-4000 RPM. features have been designed into the core of the program, which is accessible from remote systems running a CWS Check Weigher Modular check weighing system permits up to 50 variety of operating systems. different test samples. Unit automatically individualizes the samples and transport them to a balance, then Contact: Tamar June displays & transports samples to a container.
MACHINERY & LABORATORY EQUIPMENT AND SOFTWARE Powder and Granulate Tester Three different models designed to offer measurement CAPSUGEL of flow time according to specified amount (weight or 535 North Emerald Road volume) or amount (weight). Greenwood, SC 29646 Suppository Testers Four different units designed to measure sample Phone: (888) 783-6361 Fax: (888) 783-6360 hardness and disintegration. Single and multiple test email: [email protected] cells are available. www.capsugel.com All Purpose Drive The AR 402 is the drive system which permits the use Type & Brand Name of Instrument/System: Application: of twenty-one different attachments. Some modules include wet or dry granulator, planetary stirrer, sieve Xcelodose® Precision micro-filling system eliminates the need for analysis, pelletizer, homogenizer & tablet press. formulation or excipients for first-in-man trials. Precise from 100 micrograms to 100 milligrams with an RSD of Fluid Bed Tester Lab unit designed to accommodate all aspects of less than 2% fluidizing (i.e. powder, crystals, granules, extrudates, pellets, etc.) Two sizes are 50-300 grams, as well as CFS 1000 Liquid filling and sealing system for up to 1200 capsules 250-1000 grams. See Company per hour for R&D Profile VDT Blister Tester Vacuum blister density checker permitting samples in Profill 300 Bench-top capsule filling system for up to 7,000 capsules an external pressurized container (-1200 to -800 mbar) per hour which is then filled with liquid; then tested within a range of up to 99 minutes and 50 seconds. Ultra 8 II Semi-automatic production scale capsule filling machine Contact: JR Alicea Contact: Glenda Oliver-Smith
Drug Delivery Technology November/December 2006 Vol 56 No 10 109 DDTNov-Dec2006FINAL11/13/069:48AMPage111 * 110 distribution oftheir message. advertisers withglobal edition alsoprovides Web site.Theelectronic with activelinkstotheir Drug DeliveryTechnology electronic edition of also appearinthe in ourprintedition will All advertisersappearing EDITION ELECTRONIC NEW- SprayVIEW ye&BadNm fIsrmn/ytm Application: SprayVIEW Type &BrandNameofInstrument/System: DLSparticle sizeanalyzermeasuring1nm-6micronsover measuringdispersionsor Fullrangeparticle sizeanalyzer, Contact: Particle Size Analyzer -LB550 Application: Particle Size Analyzer -LA930 Type &BrandNameofInstrument/System: BioPharmasmalltomediumscaleliquidfillings R&Dpilotandproduction Liquidfillingforlabs, Application: tofullyautomatic semi-automatic Liquid fillingmachinery: Peristaltic LiquidFilling Dispenser Type &BrandNameofInstrument/System: Contact: Drug DeliveryTechnology Duncan Griffiths Dino Farina ® ® Actuation System Automated actuation systemforpharmaceuticaldrugnasal actuation Automated System Actuation Measurement System Automated measurementsystemforpharmaceuticaldrug Automated Measurement System MACHINERY &LABORATORY EQUIPMENTANDSOFTWARE MACHINERY &LABORATORY EQUIPMENTANDSOFTWARE AHNR AOAOYEQUIPMENTANDSOFTWARE LABORATORY & MACHINERY hn:(4)2041 Fx (949)250-0924 (949)250-4811Fax: Phone: hn:(0)6733 Fx (802)657-3202 (802)657-3232Fax: Phone: hn:(7)4318 Fx (978) 443-8942 (978) 443-1989Fax: Phone: mi:[email protected] email: November/December 2006 mi:[email protected] email: H www.flexiconamerica.com 17671 Armstrong Avenue17671 Armstrong F ORIBA www.imagetherm.com ulntn VT05401 Burlington, LEXICON ubr,MA01776 Sudbury, 156 College Street rie CA92614 Irvine, www.horiba.com 142 North Road I MAGE I NSTRUMENTS A T MERICA HERM testing of spray pattern andplumegeometry.testing ofspraypattern metereddoseinhalersandoralsprayforthe nasal sprays, distribution shape and modes without operator input. andmodeswithoutoperator distribution shape measurementof Accurate widerangeofconcentrations. a withafullrangeofaccessories. accuracy andresolution, withcomplete from0.02-2000microns, powders dry manufacturing. automated deviceactuation. automated metereddoseinhalersandoralsprayfor sprays, I ,I NC NC . Vol 6No 10 . Contact slurriesandaerosols ZetasizerNano Zeta Potential andsub-micronparticle liquids, size, For particle sizeinsolids, Application: Pipeline Technologies/Platforms Also on-lineparticle sizingwithInsitec Spraytec, Mastersizer2000, Laser DiffractionSystems, Type &BrandNameofInstrument/System: EZ Spray ™ Low-cost alternative to optical spray pattern toopticalspraypattern alternative Low-cost Application(s): Contact EZ Spray™ Type ofSoftware&BrandName: Application: Type &BrandNameofInstrument/System: Laboratory Marumerizer QJ-230T Easily evaluates oftheeffectiveness Easilyevaluates developerstoevaluate formulation/product Allows Contact MarumerizerQJ-230T Laboratory Application: MG-55 Multi Granulator Type &BrandNameofInstrument/System: Automated Extraction Station ExtractionStation Automated MDI DW-Dose Weight Station MDI FD-10-Fire-Down Station Station Collection - Actuation, MDI AS MDI AC2 - CanisterCutter Automated NSPDWC-Dose Weight withCollectionStation - NSPDW-Dose Weight Station - OSA-OpticalSpray Analyzer - PAWS -Pump & Actuation Weight Station - Velocity-Controlled Station, NSPVA Actuation - Force-Controlled Station, MightyRuntActuation - as rsr (508)480-0200 MansaFraser, : LorenWagner : SamHabash : MACHINERY &LABORATORY EQUIPMENTANDSOFTWARE MACHINERY &LABORATORY EQUIPMENTANDSOFTWARE AHNR AOAOYEQUIPMENTANDSOFTWARE LABORATORY & MACHINERY hn:(0)4000 Fx (508)460-9692 (508)480-0200Fax: Phone: hn:(5)7201 Fx (856)722-0042 (856)722-0410Fax: Phone: hn:(0)3484 Fx (704) 392-8507 (704)394-8341Fax: Phone: mi:[email protected] email: www.malverninstruments.com mi:[email protected] email: otbruh MA01772 Southborough, hrot,NC28297-8804 Charlotte, www.innovasystems.com mi:[email protected] email: 4 eoaRa,Unit 8 840 Lenola Road, orson NJ08057 Moorestown, M I NNOVA 10 Southville Road ALVERN LCI C www.lcicorp.com PO Box 16348 S ORPORATION YSTEMS I NSTRUMENTS ,I emulsions For comprehensiveanalysisofsuspensions and Application(s): Pattern Test parameters. andcomputesFDA-recommendedSpray plates on EZSpray™scanspatterns TLC technology. desktopscannerbased analysis viaeasy-to-use, spheres inavarietyofapplications. uniform cylindrical extrudedgranulesintosmooth, onextrudedproducts;convertsmoist spheronization one bestsuitstheirproduct. andaxialextrusion—anddetermine which radial, techniques—dome, pressuregranulation three low preparation foranalysis. preparation andmixesin caps dilutes, sample totargetweight, dispenses Weighs, CreamsandPastes. Ointments, of toSupportSamplePreparation Automation DoseWeights • Particle Sizing • LeakRate • Tail-Off Profile • Priming/Repriming • Wasting • CuttingCans- Total CanContent • toSupport Automation Testing ofInhalerstoinclude: • Wasting to include: DosingDevicesandOphthalmicSolutions Products, Supporting Automation Testing ofNasalSpray NC . PlumeGeometry • SprayPattern • Uniformity DoseWeights/Content • DropletSize •
Drug Delivery Technology November/December 2005 Vol 5 No 10 * DDT Nov-Dec 2006 Round 5 11/10/06 8:26 PM Page 112
MACHINERY & LABORATORY EQUIPMENT AND SOFTWARE MACHINERY & LABORATORY EQUIPMENT AND SOFTWARE
MISTRAL PHARMA INC. OSG NORWICH PHARMACEUTICALS,INC. 2101 Halpern 6826 State Highway 12 St-Laurent, Quebec H4S 1S3 - Canada Norwich, NY 13815 Phone: (514) 920-0909 Fax: (514) 920-0404 Phone: (607) 335-3000 Fax: (607) 335-3100 www.mistralpharma.com email: [email protected] e-mail: [email protected] www.norwichpharma.com Type & Brand Name of Instrument/System: Application: Type of Software & Brand Name: Application: Dissolution Tester – VARIAN/SOTAX Test drug release from solid dosage forms at different predetermined time intervals. Different SAP Full version of SAP to run the business methods can be used: paddle or baskets depending Type & Brand Name of Instrument/System: Application(s): of tablet design. Dissolution bath is coupled to a pump (for sample withdrawal) and then to a Complete analytical, micro, and stability labs including but not Provide outsourcing services to our clients to support UV/visible spectrophotometer. limited to HPLC, GC, UV/Vis Spec, FTIR Spec, Dissolution (manual the manufacturer and packaging of products for them and automated), Auto-titration, Complete wet chemistry, Bacteria/ Disintegration Tester – Globe Pharma Tablets are subjected to up and down movement at Yeast/Fungal ID, Method development and transfer, Product a constant frequency rate (29-32 cycles/min) and screening using Steri-Screen, Sterile products testing, Autoturb, time for complete disintegration is recorded. Biolog, Bioluminescence. Full ICH Chambers available: 30˚C/65%RH, 25˚C/60%RH, Hardnes Tester (Pharma Test) Test tablet hardness. Pressure parallel to tab 30˚C/60%RH, 40˚C/75%RH diameter is applied until tab breaks. 30˚C/70%RH, (Zone IV), 30˚C/ambient
Friabilator (Globe Pharma) Test tab friability. Tablets are subjected to an upward Contact: Bob Calabro circular motion & downward drops (25/min). Differences of weight (before and after) should not exceed 1%. MACHINERY & LABORATORY EQUIPMENT AND SOFTWARE XFORD ASERS NC Infrared Balance (Mettler Toledo) Test humidity of powders & granules. O L I . 2 Shaker Road, Unit D201 Tap Density Tester (Globe Pharma) For powders & granules. To test tapped density. Shirley, MA 01464 Known mass is placed in a cylinder and volume is Phone: (978) 425 0755 or (800) 222-3632 Fax: (978) 425-4487 measured. Then cylinder is subjected to predetermined taps (vertical) process is continued www.oxfordlasers.com till volume no longer changes. e-mail: [email protected]
Sonic Sifter (ATM Corporation) To measure particle size distribution. Powders/granules are placed on top of a series of Type & Brand Name of Instrument/System: Application: screens. The set is subjected to vibration & shocks EnVision Pharma Software Software to determine spray pattern data (shape, size and orientation) and plume geometry (angle, width, orientation, and length) in accordance with FDA guidelines for MDI and nasal devices. Contact: Alain Desjardins VisiSizer Software Image-based particle size analysis software MACHINERY & LABORATORY EQUIPMENT AND SOFTWARE Vector analysis software Used to determine velocity vectors over defined NATOLI ENGINEERING region. When used in combination with EnVision system, will report velocity changes over event 28 Research Park Circle duration. St. Charles, Missouri 63304 Phone: (636) 926-8900 Fax: (636) 926-8910 EnVision Pharma QC system Imaging system provides plume geometry and spray email: [email protected] pattern information in accordance with FDA www.natoli.com guidelines, system configured for nasal and MDI devices, 21CFR Pt 11, automated analysis Type & Brand Name of Instrument/System: Application: EnVision Pharma R&D system Advanced imaging system for R&D environment for Manufacturing and Tablet Compression, Tablet Presses, and Production & Quality Control device development provides standard plume Replacement Parts geometry and spray pattern information, also, Type of Software & Brand Name: Application(s): particle size, velocity vector analysis and high-speed imaging. Tablet CAD Tablet design Micro-Machining Systems Advance machining system, for small hole and Tool Management II (TMII) New Version 4.1 Inspections & tool record keeping features, in a wide range of materials, product and R&D systems available.
Contact: Dale Natoli Micro-Machining Job shop Advanced machining labs for product development and batch processing. Machine features to +/- 1 micron and hole size down to 1 micron. Range of pinholes available for calibrated leak testing.
Contact: Dr Séamus D. Murphy, [email protected], (978) 425 0755
Drug Delivery Technology November/December 2006 Vol 6 No 10 111 DDTNov-Dec2006Round511/10/068:26PMPage113 * 112 ye&BadNm fIsrmn/ytm Application: Type &BrandNameofInstrument/System: On to5grams. samplesdown Successfulincoating Special tograms. samplesfrom25mg. Candry Contact Mini-Fluid-Bed Application: SprayDryer Micro-Capacity Type &BrandNameofInstrument/System: Contact ye&BadNm fIsrmn/ytm Application: Hot RoadChemistry Type &BrandNameofInstrument/System: Contact I-neb Insight I-neb Target Mode(TIM) Inhalation (AAD) Delivery Aerosol Adaptive Drug DeliveryTechnology oetSak,eal [email protected] email: RobertSparks, : MarkElphick : lzbt ika,[email protected],(858)587-8783 [email protected], ElizabethHickman, : MACHINERY &LABORATORY EQUIPMENTANDSOFTWARE MACHINERY &LABORATORY EQUIPMENTANDSOFTWARE ® MACHINERY &LABORATORY EQUIPMENTANDSOFTWARE HC omlto cenn i Designedtosolublizeeventhemostdifficultdrug (HRC) Formulation ScreeningKit hn:(0)9216 a:(724)387-5270 (800)962-1266Fax: Phone: hn:(1)5511 a:(314)535-1514 (314)535-1516Fax: Phone: hn:(5)5788 Fx (858)587-8771 (858)587-8783Fax: Phone: P R RIL AND ARTICLE -al [email protected] e-mail: ESPIRONICS mi:[email protected] email: P November/December 2006 66OelnDie Suite 100 Drive, 5626 Oberlin mi:[email protected] email: HARMATEK 5445 Highland Park5445 Highland Drive ea rv,NJ07009 Cedar Grove, a ig,CA92121 San Diego, www.respironics.com t oi,MO63110 Louis, St. www.pharmatek.com www.pctincusa.com 41 CanfieldRoad R C ESPIRATORY OATING home, rather thansolelyrelyingonin-personcare. rather home, careat patient continuous vitalsignmonitoringandfacilitate equipment toprovide andtelecommunication technology whichincreasinglyusescomputer of atelemedicinenetwork, Theanalysismightalsobeanimportantpart failures. treatment couldlead to problemsthat whomighthave identify patients analysis canthenbeusedbyhealthcareprofessionalsto This for theanalysisofadherenceandcomplianceinformation. usefultool andInsightcanprovideavery of thePLSfunction, thecombination analysis indicates Thedata with cystic fibrosis. TheI-nebInsightfunctionalityhasbeentestedinpatients (PLS). logging system storedinthepatient thedata used todownload Insightis For monitoring, data cycle. to optimizetheirinhalation monitoringandatoolfortrainingpatients provide atoolfordata I-neb Insight™wasdevelopedforthe AAD systemto the depositionofdruginlungs. canbealteredtoincrease arevariablesthat pattern breathing particle sizeand andofthesethreevariables, pattern, breathing andthepatient’s particle size, dependent onairwaygeometry, aerosoldepositioninthelungsismainly the assumptionthat The TIM modeisbasedon feedback. viaavibration inspiration istrainedtolengthen thepatient Witheachbreath, inspiration. anddeep isguidedtoaslow thepatient In TIM mode, technique andcompliancetotherapy. feedbacktoensureoptimalpatient provide valuablepatient theI-neb AAD systemcanalso patterns, monitoring breathing By minimizingwasteofdrugtotheenvironment. medication, reducesexhaledorescaped deep intothelungsandgreatly thebestopportunitytoreach This timinggivesthemedication in. breathes onlywhenapatient AAD deliversthemedication I-neb patient’s throughoutthetreatment. pattern breathing a Itmonitors patterns. regardlessofsizeorbreathing the patient to AAD wasdesignedtodelivertherightamountofmedication L ABORATORIES T ECHNOLOGIES D market early2006. etc.)Onmarketearly2006. hormones, handling forhighlyunstablemolecules(peptides, compounds for formulations. orallyavailable FDA-approved, eight non-toxic, RUG I D Vol 6No 10 NC ELIVERY . in vivo ,I NC . nmltsig Thekitcontains animal testing. a est etr OA D2Compactmicrocontroller-based densitytesterfor tap Thefriabilitytestersbuiltwithuniquefrontloading Performs avarietyoftestconditionsincluding SOTAXTap TD 2 Density Tester: Fasted tablet testingsystemwith Automated SOTAX F1/2 Friability Tester: testing offouressentialphysical Semi-automated SOTAX FT300 Flowability Tester: Testing offouressentialphysicalparameters: HT100 SOTAX: Hardness Tester: endpoint–themost Detectionofdisintegration SOTAX HT10 Hardness Tester: SOTAX HT1 Hardness Tester: SOTAX DT2 Disintegration Tester: serialreleasetestingforUSP1/2 Fullyautomated 7 CE SOTAX Dissolution Tester: SOTAX ATDissolution Tester: 70BS60 SOTAX AT70 Dissolution Tester: Application: SOTAX AT7 Dissolution Tester: Type &BrandNameofInstrument/System: hscltsigsfwr:QDcQ-Docphysicaltesting softwareisavalidated menu-drivendissolutionsoftware Thisadvanced, Contact Application(s) Q-Doc Physical testingsoftware: WinSOTAX Dissolution software: Type ofSoftware&BrandName: ae tat inMr,MajeskiRay Finn Marc, Stuart, Bates : MACHINERY &LABORATORY EQUIPMENTANDSOFTWARE hn:(1)4210 Fx (215)442-1514 (215)442-1500Fax: Phone: smart smart smart 1 aeenDie Suite A 411 Caredean Drive, mi:[email protected] email: osa,PA 19044 Horsham, www.sotax.com SOTAX substances. flakesandotherbulk peelets, granulates, powders, Testing of density. simple measuringofthetapped dischargesystem. and automatic andgranulates. characteristics ofpowders reproducible resultsontheflowability Producespreciseand settings. mixing andvibration afterbatch. andsizesoftabletsbatch shapes trouble-freeresultsforall consistent, ensures, revolutionary Auto devices Alignment/Auto Separator device. Auto Alignment Withtherevolutionary (upto20tablets). batch a hardness/thickness/diameter/weight of parameters: all commontabletformsfortesting. Revolutionary Auto aligns Alignment devicerapidly hardness/thickness/diameter/weight ofatablet. either manuallyorautomated. time, efficient wayoftestingthedisintegration on-/offline. offline, Available online, media/pH changesforsimplein-vivosimulation. formswitheasy Suitableforalldosage (USP 4). methodtests systemforflow-through Automated Easytovalidate. system. sample throughputcombinedwithefficientcleaning Maximumflexibilityand tests withbasketstation. Easytovalidate. efficient cleaning system. Highsamplethroughputcombinedwith tests. 2 serialreleasetestingforupto15USP Fully automated alone unit or upgraded to automatic system. alone unitorupgradedtoautomatic Stand- dailyroutinevalidation. eliminating concept, Designedwiththe Autocompliance laboratory. dissolution Ideal forUSP1/2/5/6Methodsandevery available withLIMScapabilities. available Q-Docisalso complies with21CFRPart 11. (98/NT/2000/XP)softwarewhichfully Windows 21 CFRPart 11. ISO9001)andcompletelycomplieswith GALP, (GAMP, regulations was developedunderthelatest
Drug Delivery Technology November/December 2005 Vol 5 No 10 * DDT Nov-Dec2006FINAL12/5/0610:22AMPage114 Contact MetaboL T Application: ACQUITY UltraP Type &BrandNameofInstrument/System: eLab Notebook™Software SunFire™ columns State-of-the-art reversed-phaseC18bondedsilica, State-of-the-art SunFire™ columns The Waters Micromass The Waters The Waters Contact Application: Type &BrandNameofInstrument/System: ype ofSoftware&BrandName: Computational FluidDynamicssoftware Computational Particle Image Analyzer L Particle Doppler Phase Analyzers andoptimizingsprayconditions. headers, prototypespraynozzlesand designingandfabricating sprays, ofcharacterizing capable artspraylaboratories State-of-the Drug Delivery Technology November/December 2005 Vol 5 No 10 aser DiffractionParticle Analyzer ra .Mrh,(508)482-2614 Murphy, BrianJ. : ElizabethKucharz : ynx™ software ® rti xrsinSse Industry’s firstmultiplexedsystemtoquantitatively Protein ExpressionSystem romneLqi hoaorpy First-of-its-kind LCsystemdesignedtotakefull erformance LiquidChromatography™ MACHINER MACHINERY &LABORATORY EQUIPMENTANDSOFTWARE ® Q-Tof Premier Mass Spectrometer Hybrid quadrupole, orthogonal acceleration time-of- orthogonalacceleration Hybridquadrupole, Q-Tof PremierMassSpectrometer hn:(0)4820 Fx (508)872-1990 (508)478-2000Fax: Phone: mi:[email protected] email: Y & LABORA W ifr,MA01757 Milford, ATERS www 34 Maple Street hn:(0)9-pa Fx (630)260-7593 (800)95-Spray Fax: Phone: TOR .wat C S Y ORPORATION PRAY -al [email protected] e-mail: ers.com EQUIPMENT ANDSOFTW www.sprayconsultants.com A Application(s): analyses. proteomicsandstructural metabolism studies, fra exact massmeasurementofprecursorand F flight massspectrometertha systems, times upto9Xshorterthantoday’s fastestHPLC run Provideschromatographic micron particles. subtwo- ofthepotentialproprietary, advantage identifica protein performing enhancedqualitative assess changesinproteinexpressionwhile Allo drug metabolites. theprocessofidentifying setsandaccelerating data which providesthebestpeaksha notebooks. laboratory researchers entermanuallyintopaper and textualinforma mathematical, —graphical, scientific information and 3Xbetterroutinesensitivity stability andefficiency. using actualcustomerprocessconditions Used tosimula sprays emitted frombothopaqueandtransparentliquid ofdrops Used tomeasurethesizeandshape sprays powder U s Used tomeasuredropsizeandvelocityofliquid AYI AND NALYSIS ea prays sed tomeasuredropsizedistributionofliquidor gment ionstoyieldthehighestconfidencefor tures advancedtoolsforminingcomplexLC/MS ws companiestodigitallyca hao,IL60187 Wheaton, ..Box 7900 P.O. tion -allwithinthesameLC/MSrun. up to2Xbetterpeakca te andpredictsprayperformance R tion ofalltypes—tha ESEARCH ARE t enables automa . pture andstore pacity orresolution, S pe, ERVICES lo w-pH ,today, t, ted Model 603 Model 628 Model 624 Model 640 ASEP-TECH T DynaPro Contact: instrumentsfor Multi-anglelightscattering DynaPro Application: DAWN detectors lightscattering Type &BrandNameofInstrument/System: xrcal ecalsTsig Tests ofdrugproducts thecompatibility andevaluates Extractable Leachables Testing T Contact p rn aeo ntuetSse:Application: ype &BrandNameofInstrument/System: p rn aeo ntuetSse:Application: ype &BrandNameofInstrument/System: enfrRtr [email protected] JenniferRiter, : Titan Plate Reader Automates the dynamic light scattering touse lightscattering thedynamic Automates Titan Reader Plate T Geofrey Wyatt itan LightSca ® MACHINERY &LABORATORY EQUIPMENTANDSOFTWARE MACHINERY &LABORATORY EQUIPMENTANDSOFTWARE MACHINERY &LABORATORY EQUIPMENTANDSOFTWARE Drug DeliveryT ttering instrument hn:(0)2130 Fx (610)594-3000 (800)231-3000Fax: Phone: Pho W ne: EST (805) 681-9009F
S P echn Santa Bar e e HARMACEUTICAL www.westpharma.com e C 6300 H P mail:
inil,PA 19341 Lionville, o W r 101 Gordon Drive o m
ology f i p www.wyatt.com l Y e a hn:(4)6740 Fx (847)697-4915 (847)697-4900 Fax: Phone:
A n y T mi:[email protected] email: inf T ol bar T No [email protected] list ECHNOL a, v e ember/December 2006 www.weilerengineering.com r CA 9 W ax: A S EILER v phli,Nutraceutical Opthalmic, Respiratory Therapy, parenteral(Injectable), Oral, with theirpacka industries. andmedicaldevice biotechnology pharmaceutical, preparation andaanalysistimebyafactorof10. preparation Reducessample standard 96and384-wellplates. nanoparticles insolution determining solutionpropertiesofproteinsand instrumentsfor Dynamic lightscattering polymers andbiopolymersinsolution determining absolutemolarmassesandsizesof 1395 Gateway Drive ERVICES e O nue (805) 681-0123 li,IL60123 Elgin, 3117 GY o m E NGINEERING ,I NC ging ordeliver . ,I V ol 6N NC y system forthe . o 10 113 DDTNov-Dec2006Round511/10/068:33PMPage115 *
114 DrugDrug Delivery Delivery Technology Technology November/DecemberNovember/December 2005 2006 VolVol 5 6 No No 10 10 and DelPouch inhaled technologies;andtopicalMicrosponge and EnSolv visit (866)[email protected]; Cardinal Healthat gelatin capsules; Zydis capsules; gelatin Technologies include soft systems. fordrugdelivery applications and patent CardinalHealthholdsmorethan1,500patents topicals. frominhaledformsto oralformstosterileproducts, proprietary -fromtraditionaland manufacturing optionsintheindustry www.dptlabs.com. (866) CALL-DPTorvisit contactDPTat more information, For forbothconventionaland specializedpackaging. necessary encompassengineeringand procurementresources services Packaging andcompletesupplychainmanagement. Class II-IV, controlledsubstanceregistration scale commercialproduction, full- clinical trialmaterials, includecapabilities fourcGMPfacilities, Specialized production throughprocessdevelopment. validation, analyticaldevelopment and biopharmaceutical development, www.cardinal.com/pts. A DVANCED D ® for oralmodified-releaseproducts;lyophilization; RUG ® o ntdsn.Frmr nomto,contact For moreinformation, for unitdosing. D ® EVELOPMENT fast-dissolve dosage form;EnCirc fast-dissolve dosage D ELIVERY preformulation, formulation and formulation preformulation, rangefrom services Drugdevelopment forms. semi-solid andliquiddosage and pharmaceuticalproductsin solutions forbiopharmaceutical andpackaging manufacturing, development, integrated DPTprovidesfully capabilities, with unlimitedproduction Combining decadesofexpertise andbeyond. commercialization and liquids—fromconceptto DPT isthesourceforsemi-solids development and range ofdose-form offersthebroadest company The industries. biotechnology pharmaceutical and theworldwide serving services, product commercialization and packaging, manufacturing, contract technologies, drugdelivery services, pharmaceutical development leader inprovidingoutsourced Cardinal Healthistheglobal T ECHNOLOGIES S ® ERVICES for timed-release ® EnVel , ® , 898-9669 or at 898-9669 orat (937) contactEurandat For moreinformation, push-through blisters. AdvaTab ineitherbottlesor tabletscanbepackaged release properties. AdvaTab formtoprovideafast-dissolvetabletwithsustained- dosage intothe Modified-release druggranulescanalsobeincorporated masked druggranulesissuitablefordeliveringhighdoses. andthesmoothmixture ofcarrierexcipientsandtaste- 30 seconds, AdvaTab inthemouthwithin15to tabletsdissolverapidly mouth-feel. experience inEUDRAGIT Basedonmorethan50yearsof andProtectiveCoatings. Release, EUDRAMODE www.pharma-polymers.com (877)764-6872 (Option 4)orvisit America LLCat Rohm contactDegussaCorporation, For moreinformation, strategies. the developmentofcustomer-specific solutionstoout-licensing technologiesrangefrom ofthesedrugdelivery commercialization PharmaPolymers’ businessmodelsfor development effortsofar. EUDRAGIT forthepharmaceuticalindustry.and supplyingoffunctionalcoatings Pharma Polymers isoneoftheworldleadersinmanufacturing The differentbrandsofEUDRAPULSE technologies. intellectual propertyonadvancedoraldrugdelivery PharmaPolymers hasdeveloped for pharmaceuticalapplications, P OLYMERS O RALLY ® oyesaeielfrEtrcDlvr,Controlled polymers areidealforEntericDelivery, TM [email protected]. are theachievementsofthisintensiveresearchand &D D ISINTEGRATING ® ELIVERY polymer design and formulation know-how polymer designandformulation TM EUDRACOL , T ODT withsuperiortasteand toprovidean technology Microcaps leading with Eurand’s AdvaTab canbecombined and arobusttablet. modifiedrelease, dosing, flexible unparalleled taste, – unique applications and distinct advantages offers that technology ofODT generation AdvaTab ECHNOLOGIES T ABLETS ® TM is anew ® and , taste-masking DDTNov-Dec2006Round511/10/068:34PMPage116 *
Drug Delivery Technology November/December 2005 Vol 5 No 10 visit (800)643-8086or Systemsat contact3MDrugDelivery information, For more and manufacturingtogetitspartnersmarkersooner. regulatory, providingexpertiseinproductdevelopment, corporation, multinational withtheresourcesofamajor, company delivery ofaleadingdrug combinestheagility Thecompany continents. Systems arecurrentlysoldinmorethan60countrieson6 Productsmanufacturedby3MDrugDelivery transdermal system. andthefirststand-alone7-day HFA MDI, of thefirstMDI, proventrackrecordincludes development 3M’s commercial success. andincreasedprobabilityoftechnical speedtomarket, products, provide pharmaceuticalandbiotechcompanieswithdifferentiated andexperiencecan expertise, 3M’s technology, system components. andabroadrangeofcustomizable commercial manufacturing, expertise, globalregulatory product developmentservices, 4-10et 281orvisit 440-0100 ext. (781) at contact BaxterHealthcareCorporation more information, For challenges?LetBaxterhelpyouovercome them. formulation Pulmonary thedrug’spreserve proteinstructureandactivity. to Thishasbeenshown iswater-basedthat wheneverpossible. gentleprocess robust, manufacturing processconsistsofasimple, ThePROMAXX equipment withtheirmanufacturingprocess. transfer offersclientsprocessing formulation theoptionto integrate Baxter’s experiencewithtechnology stability ofthestartingmaterial. toavarietyofdrugclassesapplied andhasthepotentialtoimprove canbe platform Thisversatile toandthroughthelung. delivery I www.3m.com/dds. NHALATION P ULMONARY &T www.baxterbiopharmasolutions.com. RANSDERMAL F ORMULATION proven technology, and offers innovative 3M commercialization, to discovery From drug delivery. and transdermaldrug forinhalation innovator globalleaderand a is Systems DrugDelivery 3M distribution idealfor particle size narrow offers technology microsphere The protein success. formulation designed toenhance is technology, delivery drug proprietary Corporation’s Healthcare Baxter PROMAXX, D ELIVERY Medical - Pharmaceutical Systems at (201)847-4017orvisit Medical -PharmaceuticalSystems at contactBD For moreinformation, needs. and parenteraldrugdelivery it toproposesuitablesolutionsforallregionalmarkets allow know-how andpharmaceuticalpackaging marketawareness, worldwide presence, BD’s needsforcomfort. safety andconveniencetofulfillpatients' devices aredesignedtomeethealthcareprofessionals'demandsfor Allofitsprefillable ofdrugtherapy. contribute totheoptimization pharmaceuticalproductsand whichdifferentiate methods, delivery toconventionaldrug delivercost-effectivealternatives We partner. inapackaging experience requiredbythepharmaceuticalindustry Medical -PharmaceuticalSystemsprovidestheexpertiseand BD aninjectionorself-injectiondevice, drug reconstitutionsystem, dry www.bdpharma.com. OROS (650) 564-5000orvisit at contact ALZA Corp. For moreinformation, efficacy. therapeutic profilestooptimizeadrug's delivery tailored tomeetpatterned OROScanbe profile. zero-orderisnottheoptimaldelivery drugs, For many solubility. ofdrugswithlow also enhancethebioavailability L-OROScan efficient drugabsorptionandenhancedbioavailability. mayprovide more OROStechnology specific areasoftheGItract, Targeting solubility. ofdrugswithlow can enhancethebioavailability eurmns L-OROS requirements. can beusedtodeliverhighdrugdosesmeetinghigh-drugloading OROS including poorly solubleorhighlydrugs. compounds, forupto24hoursandcanbeusedwitharangeof drug delivery ® P ehooyeposomsst rvd rcs,controlled osmosisto provideprecise, employs technology REFILLABLE O SMOTIC TM www.alza.com technology, adapted forliquidformulations, adapted technology, D T ECHNOLOGY ELIVERY . aa pa ytm a nasal spraysystem, a prefillable syringe, glass orplastic Whethera industry. of thepharmaceutical designed tofittheneeds systems drug delivery developing prefillable to is dedicated Pharmaceutical Systems BD Medical- S YSTEMS
115 Drug Delivery Technology November/December 2006 Vol 6 No 10 Drug Delivery Technology November/December 2005 Vol 5 No 10 www.assainternational.com/workshops/IWPCPS_9/IWPCPS_9.cfm DDTNov-Dec2006Round511/10/068:34PMPage117 *
116 DrugDrug Delivery Delivery Technology Technology November/DecemberNovember/December 2005 2006 VolVol 5 6 No No 10 10 +1 2033120682. or [email protected] contact usat nomto n btatsbiso,visitour andabstractsubmission, information For detailed PerkinElmer; Japan; TA Instrumentsandmore. of Toho, NewZealand;University University, Otago Germany; Lederer &Keller, UK;Panalytical; AstraZeneca; Sanofi-Aventis;Setaram; Teraview, companies include GSK;BoehringerIngelheim; Amgen Inc; Supporting andsoftware. introduce theirnewestinstrumentation the-artpharmaceuticalequipmentwhowill state-of- analytical, visit (914)681-9790 or at contact NOFCorporation more information, For customers. development ofnewproductsfor DDSandsatisfy the in thenewbuildingnexttoDDS planttoaccelerate hasjustbeenestablished anewDDSResearch Laboratory addition, In frompharmaceuticalcompaniesacrosstheglobe. attention increasing been attracting PEGsandnewplanthave Activated Thecompany’s offers afive-foldincreaseinproductioncapacity. 200,000-sq-ftDDSplantnow Thenewthree-story, October 2005. undercGMPsince PEGshasstartedcommercialoperation Activated NOF’s newDDSplantformanufacturing improved efficacy. longerin thebloodstreamwith stabilized drugscancirculate PEG- withproteindrugssothat beenusedtoconjugate PEGs have P HYSICAL www.nof.co.jp/dds. N C HARACTERIZATION EW DDS F Exhibition withvendorsof days ofaCommercialIndustry Therewillbe5 future outlooks. results indrugdevelopmentand research presenting thelatest and issues, recent regulatory reviewingmost characterization, methods forsolid-state aboutcutting-edge information willbepresenting MA, Boston, in 2007, June24-20, Solids, ofPharmaceutical Characterization Workshop onPhysical IWPCPS-9 NinthInternational ACILITY h ol.Its Activated the world. companies throughout pharmaceutical Polysorbate to and high-performance purity phospholipids, high- PEGs, Activated has beensupplying NOF CORPORATION website W ORKSHOP or Pharma at visitSCOLR For moreinformation, lifeandeasyenforcement). patent protection(full andstrong patent compared toothertechnologies), higherpayload(when effective (utilizesstandardtabletingexcipients), cost conventionalmanufacturingequipment), manufacture (employs easy to ofawiderangereleaseprofiles), programmable (capable including highly distinctadvantages, Pharma's CDT®hasthemany SCOLR uponfinancialarrangements. orothermutuallyagreed contracts, manufacturing royalties, include licensingfees, arrangements that SCOLR Pharmapartnerswithcompaniesundercontractual 7383 orvisit (801)994- at Inc., contactLipocine, For moreinformation, products. foodordrug inapproved excipientsalready other formulation aregenerallyacceptedlipidand Thesematerials lipid materials. formsutilizingabroadspectrumof produce practicalsoliddosage Nanosplodeoffersnovelcompositionsandprocessesto attributes. theirrespectiveperformance whilepreserving technologies, hydrophilic drugswithpoororalabsorptionpotential)delivery of and Hydroance(foroptimalnon-invasivedelivery bioavailability) formoptions ofLipocine’sdosage Lipral(foroptimaloral Nanosplodeexpandsthe andsuboptimal. potential isoftenslow formofdrugswithpoorabsorption from aconventionalsoliddosage drugabsorption For andsuperiortherapy, diseasesrequiringrapid C ONTROLLED www.scolr.com. S OLID www.lipocine.com. -L IPID D ELIVERY D CDT itspatented SCOLR Pharmaapplies conventional productionequipment. and standardmaterials available be manufacturedusingreadily periods forupto24hoursandcan can beusedforcontrolled-release These elegantlysimpletechnologies andnutraceuticalproducts. OTC, for companieswithpharmaceutical, Technologies todevelopformulations ISPERSIONS ® Controlled Delivery P LATFORM DDTNov-Dec2006Round511/10/068:34PMPage118 * www.genzymepharmaceuticals.com. (800)868-8208orvisit Pharmaceuticals at contactGenzyme For moreinformation, excreted unmetabolized. thecarrieritselfis that reversible andhasbeendemonstrated tobe Thispermeabilityhasbeenshown in aselectedhemisphere. forincreasedconcentration both hemispheresofthebrainallowing compounds orpharmaceuticalactivescanbedeliveredintoone intracarotic injectionsofasimplemixtureLipobridgeandmodel inseverallaboratories, Demonstrated 100 withouttoxicsideeffects. Drug Deliverywww.hovione.com. visitHovioneat For moreinformation, than 5yearsago. TechnologyMore thanhalfoftoday'ssalesconsistsproductslaunchedless large pharmaandbiotechcompanies50%genericproducts. businessis50%customsynthesisfor Hovione’s customer service. forsuperior economical hasgiventhemaworldwidereputation aredependableand provide customerswithtimelysolutionsthat itsabilityto time, Overthat on morethan40yearsofexperience. compliancetocGMPstandardsisbased andregulatory chemistry thecompany’s expertiseinprocess complex chemicalentities, M ANUFACTURER BBB T RANSPORTER Lipobridge reaching theCNSbyafactorupto can increasedrugconcentration someofthesemolecules that shows Data theBBB. and therebypermeate pharmaceutical activesintotheCNS anduptakeof distribution, thedelivery, tofacilitate been shown Short chainoligoglycerolipidshave brain-barrier (BBB)andintotheCNS. transport ofdrugsacrosstheblood- APIS & industrial productionof withthe associated solving theproblems to Dedicated intermediates. and regulated pharmaceutical ingredients and manufactureofactive the processdevelopment specializesin that company Hovione isafinechemicals TM compounds facilitate PECIALIST OE t(801)975-1191orvisit IOMED at contact For moreinformation, areavailable. and marketingagreements co-development, Licensing, unmetmedicalneeds. designed tosatisfy withspecialtypharmaceuticalstoofferuniqueproducts in combination systems pursuing opportunitiestoutilizeitsnon-invasivedrugdelivery isactively Thecompany profiles forlocalandsystemicapplications. forcustomdelivery allows transdermal andtrans-scleral technology IOMED’s versatile iontophoresis. employ systemsthat drug delivery andsaleofactive manufacture, IOMED isaleaderinthedevelopment, visit [email protected](858)794-8889; at Therapeutics) VicePresidentofBusinessDevelopment(Halozyme Wilson, contactMark For moreinformation, comfort. and improvepatient withoutEnhanze, toSub-Qdelivery speed onsetofactionrelative drugs, oflargevolumes(upto10cc)antibody administration topermit theSub-Q withEnhanzeisanticipated co-delivery action, Baseduponthismechanismof clear thesubcutaneous “jungle.” to fully humanrecombinantenzymeactasa “molecular machete” compounds? With Enhanze compounds? With orenhancethedispersionofyourexistingSub-Q (Sub-Q) delivery Would youliketoconvertyourdrugsfromIVsubcutaneous www.halozyme.com. I ONTOPHORESIS S UB -Q P ROTEIN TM ehooy microgramquantitiesofa Technology, www.iomed.com. T ECHNOLOGIES D ELIVERY 117 DrugDrug Delivery Delivery Technology TechnologyNovember/DecemberNovember/December 2006 2005VolVol 6 5 No No 10 10 DDTNov-Dec2006Round511/10/068:34PMPage119 *
118 DrugDrug Delivery Delivery Technology Technology November/DecemberNovember/December 2005 2006 VolVol 5 6 No No 10 10 www.bctechinc.com. (831)459-6464ortvisit at Inc. contactBC Technology, information, For more registered andISO9001-compliantmedicalequipment. highly effectiveoutsourcingsolutionforcompaniesseekingFDA- development andmedicalproductmanufacturingteamsprovidea BC Tech’s medicalequipment products foritscustomers. consistentlyyieldshighlyeffectivemedical development processthat BC Tech's fine-tuneda seasonedteamshave specialized equipment. teamsandtheir ofitsmultidisciplinary theflow facility tofacilitate BC Tech designedanddevelopedits20,000-square-foot customers. &international national devices completedforitssatisfied more information, visit Bespak at visit Bespakat more information, For documentation. device evolutionissupportedbyregulatory of Eachstage designandengineeringlevel. a scale manufactureat developmentprogramsfromconcepttofull- expertise tomanage hastheexperienceand Thecompany customer requirements. inlinewith also offerscompletedevicedevelopmentservices Bespak andpartner, Asbothfacilitator and medicalcheckvalves. D EVICE S PECIALTY D EVELOPMENT M EDICAL www.bespak.com. &M cutr,complianceaids, actuators, inhalers(DPIs), powder dry dose inhalers(pMDIs), suchasmetered products, support theproductionof and world-class facilities Bespak’s scientificexpertise industries. and diagnostics healthcare, pharmaceutical, medical devicesforthe leading supplierofspecialty Bespakisa years ago, Founded morethan40 with morethan100medical manufacturing company medical equipment Itisestablished California. Manufacturing companiesin and Development, Medical ProductDesign, comprehensive contract one ofthemost BC Tech tobe hasgrown Throughout thepast9years, D ANUFACTURING EVICES otc iCnegnea (800)978-2462orvisit contact BioConvergenceat For more information, andConsultingServices. &Logistics, Storage andGLP Toxicology Manufacturing, Batch Development/Validation, Analytical Formulation Development, development/optimization), includeSpecific services Parenteral cycle Development (lyophilization its EnterpriseResourcePlanning(ERP)systemusedbytheentirestaff. and Notebook(ELN)systemusedbyitsscientists, Electronic Laboratory suchasits electronicallytrackallworkedperformed, systems that thefirmhasimplementedback-end To doso, need onareal-timebasis. 9249;[email protected] orvisit 9249;[email protected] contactKurve Technology (425)640- at more information, For devices. thantraditionalnasaldelivery andefficiency efficacy withgreater andnose-to-brainmedicaltherapies systemic, topical, N ASAL C ONTRACT D ELIVERY S www.kurvetech.com. Dispersion combining ControlledParticle By compliance. patient and abusewhileimproving counterfeit/competitor druguse curb that display –features andanelectronic out technology, lock- drug pedigreeconfirmation, incorporates devicethat delivery isthefirstnasaldrug atomizer ViaNase IDintranasallydelivers technologies, drug delivery The ViaNase ID The ViaNase ERVICES that they have the data they thedata theyhave that so transparency) toitsclients, electronic transparency (e- first companiestooffersecure BioConvergence isoneofthe supply chainconsulting. andengineering logistics, and storage development, pharmaceutical product as providing suchservices doesthisby The company market withspeedandquality. move productstotheclinic and BioConvergence helpsclients D EVICE TM and intelligentnasal www.bioc.us. TM electronic DDTNov-Dec2006Round511/10/068:34PMPage120 * 88 2-44 x.2671orvisit ext. (888) 327-5454, at Inc., contactLoparex, For moreinformation, release linerneeds. LooktoLoparexforallyourmedicaldevice your uniqueapplication. Loparex isuniquelyqualifiedtodevelopareleaselinerdesignedfor development, andsubstrate edge technologiesinchemistry Becauseofourcontinuingcommitmenttoleading- user iscritical. therequirementsofbothmanufacturerandend satisfy liners that RxCIPIENTS with extensions ofexistingproductscan begintestformulations whoareforecastingline products tothemarketorbrandmanagers Formulation scientistswhoarebringingnew company. delivery inhousewithouttheneedforadrug excipient youcanformulate andisthe Itprovidesconsistenttabletdisintegration packaging. forstandard tabletfriability allows withalow andstrong, seconds, Drug at Engineered Materials Delivery Technology S ILICONE ® M00tdy o oeifrain visit Huber For moreinformation, FM1000 today. S PECIALTY -C www.rxcipients.com. OATED uaiiy Manufacturingrelease cutability. anddie- moisture resistance, cleanliness, complete traceability, medical PSAproductsinclude: characteristics ofreleaselinersfor Keyperformance Dressings. and Wound Medical Devices, EKG/ECG ElectrodesandElectro- Transdermal Systems, DrugDelivery medical PSAmarketinclude: define the that The majorcategories sensitive adhesive(PSA)products. of releaselinersformedicalpressure on flexiblewebsinthemanufacture Loparex specializesinthincoatings www.loparex.com. E disintegration in5to30 disintegration withtablet It’s fast, enhances tabletdisintegration. FM1000 isanexcipientthat RxCIPIENTS brand managers. and benefits toformulators withnumerous technology FM1000 isafast-melt RxCIPENTS excipients, andotherspecialty silicates, silica, calcium carbonate, atrustednamein Materials, Developed byHuberEngineered P XCIPIENTS APERS &F ILMS ® ® BioScreen Testing Services, Inc., at (800)229-9057orvisit at Inc., BioScreen Testing Services, contact For moreinformation, Clinical &ClaimSubstantiations). Household &IndustrialProducts;and MidwestClinical Trials (Human MedicalDevice;Cosmetic, Services; Pharmaceutical &Biotechnology divisions: Therearefourcorporate submissions totheFDA. and ANDA NDA, innumerousprojectsforIND, has alsoparticipated Thecompany specialized methodsforauniqueproductorprocess. methods whenrequiredaswelldesigningorresearching ofexecutingUSP BioScreeniscapable approach. service-oriented and ablendofscienceandbusinesswith electronic signature, www.bioscreen.com. Capsugel at at Capsugel visit For moreinformation, highest levelofcustomersatisfaction. assuresthe that andpackaging ability todesignthebestcapsule andithassuccessfullyproven its with scale-upandvalidation, CAPSUGEL canassistinthetechnicaltransferissuesassociated poorlysolubleproducts. pharmaceutical developmenttoformulate canhelpexpertsin itsmostrecenttechnology Also, ormodifiedrelease. productsforimmediate such asformulating ona wide arrayoftopics, technicalinformation provide appropriate itcanhelp forexample, toitspharmaceuticalcustomers, services offersawiderangeofspecialized Thecompany extensions. customers inthedevelopmentofnewproductsandline CAPSUGEL’s mainmissionistoassistits quality capsules. P RODUCT L ABORATORY www.capsugel.com. &D EVELOPMENT T ESTING from theInternetwith analytical reportsdirect offers Itnow water. Certified totestdrinking and CaliforniaState DEAregistered, Certified, ISO9001:2000 registered, isUSFDA company The analytical chemistry. and microbiology inindustrial laboratory BioScreen isafull-service S ERVICES S supplying high- to gofarbeyond CAPSUGEL strives to understandwhy itiseasy products, pharmaceutical genesis in form hadits dosage capsule the Given that ERVICES
119 DrugDrug Delivery Delivery Technology Technology November/DecemberNovember/December 2006 2005 VolVol 6 5 No No 10 10 DDTNov-Dec2006Round511/10/068:34PMPage121 *
120 Drug Delivery Technology November/December 2006 Vol 6 No 10 cecsa (707)793-2600orvisit Sciences at Pharmaceutical contactDow For moreinformation, NDA approval. the non-clinical andclinical testingneededtotakeproductsthrough planningandfilingsaswell trial sitestoconducttheregulatory clinical anddermatology clinical affairs, expert staffwithinregulatory, provides thecompany To meet clientneeds, dermatology materials. andlabelingdistributionofclinical trial manufacturing, materials clinical stabilitytesting, method developmentandvalidation, providesanalytical Dow Laboratory. studies fromitsSkinBiology utilizing skin-penetration optimize itsclients’ topicalformulation, and develop, abletodesign, topical productdevelopmentcompany ithasbecomeafull-scope Since1977, intheworld. company (800) 648-0791orvisit Drug contactFiltertek at For moreinformation, their productsastheydo. puts as muchintothedevelopmentof Deliverypartnering withasourcethat customersareassuredof andfluidcontroldevices, filtration BychoosingFiltertek toproduce medical manufacturing precision. and technicalknowledge, takesdesigningenuity, applications T F OPICAL ILTRATION P www.filtertek.com. RODUCT &F components forcriticalmedical designing anddeveloping much ridingonperformance, Withso scientific discoveries. and new medicalapplications devices hastokeeppacewith behind themanufactureofthese Filtertek realizestheknowledge evolving, rapidly technology Withmedical for theenduser. thesedevicesaffectsafety how knows thecompany importantly, More product's success. affect amedical ultimately andfluid control filtration Filtertek understandshow www.dowpharmsci.com. LUID D EVELOPMENT C ONTROL development topical product is tobethebest Dow’s vision clients. products forits superior topical and develops Sciences creates Pharmaceutical Dow Xcelience at (813)286-0404or Xcelience at contact For moreinformation, compounds fordevelopment. anincreaseinthroughputofcandidate whichallows decision point, clinical trial reduces thetimetakentoreach “first-in-man” Thisinturn withhand-filling. possible inaccuraciesassociated oflaborcostsand nottomentiontheavoidance stability studies, process byreducingtheneedforcostlyandtime-consuming pharmaceutical companiesbenefitfromashorterdrugdevelopment ByimplementingtheXcelodosesystem, activities. preformulation www.innercap.com. (813)837-0796orvisit at Inc., Technologies, contact InnerCap For moreinformation, overthenext5years. with expiringpatents blockbuster drugs existingpatented andreformulate repackage highlypublicizedneedto beneficial solutionstotheindustry’s provides thepharmaceuticalandbiopharmaceuticalindustrieswith system Thedelivery phases withcontrolled-releaseprofiles. multiple activechemicalcompoundsindifferentphysical effectivewaytodeliver Itisavery biopharmaceutical products. C OMBINATION P RECISION C APSULE M enhance pharmaceuticaland systemwillbelicensedto delivery The and healthcareproviders. patients, pharmaceutical companies, solutions toproblemsaffecting offerstheindustry technology the two-piece hardshellcapsules, Utilizing biopharmaceutical products. benefits ofpharmaceuticaland used toenhancethevalueand Thesystemcanbe system. delivery compartmentalized capsular-based multi- pending multi-phased, offersanadvancedpatent- InnerCap visit www.xcelience.com ICRO excipient compatibility and excipient compatibility theneedfor thereby eliminating with drugsubstancesalone, companies tofillcapsules allows because thisuniquetechnology That's easier ormoreprecise. production hasneverbeen for clinical trialsandsmall-scale manufacturing batches creating With theXcelodose -F T ECHNOLOGY ILLING TM system, .
Drug Delivery Technology November/December 2005 Vol 5 No 10 Drug Delivery Technology November/December 2005 Vol 5 No 10 DDTNov-Dec2006FINAL11/14/061:37PMPage122 * * DDT Nov-Dec 2006 Round 5 11/10/06 8:34 PM Page 123
Company Pg Phone Web Site
3M Drug Delivery Systems 5, 16,17 800-643-8086 www.3m.com/dds ALZA Corporation 2, 3 www.alza.com ASSA International 12 203-312-0682 www.assainternational.com BASF 18, 19 800-443-0627 www.pharma-solutions.basf.com Baxter BioPharma Solutions 11,20, 21 800-422-9837 www.baxterbiopharmasolutions.com BC Technology 4 (831) 459-6464 www.bctechinc.com Bespak 13, 22 +44 1553 691000 www.bespak.com BD 24, 25, 123 800-225-3310 www.bdpharma.com BioScreen Testing Service 6 800-229-9057 www.bioscreen.com BioConvergence 15, 26 800-978-2462 www.bioc.com Capsugel 28, 29 www.capsugel.com Cardinal Health 30, 31, 124 866-720-3148 www.cardinal.com/pts Coating Place Inc. 32, 33 608-854-9521 www.encap.com Controlled Release Society 27 651-994-3817 www.controlledrelease.org Degussa 34, 35 www.pharma-polymers.com DPT Laboratories 36, 37 866-CALL-DPT www.dptlabs.com Drug Delivery Partnerships 38,39 www.drugdeliverypartnerships.com Eurand 7, 40, 41 937-898-9669 www.eurand.com ExcipientFest 121 787-746-5080 www.exceipientfest.com Filtertek Inc. 42, 43 1-800-648-0791 www.filtertek.com Genzyme Pharmaceuticals 44, 45 800-868-8208 www.genzymepharmaceuticals.com Glatt Pharmaceutical Services 46, 47 201-825-8700 www.glattpharmaceuticals.com Halozyme 48, 49 858-794-8889 www.halozyme.com Hovione 50, 51 609-918-2600 www.hovione.com Huber Engineering 52, 53 866-881-6480 www.rxcipients.com Vol 6 No 10 Iomed 54, 55 801-975-1191 www.iomed.com Kurve Technologies 56, 57 425-640-9249 www.kurvetech.com Lipocine 58, 59 801-994-7383 www.lipocine.com Loparex Inc. 60, 61 888-327-5454 www.loparex.com NOF Corporation 62, 63 914-6819790 www.nof.co.jp/dds
November/December 2006 PharmaCircle 14 847-729-2960 www.pharmacircle.com PharmaMed Device 70 www.pharmameddevice.com RDD Europe 25 www.rddonline.com Safety Syringes 64,65 760-918-9908 www.safetysyringe.com Scolr Pharma, Inc 9, 66, 67 425-373-0171 www.scolr.com
Drug Delivery Technology Weiler Engineering 68, 69 847-697-4900 www.weilerengineering.com
122 * DDT Nov-Dec 2006 Round 5 11/10/06 8:34 PM Page 124 * DDT Nov-Dec 2006 Round 5 11/10/06 7:20 PM Page 1